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Measurement and Treatment of Oxidative Stress in Chronic Obstructive Pulmonary
Disease
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and
mortality worldwide. Oxidative stress in the lung has been associated with the
pathogenesis of this disease. Monitoring of the degree of oxidative stress and
subsequent inflammation in the lung through non invasive collection of induced
sputum and exhaled breath condensate (EBC) may improve our understanding of
this disease process. Treatment to reduce oxidative stress in COPD may improve
health status and lung function.
This thesis covers three studies. First of all the reproducibility of non invasive
biomarkers was assessed and then a cross sectional study of these biomarkers
was carried out. Finally a study of the impact of an inhaled anti oxidant on health
status and non invasive biomarkers in subjects with COPD was carried out.
The reproducibility of differential cells counts and pro inflammatory cytokines IL-1G,
IL-6, IL-8 and VEGF in induced sputum was assessed in 47 subjects. Total cell
counts and macrophage differential counts were reproducible but not neutrophil
and eosinophil differentials. IL-8 and VEGF but not IL-1R. and IL-6 demonstrated
reproducibility in induced sputum supernatant. Exhaled breath condensate was
measured in 24 subjects. 8-lsoprostane but not hydrogen peroxide was
reproducible.
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Exhaled breath condensate was collected in 78 with COPD and 61 controls.
Groups were subdivided into current and ex-smokers. Levels of 8-lsoprostane and
hydrogen peroxide were measured. No significant differences were seen between
the mean levels of these two biomarkers measured in COPD and control groups.
Levels of oxidative stress biomarkers were compared to health status, symptom
scores and lung spirometry in the COPD population. No significant associations
were noted in the current smokers. COPD ex-smokers from the lowest quartile
(Q1) of 8-lsoprostane measured had lower health status and exacerbation
frequency compared to the highest quartile (Q4). Lung function was worse in the
highest 8-lsoprostane quartile. Hydrogen peroxide levels in EBC did not relate to
health status or symptom scores.
Fifty-eight subjects with moderate to severe COPD participated in a 12 week
double blind placebo controlled trial of an inhaled lyseine salt of N-Acetylcysteine.
Fewer of the subjects in the low dose treatment arm of the study had clinically
significant exacerbations compared with placebo. The low dose treatment arm also
demonstrated improvements in terms of diary card reporting of breathlessness
when compared with placebo.
In summary, some non invasive biomarkers of oxidative stress in COPD are
reproducible. However the overall utility of EBC 8-lsoprostane and hydrogen
peroxide measurement in COPD appears limited. 8-lsoprostane levels in ex-
smokers with COPD may reflect disease activity. Treatment with low dose inhaled
antioxidant demonstrated some improvement in health status.
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Chronic Obstructive Pulmonary Disease (COPD) is a common condition which
presents later in life with exertional breathlessness and cough. COPD is strongly
associated with cigarette smoking, although other factors can contribute to its
development. The disease has a major impact on the lives of patients and their
carers, health care services and society as a whole. The burden of disease and
mortality of this condition are predicted to rise.
The pathogenesis of COPD is associated with a variety of inhaled toxins, including
cigarette smoke. One consequence of this is an increased burden of free radicals
in the lung creating an oxidant / antioxidant imbalance resulting in oxidative stress.
Increased oxidative stress is thought to enhance inflammation responses both in
the lung and systemically. Assessment of this process should assist in our
understanding of the disease. Interventions to reduce the oxidative stress may
decrease levels of inflammation in the lungs with the potential to improve morbidity
and mortality in COPD.
The introduction of this thesis will include a summary of the epidemiology of COPD
along with the clinical features and management of this condition. The underlying
mechanisms associated with the pathogenesis of COPD will be discussed along
with methods of assessing these mechanisms. Finally previous trials of anti-oxidant
therapy in COPD will be reviewed.
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1.1 ERS/ATS Consensus Statement - Definition of COPD
"Chronic obstructive pulmonary disease (COPD) is a preventable and treatable
disease state characterised by airflow limitation that is not fully reversible.
The airflow limitation is usually progressive and is associated with an abnormal
inflammatory response of the lungs to noxious particles or gases, primarily caused
by cigarette smoking.
Although COPD affects the lungs, it also produces significant systemic
consequences."(1)
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1.2 Epidemiology and Risk Factors in COPD
Cigarette smoking has the strongest association with the development of COPD
although a variety of other factors have also been implicated. It is uncommon for
patients with COPD to present under the age of 40 (2). As COPD presents later in
life, identification of agents, both endogenous and exogenous, which are implicated
in the pathogenesis of COPD is problematic. Subjects will have been exposed to a
multitude of environmental risk factors throughout their lives which may have had a
role in the development of COPD at the time of presentation. The innate
susceptibility of each individual to this environmental exposure is also important in
the development this disease.
For the purpose of this review, risk factors have been divided into those which are




The association between COPD and smoking dates back to the 1950s when
Fletcher et al demonstrated a clinical relationship between smoking and cough
and sputum production(3, 4).Pathological studies have also demonstrated a
relationship between smoking, mucus hypersecretion and subsequent
development of chronic bronchitis and emphysema(5). Mucus hypersecretion is
associated with a decline in Forced Expiratory Volume in 1 second (FEVi), a
measurement of airflow limitation, in patients with COPD independent of age,
height, weight change and smoking(6).
Relationships have also been shown between smoking and airflow limitation and
also on the impact of smoking on the rate of decline of FEVi. In a recent open
survey in Poland of patients older than 40 years of age with no previous history of
asthma, bronchiectasis or tuberculosis, a higher percentage of subjects who are
current or former smokers have evidence of airflow limitation on spirometry (23%)
compared with lifelong non smokers (12%). A trend has also been demonstrated
between worsening airflow limitation and increasing smoking history(7). On
average ex-smokers have higher FEVi values than current smokers(8).
A strong relationship has been reported between cigarette smoking and the rate of
decline of FEVi(9), with non smokers losing on average 25ml of FEVi per year
compared with 50ml per year in smokers and 100ml per year in heavy smokers(4).
Cross-sectional data indicates that quitting smoking is associated with reduced rate
of decline in FEVi(9, 10). The association between the rate of decline in FEVi and
smoking is independent of the maximum obtained lung function in
adolescence(11). There is also some evidence that exposure to passive smoking
may have an impact on the rate of decline of FEV-i, in the region of 3.8ml/year(12).
The Lung Health Study demonstrated that there is a significant variation in the rate
of decline of FEVi in smokers with COPD(13), the "rapid declining" falling by 150ml
per year compared to 15ml per year in the "non declining" cohort.
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Despite this strong evidence of the effect of smoking on development of chronic
bronchitis and airflow limitation, the relationship is not absolute. COPD is present
among lifelong non-smokers(14), more than 15% of subjects worldwide who die
from COPD are non smokers. Less than 25% of subjects who have a significant
smoking history go on to develop COPD.
1.2.1b Enviromental Toxins
Other inhaled environmental agents have been identified in the development of
COPD. A link exists between high levels of indoor air pollution and the incidence of
COPD(15). Furthermore increased outdoor particulate pollution levels result in
increased mortality in subjects with COPD, both in COPD deaths and deaths from
other causes(16). Several occupational agents have also been implicated in COPD
pathogenesis. These include welding fumes, grain, isocyanates, cadmium and coal
dust(17)..
1.2.2 Host Response
The fact that the relationship between smoking and COPD is not absolute
highlights the fact that it is not simply the inhaled insult that results in the
devolvement of COPD; the host response to the inhaled insult also plays a major
role. Several factors have been implicated in the host response including genetics,
health and illness in early life, environmental factors, nutrition and bacterial
colonisation.
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1.2.2a Genetics of COPD
The strongest evidence of a genetic relationship in COPD is the deficiency of the
anti-protease a1-antitrypsin. Deficient release of this his molecule results in early
development of COPD. ZZ homozygotes produce very low levels of a1-antitrpysin.
These patients have an Odds Ratio greater than 30 of developing COPD(18).
Milder forms of this deficiency also have an increased incidence of COPD, MZ
heterozygotes for example have an odds ratio between 1.5 and 5 of developing
COPD(19). Overall however the incidence of a1 AT deficiency in the COPD
population is low, and is implicated in less than 1% of patients with COPD(20).
Genetic factors other than a1-antitrpysin deficiency exist. The relationship between
these factors and COPD development is not as strong as a1-antitrpysin.
Furthermore there is a significant variation in the strength of these relationships
between populations.
Genes which have been implicated include glutathione-s-transferase
polymorphism(21), a1-antichymotrypsin(22, 23). Genetic predisposition may also
be associated with the TNFa gene which exists in two forms, the TNFa2 iso-form is
associated with increased levels of chronic bronchitis(24).
1,2.2b Development
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Health in early life appears to be a major factor in the development of COPD. An
association exists between maximum obtained lung function and subsequent
development of COPD in later life. Factors which influence maximum obtained
function include birth weight, time of gestation and fetal and peri-natal smoke
exposure(25-27). Sub-optimal lung function in adolescence is associated with
subsequent development of COPD(28). Airways hyper-responsiveness in early
adulthood is associated with subsequent development of COPD(29). Smokers with
airways hyper-responsiveness have been shown to develop COPD more rapidly
than smokers with no airways hyper-responsiveness(30).
1.2.2c Nutrition
Nutrition also appears to have a role in development of COPD. Low fresh fruit
intake is associated with lower FEVi(31). Poor nutrition as defined by Body Mass
Index (BMI) is also associated with COPD. Weight loss or a low BMI is associated
with COPD mortality, this relationship being strongest in severe COPD(32, 33)and
is independent of weight or sex(34). Development of airflow limitation is associated
with reduced dietary vitamin C intake(35, 36) whilst high intake of fruit and whole
grains appears to protect against declining lung function(31).
1.2.2d Gender
Gender may also be a factor in COPD pathogenesis, independent of smoking




Socioeconomic status appears also to play a role, with subjects from the lowest
end of the socioeconomic spectrum having between 200 and 400ml lower mean
FEVi values compared with the highest end, independent of other risk factors
including smoking(38). Admission rates have also been noted to be higher in
subjects with lower socioeconomic status(1).
1.2.2f Bacterial Colonisation
Bacterial colonisation in COPD is associated with declining FEV-|. Increased
bacterial load is associated with increased rate of decline in FEVi(39). Subjects
with severe COPD have increased frequency of exacerbations of COPD compared
with milder forms of the disease(40).
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1.2.3 Prevalence and Incidence of COPD
There is a large variation in published data on the prevalence of COPD. One
reason for this is that a proportion of the population will have evidence of airflow
limitation on spirometry without any symptoms consistent with COPD. Prevalence
studies which screen for airflow limitation independently of symptoms will therefore
demonstrate a higher prevalence compared with studies which require both
spirometric and clinical features of COPD.
The prevalence of chronic bronchitis varies throughout Europe, averaging 4% in
Europe, ranging from 3.2% to 5.4%(41). In the United States of America, the
National Health Interview Study in 1996 demonstrated 6% of the population over
the age of 25 reporting that they suffered from chronic bronchitis or
emphysema(42). In 1997 5.9% of the US population reported that they had
physician diagnosed chronic bronchitis or emphysema(42).
Airflow limitation alone is more prevalent than symptoms of chronic bronchitis. In
the United Kingdom 10% of males and 11% of females aged between 18 and 65
had FEV-i values at least 2 standard deviations below predicted values for age and
height(43). 33.5% of patients with significant airflow limitation do not report any
respiratory symptoms(7). This is more apparent at higher levels of FEVi. Lower
levels of FEN^ are associated with increase rates of admission and also increasing
respiratory symptoms(44).
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In the US, the National Health and Nutrition Examination Survey III (NHANES III)
demonstrated that 14.3% of the adult population had spirometric abnormalities
consistent with COPD. However in association with physician diagnosed
emphysema or chronic bronchitis this dropped to 2.9% of the population. Only
1.4% of the population had an FEVi less than 50% predicted. 71.7% of subjects
with mild airflow limitation had no formal diagnosis of COPD(45).
Worldwide prevalence of COPD is lower than levels reported in Europe and the
United States, reflecting higher cigarette consumption in these countries. The
GOLD report estimated the global prevalence of COPD in 1990 to be 9.34 per
1000 men and 7.33 per 1000 females of all ages(46).
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1.2.4 Morbidity and Mortality of COPD
The morbidity associated with COPD can be quantified in several ways, including
the impact on individuals, the health service and society as a whole.
COPD has a major impact on the individual. In the UK 73% of patients with
physician diagnosed COPD reported that they were unable to undertake important
activities due to their condition and tha forty-five percent with a clinician diagnosis
of COPD, emphysema or Chronic Bronchitis were either unable to work or had
stopped work early because of COPD.(47).
Management of COPD is a major consumer of health services worldwide, in terms
of out-patient review, emergency consultations and hospital admissions. Two
recent surveys in the US have established that COPD is responsible for 82
ambulatory visits per 1 000 population per year(48), and 8.3 visits to emergency
room per 1 000 of the population per year(49). COPD also has a large impact in
terms of hospital admissions, a recent survey of US hospital admissions in 1998
demonstrated 38.3 admissions per 10 000 of the population per year. These
admissions accounted for 1.9% of the total hospital admissions. A further 7.0% of
total hospital admissions identified COPD as contributing to hospitalisation^, 51).
A recent telephone survey of the impact of COPD demonstrated that 12.8% of
diagnosed patients had been hospitalised in the last year due to exacerbations of
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C0PD(41). The number of hospital admissions due to exacerbations of COPD is
increasing(52).
Disability adjusted life years can be used to express the overall burden of a
disease on society. The World Health Organisation (WHO) estimated that 2.1% of
all disability life years were as a result of COPD in 1990, the 12th most prevalent
cause of years lost due to disability. This value is predicted to rise to 4.1 % in 2020,
ranking as the 5th largest cause of disability adjusted life years(53).
The mortality related to COPD is also predicted to rise during the same timeframe.
The WHO ranked COPD as the 6th most frequent cause of mortality in 1990 and
estimates that this will increase to 3rd by the year 2020(54). This increase appears
to be predominately in females. Current death rates in the US are 53.1 per 100 000
males per year which is a stable figure and 32.1 per 100 000 females, a figure
which is rising(55). Between the years 1974-1993 a 126% increase in female
mortality due to COPD was recognised in the US(56). A similar increase in
mortality in females has been reported in Australia, where a 2.6 fold increase in
female mortality was noted between 1964 and 1990(57). Overall 8.2% of all
patients dying in the US had obstructive lung disease listed as a cause(56).
Mortality figures in Europe are similar to those in the US, although a large variety is
seen between countries, ranging from greater than 30 per 100 000 of the
population in Hungary and Denmark(58, 59) to less than 10 per 100 000 population




Chronic Obstructive Pulmonary Disease is characterised by chronic respiratory
symptoms of breathlessness, cough, sputum production and wheeze.
Breathlessness is often progressive with a gradual decline in symptoms over many
years. In a similar fashion cough may initially be mild and only present first thing in
the morning, i.e. a "smoker's cough", then gradually become productive, persist
throughout the day and increase in severity.
Patients normally present later in life, usually over the age of 40, unless there is a
genetic predisposition to the disease such as a1 antitrypsin deficiency. In the
majority of cases there is a significant history of exposure to cigarette smoke.
Patients with COPD are prone to acute exacerbations of their disease. These
exacerbations can be precipitated by viral or bacterial lower respiratory tract
infections. Increased levels of air pollution are also associated with some
exacerbations. Exacerbations which result in hospital admission are associated
with a high mortality.
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Subjects with COPD may go on to develop respiratory failure. Clinical symptoms of
right sided heart failure such as ankle oedema may be noted. Chronic type II
respiratory failure with carbon dioxide retention may result in symptoms of
intermittent drowsiness and confusion.
There is a wide clinical spectrum in COPD. This ranges from mild airflow limitation
without symptoms late in life, to a more aggressive disease with recurrent hospital
admissions and premature death.
Historically patients with smoking-related lung disease were previously diagnosed
as having chronic bronchiolitis, chronic bronchitis or emphysema, thought to be
separate disease processes. Chronic bronchitis is defined clinically as a cough
productive of sputum most days for 3 consecutive months for two consecutive
years. Emphysema is a pathological diagnosis dependant on evidence of
enlargement and destruction of alveolar walls distal to the terminal bronchioles.
Chronic bronchiolitis is defined pathologically as chronic inflammation of the
peripheral airways. This occurs early in the disease and is often an asymptomatic
finding (61). Matsuba et al demonstrated that the internal diameter of respiratory
and membranous bronchioles in subjects with a FEVi greater than 75% correlates
with the FEVi(62). A similar relationship is present with more significant airflow
limitation(63).
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There is a large clinical overlap between these conditions. Furthermore they are
frequently characterised by breathlessness and progressive airflow limitation. This
led to the introduction of the term Chronic Obstructive Pulmonary Disease
encompassing chronic bronchiolitis, chronic bronchitis and emphysema.
Differentiation from other obstructive airways diseases such as asthma can
sometimes be problematic. Salient points in the history include character, duration
and onset of symptoms, history of atopy, smoking history and family history.
Sudden deterioration and variability in symptoms with obvious triggers are more
characteristic of asthma. Predominant nocturnal symptoms are also more likely in
asthma. A history of atopy or childhood asthma would make the diagnosis of
asthma more likely, as would a family history of asthma. Presentation under the
age of 40 in a non smoker is unusual in COPD.
1.3.2 Clinical Examination and Investigation
Clinical examination is of limited usefulness in the diagnosis of COPD, with many
clinical findings being non specific. Salient points on examination include
tachycardia, tachypnoea and hyperinflation of the lungs with reduced chest
expansion and air entry, with or without wheeze.
Respiratory failure as a consequence of COPD may result in abnormalities on
clinical examination. Carbon dioxide retention can cause a bounding pulse,
papilledema and a flapping tremor. Evidence of right sided heart failure as a
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consequence of respiratory failure may be noted with right ventricular hypertrophy
and peripheral oedema. ECG changes demonstrating right sided hypertension and
right ventricular hypertrophy may also be apparent.
Oxygen saturations should be assessed by pulse oximetry and arterial blood gas
measurement made if there is evidence of hypoxia. Nutritional assessment should
be made by measuring the Body Mass Index.
Chest Radiographs may demonstrate evidence of emphysema. If the condition is
severe, emphysema can also give rise to bullae, hyperinflation of the lung with
flattening of the diaphragms.
As stated above, COPD is characterized by chronic airflow limitation. Spirometry
measures the volume of air which can be expired by in one second (forced
expiratory volume in one second, FEV-|) and the total lung volume which can be
exhaled, the forced vital capacity, FVC. The ratio between these two values defines
the presence of airflow limitation. Subjects with airflow limitation have reduced
airway calibre and consequently the rate at which a subject's lung volume can be
exhaled is reduced. This causes less lung volume being exhaled in the first second
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when compared with healthy individuals. The spirometric definition of COPD
therefore includes a reduced FEVh and an FEVi / FVC ratio less than 0.7.
The severity of COPD can be defined using lung function testing. Mild, moderate,
severe and very severe airflow limitation is then defined according to the level of
FEVi compared with the percent predicted for that individual. Percentage predicted
values take into account the height, sex, age and race of the subject. A variety of
formulae are used to allow calculation of percentage predicted values, the
European Coal and Steel Community formulae are frequently used in the UK(64)
Measurement of airflow obstruction before and after administration of an inhaled or
nebulised bronchodilator is commonly used to assess the degree of reversibility of
airflow obstruction. Subjects with asthma are more likely to have evidence of
bronchial lability compared with patients with COPD. The use of reversibility as a
diagnostic tool in COPD however is becoming less common. The recently
published NICE guidelines have not included reversibility testing in routine COPD
investigation(65)
1.3.3 Management of COPD
Current therapy for COPD includes inhaled bronchodilators, both short and long
acting. Short acting bronchodilators may also be given in nebulised form. These
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therapies can improve health status and symptomatic control but have no impact
on mortality(66-69). Inhaled corticosteroids (ICS) also have a role in COPD and
can improve health status and reduce exacerbation rates(70, 71). Inhaled
corticosteroid therapy in combination with long acting bronchodilators have been
shown to be of greater benefit that ICS alone (72, 73). Treatment with ICS is
currently recommended for subjects with an FEVi less than 50% who have more
than one exacerbation per year(1). Treatment with oral mucolytics may reduce the
number of exacerbations and is discussed in detail later in this chapter.
Vaccination against influenza virus and streptococcus pneumoniae is also
recommended(74, 75).
Subjects with COPD should be assessed for respiratory failure. Long term oxygen
therapy is of benefit in subjects with significant respiratory failure and can improve
mortality and morbidity(76, 77). There is also evidence that pulmonary
rehabilitation improves mortality and morbidity in selected patients with COPD(78).
Other management considerations in COPD include assessment for genetic
predisposition in those subjects who present earlier in life, nutritional
supplementation, CT scanning to assess suitability for surgery such as bullectomy,
lung volume reduction surgery and also suitability for referral for single lung
transplant.
To summarise, COPD is diagnosed clinically from symptoms and confirmed by
lung function testing. Clinical examination and chest radiography may aid in the
diagnosis. The mainstay of management is symptomatic treatment with inhaled
therapy as no pharmacological treatments have been shown to improve mortality.
1.4 Pathogenesis of COPD
Epidemiological evidence indicates that cigarette smoking and inhalation of other
toxins contributes to the development of COPD. The response of the body to these
inhaled toxins plays a crucial role in the pathogenesis of this disease. Various
mechanisms have been implicated in this process. One hypothesis is that
inhalation of toxins rich in free radicals results in oxidative stress in the lung. The
lung responds to this oxidative stress by producing pro-inflammatory cytokines with
a resultant influx of inflammatory leukocytes. The subsequent inflammation
damages lung tissues, generates further oxidative stress and causes an imbalance
between protease and antiprotease enzymes in the lung with further lung tissue
damage.
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1.4.1 Sources of Oxidative Stress
Oxidative stress results from an imbalance between oxidants and antioxidants in
favour of oxidants. This can occur from either an increase in oxidant burden or a
decrease in antioxidant or both. An increase in oxidant burden in the lungs can
result from inhalation of toxins such as cigarette smoke or air pollution which
generate oxidants, or because of inflammation in the lung. In the majority of
patients the development of COPD is a consequence of chronic cigarette smoking.
Cigarette smoke contains a variety of agents which are toxic to the lung. It is
estimated that cigarette smoke contains 1017 free radicals per inhalation(79) Also
present in tobacco smoke are high concentrations of reactive oxygen species
(ROS), both non-radicals such as hydrogen peroxide and oxygen radicals such as
superoxide ion(80) and reactive nitrogen species (RNS) such as nitric oxide (NO.)
which is present in smoke in concentrations of 500-1000 parts per
million(81).Tobacco smoke contains aromatic hydrocarbons, such as benzene,
which are also toxic to the lungs(80).
Chronic inhalation of cigarette smoke results in a significant oxidant burden for the
lungs. It has been hypothesised that the ability of the lungs to cope with this
oxidant burden is a important role in the development of COPD(82).
Smoke inhalation is not the only cause of oxidative stress in the lungs. Alternative
sources of oxidative stress can be either exogenous such as from air pollution (83)
or endogenous from inflammatory cells in the airways. Neutrophils, macrophages,
eosinophils and structural epithelial cells have all been identified as further
potential sources of oxidants (84).
Inhaled Toxins and Free Radicals
resulting in Oxidative Stress
Chronic Obstructive Pulmonary Disease
Figure 1.4.1 Oxidant Burden in the Lung
47
1.4.2 Generation of Reactive Oxygen Species
The presence of free radicals in the lungs results in generation of reactive oxygen
species and reactive nitrogen species, which can lead to lung damage.
Free radicals in the lungs interact with oxygen to produce superoxide ion, figure
1.4.2. The nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system
is a major source of superoxide production from inflammatory cells in the lung1.
Other sources of superoxide production are mitochondrial metabolism, arachidonic
acid metabolism and molybdenum hydrolase reactions within cells (85, 86).
Superoxide is metabolised enzymatically by superoxide dismutase to produce
hydrogen peroxide, figure 1.4.2. Superoxide ion and hydrogen peroxide can
combine via the Fenton reaction to produce hydroxyl radicals (60, 84). Iron is the
major catalyst of this reaction. Furthermore it has been shown that there is an
excess of iron in the alveolar macrophages of smokers(87). In the lungs,
granulocyte peroxidases, such as myeloperoxidase, metabolise hydrogen peroxide
and chloride ions producing hypochlorous acid (HOCI).(88) Alternatively hydrogen
peroxide can be dismuted by the enzyme catalase to water(89).
Superoxide ion and hydroxyl radicals are unstable molecules with a very short half
life, making direct quantification of these molecules activity in vivo problematic.
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Hydrogen peroxide is a stable compound which can be measured in Broncho-
Alveolar Lavage (BAL) and exhaled breath condensate. Studies have shown
elevated levels of hydrogen peroxide in expired breath of patients with COPD
compared with healthy smokers and non smokers(90), with hydrogen peroxide
rising further during exacerbations(91).
In summary free radicals in the lung interact with oxygen resulting in the production
of the highly toxic molecules such as superoxide ion and hydroxyl radicals. These
can be metabolised to hydrogen peroxide which itself is toxic to the lung. Hydrogen
peroxide can by dismuted to water or can react with chloride resulting in the






























Figure 1.4.2 Free Radical, Reactive Oxygen Species and Reactive Nitrogen
Species
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1.4.3 Generation of Reactive Nitrogen Species
Production of reactive oxygen species (ROS) in the lung results in direct damage
and inflammation. Along with these processes, which are discussed in section
1.4.2, ROS can interact with nitric oxide producing toxic molecules known as
reactive nitrogen species (RNS).
Production of nitric oxide (NO) is a major factor in the generation of reactive
nitrogen species. There are three iso enzymes involved in the production of nitric
oxide, these being constitutive, inducible and neuronal nitric oxide synthase(92,
93). The cytokines TNF-a and IL-1B stimulate inducible nitric oxide synthase
resulting in increased production of nitric oxide(94). At low concentrations nitric
oxide is thought to be a signalling molecule(95). Increased levels of exhaled nitric
oxide in smokers are associated with tobacco smoke lung damage(96).
Measurement of nitric oxide in COPD is controversial with contradicting studies
indicating that NO is either elevated or reduced in this disease (97-99). Rutgers et
al measured the inducible Nitric Oxide iso-enzyme (iNOS) in sputum macrophages
with no difference seen between COPD and control(IOO). However, in subjects
with COPD the number of pneumocytes with iNOS present in the alveolar wall of
the lung parenchyma is elevated when compared with control subjects(101). Acute
inhalation of cigarette smoke converts tyrosine to 3-nitrotyrosine and dityrosine,
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this reaction can be inhibited by antioxidants such as glutathione, ascorbic acid
and uric acid(102).
Nitric oxide at higher concentrations can both have a direct toxic effect(103) and
interact with superoxide ion resulting in production of perioxynitrite(89) which
reacts with tyrosine to produce 3-nitrotyrosine(104).
Perioxynitrite is not a stable compound and cannot be directly quantified. 3-
nitrotyrosine is a product of perioxynitrite and can be measured by
immunohistochemistry. Increased levels of 3-nitrotyrosine are demonstrated in
sputum leukocytes of patients with COPD compared with control subjects(105,
106).
To summarise, there is evidence of increased reactive nitrogen species in COPD
compared with controls, produced by reactions between NO and reactive oxygen
species. Furthermore production of NO may be increased by oxidative stress in the
lung.
1.4.4 Other sources of oxidative stress
In addition to the production of reactive oxygen and nitrogen species mentioned
above, cigarette smoke contains many aromatic compounds which can cause
damage to the lung.
Metabolism of these xenobiotics by cytochrome p450 results in the production of
epoxides which are highly reactive and toxic to lung tissue. These epoxides are
metabolised by conjugating enzymes such as glutathione-s-transferases epoxide
hydrolases, which neutralise these toxic metabolites(107). Polymorphisms of
microsomal epoxide hydrolase gene which are associated with reduced
metabolism of epoxides are more commonly expressed in subjects with COPD
compared with control subjects(108).
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1.4.5 Effects of Oxidative Stress
Inhalation of toxic particles and gases in cigarette smoke and the subsequent
oxidative stress can cause direct damage to lipids, proteins and DNA in the
lungs(109, 110). Various mechanisms are involved in this process, figure 1.4.3.
These include increased proteolytic degradation, impaired protective mechanisms
and impaired cell membrane function.
Figure 1.4.3 Effects of Oxidative Stress
The lung parenchyma and airways can be permanently damaged directly by
oxidative stress(111) with fragmentation of elastin and co!lagen(112) along with
reduced production of these structures.
53
Human respiratory tract epithelial cells treated with gas phase cigarette smoke
show increased DNA strand breakage(113). Oxygen radicals in the lung cause
modification to amino acid side chains resulting in cleavage of peptide bonds,
resulting subsequently in proteins that are more susceptible to proteolytic
degradation^ 14, 115). This direct damage can cause increased inflammation in
the lung(116).
Reactive oxygen species, such as hydrogen peroxide and hydrochloric acid, impair
host protective mechanisms with resultant damage to the lung. Oxidative stress in
the lung results in impairment of cilia function(117), increased levels of high
molecular weight mucus production^ 18) and increased epithelial
permeability(119). Cigarette smoke inhalation also results in cell injury and
reduced surfactant activity in fibrob!asts(120).
Cell membrane function is also impaired by oxidative stress. Free radicals remove
hydrogen atoms from side chains of lipids producing lipid radicals which react with
oxygen to give peroxyl radical. This action results in polyunsaturated fatty acids
changing to lipid hydroperoxides(121). Lipid hydroperoxides have numerous toxic
effects on the lung, including impaired membrane function, inactivation of
membrane bound receptors and enzymes, and increasing epithelial
permeability(122). Lipid hydroperoxides also interact with antioxidants or metal
ions producing hydrocarbon gases and unsaturated aldehydes(123).
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1.4.6 Oxidative Stress and Gene Expression
Section 1.4.5 discusses the process with which the lung is directly damaged as a
result of oxidative stress. In addition to this direct damage, molecular pathways at
stimulated by oxidative stress(124) resulting in increased gene expression,
production of pro-inflammatory cytokines, influx of inflammatory leukocytes and
subsequent enhanced inflammation in the lung.
Increased Gene Expression and Production of
Pro-Inflammatory Cytokines in COPD
Inhaled Toxins, Free Radicals
+ROS / RNS






Chronic Obstructive Pulmonary Disease
Figure 1.4.4 Oxidative stress and gene expression
The transcription molecule Nuclear Factor kB appears to have an important role
oxidative stress induced gene expression of inflammatory mediators such as
cytokines, chemokines, adhesion molecules and inflammatory mediators(125,
126). ROS/RNS have been shown to activate NF kB(127) via an enzyme
dependant pathway(128, 129).
NFkB is normally bound to its inhibitory protein Inhibitory kB (IkB) in the cell
cytoplasm. Production of ROS/RNS as well as other stimuli results in
phosphorylation of IkB. As a consequence of this p65, a nuclear localisation signal
molecule is released with resultant activation of NF kB. Activated NF kB then
translocates to the nucleus and stimulates transcription factors resulting in the
production of pro-inflammatory cytokines such as IL-1S, IL-6(130), IL-8(131, 132),
TNFa(133), SLPI(134), and ICAM 1(135, 136). Transactivation of NF-kB by
ROS/RNS is synergised by TNFa and IL1I3> by inducing loss if IkB from the cell
cytoplasm (137, 138).
Cellular expression of p65 can be used as a marker of NF-kB activation. Bronchial
epithelial biopsies have demonstrated that p65 expression is increased in smokers
with or without COPD compared with healthy non smokers. Furthermore, levels of
p65 in these cells correlate with FEVi(136).
Several other pathways have been implicated in the production of pro-inflammatory
cytokines as a result of oxidative stress. Intracellular antioxidant depletion and
ROS production results in AP-1 activation(139). The AP-1 pathway is involved in
the production of the pro inflammatory cytokines IL1R>, TNFa and IL6 along with
stimulating the cyclo-oxgenase 2 and prostaglandin synthase 2 pathways with
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subsequent increased production of prostaglandins(140, 141). This results in
disruption of the structure of the nucleosome(142) and chromatin remodelling(143).
Oxidative stress has also been shown to stimulate the Mitogen activated protein
kinase pathways(144).
1.4.7 Antioxidant defence systems
The human lung copes with oxidative stress through various antioxidant
systems(145) present in the major airways, the alveoli, the epithelial lining fluid and
within the lung cells. Free radicals, reactive oxygen species, reactive nitrogen
species and benzenes interact with these antioxidants as they are inhaled. If the
amount of these molecules in the lung exceeds the capacity of the antioxidant
defence systems then oxidative stress occurs. This results in direct damage to the
lung tissue and production of pro-inflammatory cytokines and subsequent
inflammatory cell influx. These effects, if chronic, may contribute to the pathological
changes in COPD.
Most of the antioxidant capacity of the lung is extra-cellular, present in the epithelial
lining fluid (ELF) of the alveoli(146). The most important antioxidant in the epithelial
lining fluid is glutathione(147). High molecular weight glycoproteins are secreted in
the major airways as a response to oxidative stress and act as a primary defence
mechanism for oxidative stress(148).
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Several factors impact on the lungs antioxidant capacity. Many of the antioxidant
systems are dependant on dietary intake. Production of several systems can be






Superoxide Dismutase Uric Acid
Catalase a-tocopherol
Thioredoxin Ascorbic Acid
Table 1.4 Anti-Oxidant Defence Systems
Antioxidant defence systems can be divided into enzymatic and non enzymatic
(149). Ascorbic acid and a-tocopherol are two non-enzymatic antioxidants which
are present in the ELF(150, 151). Other non-enzymatic systems include uric acid,
lactoferrin, glutathione and ft-carotene(152). Smoking is associated with reduced
l3>-carotene and vitamin C levels in plasma along with reduced vitamin E levels in
lung BAL(153-156). The major source of non enzymatic antioxidants is diet.
The role of dietary antioxidants in the pathogenesis of COPD is unclear. There is
some evidence that increasing vitamin C is associated with improved lung function
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in smokers, asthmatics and patients with bronchitis(157). in contrast dietary
supplementation with I2> carotene resulted in increased presentation of lung
cancer(158).
Enzymatic antioxidant systems include superoxide dismutase, catalase,
glutathione peroxidase, glutathione-s-transferase and thioredoxin(149). Cigarette
smoking leads to increased superoxide dismutase, catalase and glutathione
peroxidase activity in the lungs(159).
Superoxide dismutase is present both intra and extra cellularly and directly
metabolises superoxide producing hydrogen peroxide and oxygen(149). Three
isoforms of superoxide dismutase have been identified(160-162).
Haem Oxygenase (HO-1) is an intracellular enzyme which also exists in three
isoforms. The inducible HO, HO-1, is stimulated by oxidative stress(163) resulting
in increased production of biliverdin from haem with production of iron and carbon
monoxide(164). Bilirubin reductase metabolises biliverdin to form bilirubin, a
potent antioxidant(163). Levels of HO-1 are decreased in COPD whilst levels of
non inducible HO-2 are increased(101).
As mentioned above, the epithelial lining fluid (ELF) is the major source of anti¬
oxidants in the human lungs(146). Glutathione in the ELF acts as a key scavenger
for free radicals, hydrogen peroxide and lipid peroxides(165). Glutathione is
60
synthesised from three peptides, glutamic acid, cysteine and glycine. The two
major sources of glutathione intracellular^ are the lung and liver(166, 167). In the
lung glutathione is produced intra-cellularly and secreted into the ELF. Glutathione
can exist in two forms, reduced glutathione (GSH) and oxidised glutathione
(GSSG). Various systems exist to maintain glutathione in reduced form in the ELF.
glutathione
lipid-OH ^peroxidast^ oxidised glutathiones,
water \,,utathione
yV Reductase
lipid peroxides X X. , . . . ...
. , . . ' ^ reduced glutathione^hydrogen peroxide 3 K
\ Extracellular
glutathione synthese \ intracellular
y glutamyl cysteine + glycine ► glutathione
y glutamyl cysteine ligase
glutamic acid + cysteine ► y glutamyl cysteine
Figure 1.4.5 Intracellular Production of Glutathione
The rate of production of glutathione is controlled by three factors; the amount of y
glutamyl cysteine synthese, the amount of cysteine and the amount of glutathione
via a negative feedback loop(168). Intracellular glutathione passes into the
extracellular epithelial lining fluid by a mechanism which is not fully
understood(169). The concentration of glutathione in the lung is 100 times that of
plasma, 200-400 pM compared with 2-4pM. Most cells cannot directly import GSH
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and rely on de novo synthesis to maintain intracellular GSH levels(170). The levels
of glutathione peroxidase and GSH in lung epithelial lining fluid are elevated in a
proportion of smokers compared with non smokers(171, 172).
GSH reacts with hydrogen peroxide in a reaction catalysed by glutathione
peroxidase to produce glutathione disulphide (GSSG) and water. Glutathione
peroxidase is secreted by epithelial cells and macrophages(173). GSSG is then
metabolised to GSH by glutathione reductase,(169, 174). This reaction requires the
hexose monophosphate shunt pathway(169). The normal physiological state is to
have greater than 90% of glutathione in its reduced form(169). GSH can also
interact with superoxide to produce GS and hydrogen peroxide.
Decreased intracellular GSH levels are associated with increases in lung epithelial
permeability(119, 172). Cigarette smoke extract induced injury to alveolar epithelial
(A549) cells which could be reversed by GSH is enhanced by GSH depletion.(175)
The red blood cells of smokers have increased GSH levels compared with non
smokers, producing increased protection against hydrogen peroxide induced
damage(176).
The enzyme y Gluatmate Cysteine Ligase (previously known as y
Glutamylcysteine synthase) plays a major role in glutathione production (177,
178,179). 4-hydroxy nonenal (4-HNE) is an aldehyde which is a stable end product
of lipid peroxidation, and may play a role in regulating gene expression of y
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Gluatmate Cysteine Ligase in the lung(180). Production of 4-HNE results in
increased levels of Transforming Growth Factor 13.1 (TGF (3>1 )(181). TGF (3.1
expression correlates with airflow limitation(182, 183). High levels of 4-HNE are
associated with increased y-GCS expression in alveolar epithelial cells(170, 184)
via the MAP Kinase pathway. 4-HNE has been shown to be elevated in the
resected lungs of patients with COPD when compared with controls(179).
Xanthine Oxidase is a further enzymatic system implicated in oxidative stress in
the lung. Activation of this system results in increased generation of superoxide ion
and hydrogen peroxide. Xanthine oxidase levels are increased in the lungs of rats
exposed to cigarette smoke, associated with increased leukocyte adhesion(185,
186). Furthermore, levels have also been shown to be increased in BAL of patients
with COPD compared with healthy non smokers and are associated with increased
superoxide generation(187).
In summary, several anti-oxidant systems have been identified which protect
against oxidative stress in the lung. The function of these systems appears to play
a crucial role in subsequent development of COPD.
1.4.8 Cellular Influx
Oxidative stress in the lungs results in increased gene expression and production
of pro-inflammatory cytokines. This in turn causes both influx and activation of
inflammatory leukocytes. Increased numbers of neutrophils, macrophages,
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eosinophils and T-cell lymphocytes have all been associated with the development
of COPD.
Differential cell counts in induced sputum (IS) show increased neutrophil levels in
smokers when compared with non-smokers (187). Bronchial alveolar lavage
demonstrates similar results(188). Furthermore, IS neutrophil differentials are
higher in smokers with airflow limitation when compared with smokers having
normal lung function(184, 189, 190). There is some evidence that the percentage
of neutrophils in induced sputum correlates with the rate of decline of FEVi in
COPD(191).
Higher levels of neutrophils are also seen in the small airways and lung
parenchyma in COPD, although this is not as marked as in the larger airways(192).
Smokers with COPD have increased number of leucocytes in the small airways of
the lung on bronchial biopsy with inflammatory cell numbers correlating with
FEVi(193). Neutrophilic infiltration of airway smooth muscle has also been shown
to correlate with FEVi(194).
Neutrophils are thought to play an important role in the pathogenesis of COPD
releasing elastase, metalloproteases and free radicals(195). The passage of
neutrophils through the pulmonary circulation is dependant on the deformability of
these cells as their diameter is greater than that of the average pulmonary
capillary(196). Acute smoking results in delay in neutrophil transit in the lungs(197).
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Oxidative stress results in increased sequestration of neutrophils by reducing cell
deformability(197) an action which is reversed by antioxidants(198).
The pro-inflammatory cytokine IL-8 is a potent chemotaxin for neutrophils and
plays a role in recruitment and activation of neutrophil and alveolar
macrophages(199). The prostaglandin LTB-4 and the enzyme system xanthine
oxidase may also contribute to neutrophil PMN recruitment in the lungs(200, 201).
There is evidence that neutrophils from smokers and patients with COPD have
increased chemotaxis and proteolytic activity compared with healthy controls(202).
The peripheral neutrophils of smokers with raised levels of neutrophils in the blood
produce more superoxide ion than smokers with normal neutrophils counts or non
smokers(203). In COPD superoxide generation from neutrophils is increased
during acute infections(79).
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Neutrophil cellular influx may result in lung blood vessel damage which increases
neutrophil- endothelial cell adhesion(204). Neutrophils express a variety of
molecules on the cell surface which promotes cellular adhesions. Rabbits exposed
to cigarette smoke express higher levels of CD 18 integrins in sequestrated
neutrophils in pulmonary vessels(186). Neutrophils of patients with chronic
bronchitis express more E-selectin compared with healthy controls. Furthermore
there is increased expression of intracellular adhesion molecule 1 (ICAM-1) in
COPD patients(205). In peripheral blood neutrophils, superoxide production is
increased in COPD exacerbations(206).
Although the association between neutrophils and the pathogenesis of COPD is
the most frequently studied, other inflammatory cell types have been implicated in
the development of COPD.
Alveolar macrophages (AM) also appear to be affected by cigarette smoke and
oxidative stress. Macrophages produce pro-inflammatory cytokines and proteases
as a result of oxidative stress.
Cigarette smoke appears to influence the morphology of macrophages; AMs in
smokers are larger and more pigmented compared with non-smokers(207). When
AMs of smokers are stimulated by oxidative stress there is a resultant increase in
superoxide production compared with non smokers(208).
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Subjects with COPD appear to have higher levels of macrophages; a twenty five
fold increase in macrophage numbers is seen in resected lung from COPD patients
compared with normal smokers(209, 210). Furthermore, alveolar macrophages in
patients with COPD are more active, secreting higher numbers of inflammatory
proteins and demonstrating higher elastolytic activity compared with normal
smokers(211). There also appears to be an association between macrophage
numbers and COPD severity with higher numbers of macrophages in patients with
severe compared to mild COPD(184).
Alveolar macrophage numbers are increased in chronic smokers. Smoking
cessation has been shown to reduce the numbers of AM and PMN in lung
lavage(13, 212). As mentioned above AMs in COPD patients have greater
elastolytic activity. The major elastoltyic enzyme secreted by AM in patients with
COPD is matrix metalloproteinase 9 (MMP-9), whose activity is regulated by the
NFkB pathway which itself is strongly associated with the development of
COPD(136, 213). Furthermore nuclear staining for p65, a nuclear localisation
signal molecule associated with NF-kB, is increased in macrophages during
exacerbations of COPD(213, 214)
Together with neutrophils and macrophages, both eosinophils and T-lymphocytes
demonstrate associations with COPD. Eosinophils are elevated in airway wall
biopsies of patients with COPD(215). There is also increased production of
eosinophilic cationic proteins in BAL of patients with COPD(216). Increased T-cell
lymphocytes have also been demonstrated in airways and lung tissue of patients
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with COPD. These T-cells are predominantly CD8 positive which may contribute to
parenchymal destruction(217).
1.4.9 Protease Antiprotease Imbalance
Chronically increased levels of pro-inflammatory cytokines and inflammatory
leukocytes are associated with COPD pathogenesis. One explanation for this is
that inflammatory cells produce an excess of protease enzymes such as neutrophil
elastase (NE), over antiproteases, such as alAntitrypsin (a1-AT). This protease /
antiprotease imbalance results in lung tissue damage and subsequent
development of COPD.
Excess production of neutrophil elastase results in degradation of elastin,
proteoglycans and glycoproteins along with abnormalities in surfactant
production(218). NE also induces expression of the cytokine IL-8 in airway
epithelial cells(219).
Tracheal instillation of NE in guinea pigs induces emphysema(220). Furthermore
NE inhibition reduces cigarette smoke induced emphysema in guinea pigs(221). A
proportion of healthy smokers have increased levels of elastase in bronchial lavage
(222). There is evidence of increased elastase activity in COPD with
immunocytochemical localisation of NE on elastin fibres in emphysema(223).
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Further protease enzymes have been identified. MMP-9 is the predominant
elastoltyic enzyme released by AM in COPD and is regulated by the NFkB
pathway(213). Other serine protease include cathepsin G and proteinase 3. The
lysosomal cysteine proteases may also play a role in COPD(224).
In parallel with an excess of proteases, development of COPD is associated with
inactivation or insufficiency of antiproteases. a1-AT is the main antiprotease in lung
parenchyma. Subjects with a1-AT deficiency develop emphysema early(225).
Together with absolute or relative deficiency, inactivation of a1-AT has been
identified in COPD. Oxidative stress through cigarette smoke, peroxynitrite and
chemically generated oxidants has been shown to inactivate antiproteases in
vitro(226, 227).
The a1-AntiTrypsin protein is susceptible to oxidant damage at its methionine
site(222). Increased levels of oxidised a1-AT are present in BAL of smokers(228).
It appears that a1-AT must be inactivated by oxidants for elastase to be toxic in the
lung (229, 230). Thus oxidative stress appears to impair antiprotease function,
accelerating elastin breakdown(230).
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Other antiproteases, such as Secretory Leukoprotease-1 (SLP-1), are present in
the airways and may also be inactivated by oxidative stress(231).
1.4.10 Histological Changes in COPD
The mechanisms described above lead to oxidative stress, inflammation and
protease / antiprotease damage to the lung which results in the development of
COPD. In keeping with the heterogeneous clinical features of this disease, the
histological features of COPD are varied and can include damage to the large and
small airways(210) and destruction of the lung parenchyma, resulting in
emphysema(232).
The large airways in COPD demonstrate hypertrophy and hyperplasia of the
bronchial glands along with goblet cell metaplasia(233). Small airway changes may
be detected early in the course of the disease. Small airways have been shown to
be narrowed in COPD with increased wall thickness due to collagen deposition and
formation of lymphoid follicles. Lumen diameters are also reduced due to
inflammatory infiltrates(234).
Emphysema is a result of destruction of alveolar structures(210). Two major forms
of emphysema are recognised, centriacinar and panacinar. Centriacinar, also
known as centrilobular, relates to damage of alveoli around the respiratory
bronchioles and the central portions of the acinus. Centriacinar damage is usually
most marked in the upper lobes. Panacinar emphysema is associated with uniform
damage of airspaces distal to the terminal bronchioles and predominately affects
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the lower lobes(214). Destruction of alveolar walls results in a loss of elastic recoil
in the lung(235). Damage impairs perfusion of the lung, resulting in a ventilation /
perfusion mismatching(236).
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1.5 Non-Invasive assessment of Oxidative Stress and
Inflammation
1.5.1 Introduction
A great deal of our understanding of the mechanisms underlying the pathogenesis
of Chronic Obstructive Pulmonary Disease is derived from cell and animal studies.
Application of these models to the COPD population is problematic. Subjects with
COPD are, in general, elderly, have significant respiratory impairment and often
have several co-morbidities. As a consequence studies which require invasive
sampling, such as from bronchial biopsy, are difficult to perform in significant
numbers, with selection bias towards the healthier COPD patients. This has
resulted in increasing interest in non-invasive assessment of oxidative stress and
inflammation in the COPD population.
Various methods have been identified which may allow measurement of mediators
which are associated with COPD pathogenesis. Pulmonary biomarkers may be
obtained from the analysis of sputum or through the sampling of cooled exhaled
breath, known as exhaled breath condensate. Systemic assessment of biomarkers
can be measured from samples of blood or urine.
A large number of studies of non invasive biomarkers in COPD using the methods
described above have been published. A selection of these studies is reviewed
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below, concentrating specifically on compounds implicated in the oxidative stress
hypothesis as the cause of COPD.
As mentioned above, direct quantification of Reactive Oxygen and Reactive
Nitrogen Species (ROS / RNS) is problematic due to the short half life of many of
these molecules. Several molecules have been identified as biomarkers of
oxidative stress. These can be broken into three categories either directly
measuring ROS / RNS, measuring stable compounds which are produced when
ROS / RNS are metabolised, or measuring the effect of ROS / RNS. Various
methods exist to measure the level of oxidative stress, both locally and
systemically.
1.5.1 Exhaled Breath Condensate (EBC)
Greater than 99% of exhaled breath condensate is water(237). Non-volatile
compounds, both hydrophilic and lipophilic, are also contained within exhaled air.
These compounds appear to originate as respiratory droplets in the lung although
the precise source of these exhaled compounds is not known(238). Exhaled breath
condensate can be collected and concentrations of identified compounds
measured. The presence and concentration of these molecules in exhaled breath
may be related to disease activity in the lungs.
Various collection systems have been developed, either commercially available or
developed within research units, to enable collection of EBC. The underlying
principle of these systems is similar. Exhaled breath passes through a one way
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collection system and is cooled, usually to -20°C. As exhaled water vapour cools it
condenses and collects in a sterile receptacle. After a set collection time the
procedure is terminated and samples either analysed or frozen for subsequent
analysis.
Collection and analysis of exhaled breath condensate is a relatively novel method
and has several factors which may potentially have a major impact on the
concentration of molecules measured. The recent ERS/ATS Task Force on the
measurement of EBC identified circadian rhythm, food and drink consumption,
medication, co-morbidity, age and gender as potential sources of variability that
can effect the measured concentration of various compounds(239).
The current consensus on exhaled breath condensate collection is that subjects
should breathe tidally into a one way valve system for a fixed time period. Nose
clips reduce nasal contamination and increase sample collection and therefore
should be worn. Once collected, breath condensate should be removed from the
collection device and frozen at -70°C. Repeated defrosting of samples may affect
analysis; if multiple analyses are planned samples should be alliquoted prior to
freezing(239).
Several compounds in exhaled breath condensate have been identified as
potential markers of oxidative stress in lung disease. Hydrogen peroxide and 8-
Isoprostane have been the most frequently studied and are discussed in detail
below.
1.5.2 8 Isoprostane
As indicated previously, oxidative stress results in the generation of free radicals.
Cell lipid membranes can be damaged by these free radicals, a process which is
known as lipid peroxidation(240). F2a-lsoprostanes are stable end products of lipid
peroxidation generated from arachidonic acid and released from cell membranes
after this process(241-245). Lipid peroxidation is independent of the
cycloxygenase-1 and cycloxygenase-2 pathways(242, 246). 8-lsoprostane is one
of these stable end products and is thought to be biologically active, possibly as a
mediator of cellular inflammation(247, 248).
Previous studies have demonstrated that 8-isoprostane is a reliable marker of lipid
peroxidation in vitro(249) and in animal models(245, 250, 251). 8-lsoprostane is
measurable in plasma, EBC and urine of healthy individuals(246). 8-lsoprostane
levels measured in urine and plasma are increased in several diseases related to
controls in a wide range of non respiratory conditions including diabetes(252),
severe heart failure(253), ischaemic heart disease(254), Alzheimer's disease(255)
and pre-eclampsia(256). Respiratory diseases other than COPD also have
elevated levels of 8-lsoprostane compared to controls. This has been
demonstrated in both asthma(257) and cystic fibrosis(258).
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As a result of its role as a potential marker of oxidative stress 8-lsoprostane has
been extensively studied in relationship to smoking, both in healthy individuals and
in smoking related lung diseases.
Levels in plasma are increased in healthy smokers compared with healthy non
smokers(259). Acute cigarette smoke results in increased 8-lsoprostane levels in
exhaled breath condensate both 15 minutes and 5 hours after smoking(260). Lipid
peroxidation appears to relate to body mass index (BMI) in smokers, higher BMI
being associated with increased 8-lsoprostane. Furthermore, vitamin C
supplementation appears to reduce levels of this marker of lipid peroxidation in
smokers. This effect is most marked in subjects with a high BMI(261).
8-lsoprostane levels are elevated in the urine of patients with COPD when
compared with healthy smoking controls. Increased levels of 8-isoprostane are
also seen in the urine and EBC of patients with COPD(262, 263). Urine 8-
isoprostane correlates inversely with FEVi and PaC>2(264).
Several papers have studied 8-lsoprostane levels in subjects with COPD in
comparison to control subjects. Mean 8-lsoprostane levels are higher in the urine
of patients with COPD than healthy smoking controls(265). Furthermore oral
antioxidant supplementation results in a decrease in urine 8-isoprostane levels, this
decrease correlates inversely with changes in FEV-| during anti-oxidant
supplementation(266). 8-lsoprostane levels in exhaled breath condensate are
elevated in subjects with COPD when compared with healthy controls (260).
1.5.4 Hydrogen Peroxide in Exhaled Breath Condensate
Hydrogen peroxide, like 8-lsoprostane, is a product of oxidative stress. Superoxide
ion interacts with water to produce this molecule, a process catalysed by
superoxide dismutase. H2O2 is a stable product and can be measured in exhaled
breath condensate.
There is evidence of elevated hydrogen peroxide in a variety of respiratory
conditions other than COPD including community acquired pneumonia(267),
tuberculosis and sarcoidosis(268), systemic sc!erosis(269), mountain
sickness(270) and after inhalation of welding fumes(271).
Emelyanov et al demonstrated elevated levels of hydrogen peroxide in EBC of 70
subjects with asthma compared with 17 healthy controls. Furthermore hydrogen
peroxide levels appeared to correlate with FEV1 and bronchial hyperactivity(272).
Loukides et al were able to demonstrate a similar pattern in bronchiectasis with
elevated hydrogen peroxide levels in 37 patients compared with 25 age matched
controls and evidence of correlation between hydrogen peroxide levels and
measurement of airflow limitation(273).
Dekhuijzen et al demonstrated elevated H2O2 levels in 12 patients with stable
COPD compared with 10 healthy controls. The levels were further elevated during
exacerbations of COPD(90). Two conflicting trials have recently been published
regarding acute changes in hydrogen peroxide levels in EBC during exacerbations
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of COPD. Gerritsen et al demonstrated that treatment with high dose systemic
corticosteroid reduced levels of EBC hydrogen peroxide during the first 7 days of
acute exacerbations(274), whilst van Beurden et al did not demonstrate any
significant change in hydrogen peroxide levels in the first week after hospitalisation
due to lower respiratory tract infection in subjects with COPD(275). There is some
concern about the reproducibility of hydrogen peroxide measurement in EBC, both
COPD patients and healthy controls show diurnal variation and day to day variation
without change in symptoms, the coefficient of variation of hydrogen peroxide over
21 days in COPD patients is 45%(276).
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The effect of inhaled corticosteroid treatment on exhaled breath hydrogen peroxide
levels in COPD patients has also studied. Van Beurden et al demonstrated a
decrease in hydrogen peroxide levels in 41 patients with COPD after four weeks
treatment with both inhaled fluticasone propionate and beclomethasone
dipropionate with no significant difference between effects of the two drugs(277). In
contrast Ferreira et al did not demonstrate any significant change in levels of
exhaled H2O2 after two weeks treatment with inhaled beclomethasone in 20
subjects with COPD(278).
Several papers have examined the effect of antioxidant therapy on exhaled
hydrogen peroxide levels. Twelve months of 600mg od N-acetyl cysteine reduced
the levels of exhaled hydrogen peroxide at 9 months and 12 months completion in
22 patients with COPD(279). A subsequent study by De Benedett et al supported
this initial study with levels of exhaled hydrogen peroxide falling after 15, 30 and 60
days of 600mg bd N-acetyl cysteine(280).
Administration of nebulised N-acetyl cysteine to 8 healthy subjects resulted in a
significant drop in levels of exhaled hydrogen peroxide 30 minutes after treatment.
However 3 hours after therapy levels were higher than baseline(281). A further
study of the effect of nebulised N-acetyl cystiene in 19 subjects with COPD
demonstrated a transient rise in levels of exhaled H202 after 30 minutes with levels
returning to baseline 90 minutes after administration of therapy(282).
Hydrogen Peroxide, as with 8-lsoprostane, is a measurable product of oxidative
stress. In studies of small numbers of patients it has been shown to be elevated in
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patients with COPD, possibly rising during exacerbations. Antioxidant therapy may
reduce levels of Hydrogen Peroxide.
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1.5.5 Other Biomarkers of Oxidative Stress
Several other biomarkers have been identified as indicative of oxidative stress
when measured both locally and systemically. The results of some of these studies
are discussed below.
Assessment of the levels of xanthine oxidase (XO), an enzyme involved in the
production of superoxide anion and hydrogen peroxide, can be used as a marker in
response to oxidative stress. In BAL, levels of XO are higher in COPD compared
with healthy smokers and non-smokers(187, 283).
Nitric Oxide interacts with thiols in the epithelial lining fluid to produce nitrothiols,
which have been shown to be elevated in EBC of smokers and of patients with
COPD, when compared with healthy controls(284). Nitrotyrosine, a product of
nitrosative stress, is elevated in the EBC of patients with COPD and inversely
correlates to FE\A(97). It is also elevated in sputum leucocytes from COPD
patients (106). Inducible Nitric Oxide Synthase (iNOS) is increased in the alveolar
walls of patients with severe COPD(101).
As mentioned earlier, free radicals cause lipid peroxidation of phospholipids in cell
membranes(285). Measurement of products of lipid peroxidation is an indication of
the degree of oxidative stress. Pentane and isopentane, both products of lipid
peroxidation, are increased in EBC of smokers when compared with healthy
controls(286, 287). Elevated levels of ethane, which is generated through oxidative
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stress, are measureable in EBC of patients with COPD and correlates inversely
with FEVi(288). Products of oxidative stress such as malondialdehyde (MDA),
acrolein and n-hexanal are all elevated in the IS and EBC of patients with COPD
when compared with controls(289).
Peroxides and aldehydes are other products of lipid peroxidation. These products
react with thiobarburic acid(290). An increased level of thiobarburic acid reative
substances (TBARS) is seen in the blood and EBC of subjects with COPD(291,
292). The levels of TBARS are increased in sputum and inversely correlate with
FEV-|(210). Increased levels of MDA are present in plasma of subjects with COPD
compared with healthy controls(293). TBARS as a marker of oxidative stress
should be interpreted with caution(294). Previous studies have demonstrated
higher levels of TBARS in COPD compared with control subjects, which is most
marked after exercise(294, 295). Furthermore oral n-acetylcysteine has been
shown to attenuate the increase in TBARS seen after exercise(296). TBARS
results should be interpreted with caution. Previous work has demonstrated that
certain chemicals, including malondialaldehyde and amino acids, when present in
biological fluid can react with thiobarburic acid leading to a falsely high level of
TBARS(297, 298).
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The coenzyme Q-10 (CoQ-10) can be measured in plasma and exists in oxidised
and reduced forms. The ratio of oxidised CoQ-10 increases in response to
oxidative stress(299). Increased levels of oxidised CoQ-10 are present in COPD
versus healthy controls and are reduced with increasing inhaled oxygen(300).
Protein carbonyls are produced from amino acids as a result of oxidative
stress(301) and are elevated in plasma of health controls after acute cigarette
smoking (302).
As summarised above, there are several biomarkers of oxidative stress which may
potentially be utilised in the monitoring of a variety of disease processes, including
COPD. Application of these biomarkers to larger studies has not as yet been
performed.
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1.5.6 Previous work on Inhaled Corticosteroid and systemic
inflammation oxidative stress
Previous studies have demonstrated that inhaled corticosteroid (ICS) can have
some effect on markers of oxidative stress in COPD. Lower levels of nitrotyrosine
and inducible Nitric Oxide Synthase in induced sputum have been measured in
subjects with COPD after treatment with ICS(303). COPD patients taking ICS have
lower levels of exhaled ethane compared with COPD steroid naive patients(288).
In contrast markers of oxidative stress in the exhaled breath condensate of patients
with COPD do not appear to be altered. Steroid treatment has failed to
demonstrate any effect on levels of 8-lsoprostane, hydrogen peroxide, LTB-4,
PGE2, PGD2 and PGF 2a(263, 304-307).
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1.5.7 Induced Sputum
Induced Sputum (IS) is another non-invasive method of monitoring disease activity.
The principle of this technique is that inhalation of nebulised hypertonic saline aids
sputum expectoration. Induced sputum so obtained can subsequently be analysed
for differential cell types and markers of inflammation and oxidative stress.
This technique increases the proportion of subjects who are able to provide sputum
for analysis in clinical trials when compared with spontaneous sputum sampling.
Furthermore a higher percentage of the cells provided are viable when compared
with spontaneous sputum.
The utility of induced sputum as a marker of airways disease was first studied in
asthmatic patients, and showed increased eosinophils in asthmatic subjects
compared with controls(308). Reproducibility studies indicated that differential cell
counts and measurement of cytokines such as interleukin 8 and eosinophilic
caitonic protein were reliable in asthmatic subjects(309).
Similar studies have been carried out in subjects with COPD. Induced sputum
provides more viable cells when compared with spontaneous sputum without
affecting the differential cell count or measurement of inflammatory markers(310).
Measurement of differential cell counts and soluble markers of inflammation has
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been shown to be reproducible in patients with COPD(311). Along with evidence of
reproducibility, sputum induction is safe in subjects with airways disease even
when FEV-i is less than 40% predicted(312). Use of hypertonic saline delivered by
ultrasonic nebuliser is more successful in terms of production of viable sputum
when compared with normal saline. Saline delivered at incremental hypertonicity
from 3-5% also increases sputum cell viability(313). Induced sputum obtained by
this method can provide sufficient sample for analysis in up to 95% of patients with
COPD(314).
Previous studies have demonstrated that neutrophils and macrophages are
increased in the airways of subjects with COPD when compared with healthy
controls,(184, 315) and that the level of neutrophils are inversely proportional to the
FE\A(316). A direct relationship has been demonstrated between the proportion of
neutrophils in sputum and the degree of chronic bronchitic symptoms(317).
Neutrophils have also been associated with clinical progress. Higher levels of
neutrophils are associated with more rapid decline in FEV-i and disease
progression(318).
Recruitment of neutrophils into the airways therefore appears to be an important
factor in the development of COPD. The cytokines IL-8 and TNF-a are neutrophil
chemotaxtic agents(319), which are elevated in sputum supernatant in
COPD(320). Previous work has demonstrated a direct relationship between the
levels of IL-8 in sputum supernatant and the neutrophils cell count in both
BAL(190) and induced sputum(321, 322). Levels of IL-6 and IL-8 are higher when
87
measured in stable COPD compared to control subjects. Furthermore patients with
a high exacerbation frequency have higher levels of IL-8 and IL-6 when compared
to COPD patients with low exacerbation rates. IL-8 is also directly associated with
the rate of decline of FEV1 (318). Levels of IL-6 and IL-8 have also been shown to
be elevated in exacerbations of COPD compared to the stable state(323, 324).
An association has been demonstrated between IL-6 and IL-8 levels and
molecules implicated in oxidative stress. For example, activation of the NF-kB
pathway results in increased gene transcription of IL-6, TNF-a and IL-8.(190, 321,
325) Furthermore IL-8 also stimulates degranulation of neutrophils and production
of reactive oxygen species.(326, 327)
IL-1R. is another pro-inflammatory cytokine implicated in the development of
COPD(328). This cytokine stimulates increased production of both IL-8 and TNF-
a(329, 330). Furthermore increased production of IL-18. results in enhanced
neutrophil adhesion due to increased expression of the intracellular adhesion
molecules ICAM-1(331, 332). Elevated levels of ICAM-1 gene expression in
pulmonary fibroblasts are found in subjects with COPD (333).
The cytokine Vascular Endothelial Growth Factor (VEGF) has been shown to act
as a cell signalling agent in COPD. Increased levels of VEGF are thought to result
in endothelial cell proliferation (334) and reduced levels in endothelial cell
apoptosis(335). Recent work has suggested that VEGF has different roles in
different phenotypes of COPD. Subjects with emphysematous lungs had lower
than control VEGF concentrations in the lungs, which directly correlated with FEVi.
Subjects with predominately chronic bronchitis phenotype had higher levels of
VEGF in induced sputum than control subjects which inversely correlated with
FEVi.(336)
Several other induced sputum biomarkers have been studied in COPD.
Myeloperoxidase and neutrophil elastase are protease enzymes which are
elevated in patients with COPD(337). Matrix metalloproteinase 9 is also elevated in
induced sputum of patients with COPD. This protein is associated with extracellular
matrix remodelling associated with both COPD and asthma.(338)
In conclusion, induced sputum is a safe, reproducible method which allows non¬
invasive measurement of differential cells counts and a variety of proteins which
may aid our understanding of COPD.
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1.5.8 Biomarkers of Systemic Inflammation
COPD is not only associated with mortality and morbidity due to lung disease.
Relationships also exist between COPD and osteoporosis(339), low BMI(340),
skeletal muscle dysfunction(341) and cardiovascular disease(342). These
relationships may relate to increased systemic inflammation in COPD(343). There
is therefore increasing interest in biomarkers of systemic inflammation.
Several pro-inflammatory cytokines are elevated in plasma of subjects COPD
including IL-6 and IL-8(344). Plasma levels of TNFa are elevated in COPD
subjects with a low BMI compared with those with a normal BMI, and also healthy
controls.(345)
Acute phase proteins, such as Fibrinogen and C Reactive Protein (CRP) are
produced in the liver as a result of increased inflammation. A recent systematic
review of 14 original articles demonstrated that COPD is associated with elevated
levels of both CRP and Fibrinogen in serum when compared with healthy controls
independent of smoking history(346).
CRP appears to be closely associated with disease activity in COPD. Man et al
demonstrated a linear relationship between CRP and FEVi, smoking history, BMI
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and blood pressure in 4,803 subjects with mild to moderate COPD. Furthermore
elevated CRP levels were associated with increased all cause, cardiovascular and
cancer mortality in these subjects over a five year period. CRP did not appear to
relate to respiratory mortality(347). A similar pattern is seen in patients with severe
COPD, with elevated CRP levels associated with reduced exercise capacity and
health status(348).
In conclusion there is evidence of increased systemic inflammation in subjects with
COPD. Systemic inflammation appears to relate to disease activity and mortality in
this disease.
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1.6 Anti-Oxidant Treatment Review
Glutathione, as mentioned above, has a significant role in the pathogenesis of
COPD. Theoretically administration of glutathione in patients with COPD may be of
benefit. However this compound has poor bioavailability when given by mouth
limiting its use as a disease modifying agent. One of the major rate limiting factors
in the production of glutathione is the intracellular concentration of L-cysteine. This
chemical also has a low bioavailability. N-acetylcysteine (NAC) is an immediate
precursor of L-cysteine and in contrast is biochemically active in humans. The half
life of n-acetyl cysteine is 2.5 hours when administered orally(349) and 5.7 hours
when given intravenously(350).
In view of the bioavailability of N-acetyl cysteine and its role as a precursor of
glutathione the effect of NAC on oxidative stress and inflammation has been
extensively investigated.
In-vitro studies have examined the direct effect of NAC on reactive oxygen species
along with the role of NAC in modifying response to oxidative stress in a variety of
cell lines. Animal models have also researched the effect of oral administration of
NAC and subsequent reactions to oxidative stress.
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Studies in human populations have studied the effect of oral NAC on biomarkers of
oxidative stress and inflammation in healthy subjects and patients with COPD.
Several studies have been performed in clinical practice looking at the effect of oral
NAC on endpoints such as exacerbation rates, breathlessness scores and lung
function. These studies have included retrospective analysis of the effect of oral
NAC along with prospective interventional studies. Finally, several qualitative
database reviews exist of these interventional studies. A review of a selection of
these studies follows.
The main interventional role of NAC is to increase the level of glutathione in the
lungs. Studies have demonstrated this action in human alveolar A549 cells(351),
animal models(352) and in human populations, both healthy subjects(128) and
those with COPD(353). Along with increasing intracellular cysteine and
subsequently glutathione, there is evidence that n-acetyl cysteine may act as a
direct scavenger of free radicals. The free thiol group of this molecule can interact
with the electrophilic groups present in reactive oxygen species and protects
human bronchial fibroblasts against the toxic effects of tobacco smoke condensate
in vivo(354). When NAC interacts with ROS, NAC is metabolised to NAC
disulphide(355), (356). This process appears to have a mucolytic action in humans
when inhaled by breaking down the disulphide bridges of macroproteins(356). In a
cell free assay, NAC reduces hydrogen peroxide levels(351). In cellular models
NAC has been shown to penetrate red blood cell membranes more effectively than
glutathione and improves thiol levels in those cells(357).
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NAC also blocks lipopolysaccharide induced apoptosis and maintains glutathione
levels in cultured porcine endothelial cells(358). Human polymorphonuclear
leukocytes preincubated with NAC in high doses had attenuated response to
induced oxidative stress (359). Furthermore NAC inhibits IL-113. induced production
of ROS (8-lsoprostane) and monocyte chemotactic protein (MCP-1) and p38
mitogen-activated protein kinases in human airway smooth muscle cells(360).
As indicated above NF kB activation is a major factor in the gene expression of
pro-inflammatory cytokines after oxidative stress. Several studies have
demonstrated the effect of NAC on NF kB activation. Silica induced NF kB
cleavage in human bronchial epithelial cells is inhibited by NAC(361). In vitro NAC
treatment of fetal membranes results in a reduction in NF kB induced production of
PGF2a, IL-6, IL-8, TNFa and 8-lsoprostane after stimulation by
lipopolysaccharide(362). High dose in vitro NAC inhibits TNFa induced NF kB
activation of 'monocyte-like' U937 histiocytic lymphoma cells(361). NAC leads to
increased GSH levels both in absolute amounts and in relation to GSSG in
endothethial cells. Initial rises in GSH were associated with an increase in iNOS
gene stimulation. However at higher levels of GSH iNOS gene expression was
inhibited(363).
In an animal model, cigarette smoke inhalation induced increased airway
epithelium thickness and increased numbers of secretory cells in pathogen free
rats. Administration of oral NAC inhibited both of these effects. It should be noted
that NAC doses were very high in this study with an average daily dose of
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973mg/kg, compared with human studies of between 200mg and 1800mg per
patient per day(364). Administration of NAC after smoking cessation reduced the
time to recovery of secretory cell numbers(365). A further study examined the
protective effects of oral administration of NAC in rats prior to instillation of
elastase. This demonstrated that administration of NAC for two days attenuated
elastase induced emphysema. Assessment of induced emphysema was by
measurement of collagen content, alveolar surface area and airflow(366). Oral
administration of NAC to mice did not affect the levels of NAC measured in the lung
indicating poor bioavailability. However tobacco smoke induced glutathione
depletion in the lungs of mice was prevented by administration of NAC as were
levels of hydrogen peroxide production(354).
Two doses of NAC are commonly studied in humans, NAC 600mg three times a
day (high dose), and 600mg once a day (low dose). The short term effect of NAC
on glutathione levels has previously been studied. Administration of low dose
(600mg od) of NAC has been shown to result in increased levels of glutathione in
plasma and bronchial lavage of healthy subjects after 5 days administration(128).
Plasma levels of glutathione are not increased in patients with COPD after low
dose NAC. However high dose (600mg tds) has been shown to increase plasma
glutathione in COPD. Neither dosage of NAC has any influence on BAL levels of
glutathione in patients with COPD(353).
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8 weeks of oral NAC (200mg tds) in smokers did not affect cell numbers in BAL
however the proportion of lymphocytes increased to levels comparable to non
smoking controls. The phagocytic capacity of Alveolar Macrophages improved after
administration of NAC in 5 of the 11 smokers studied and the ability of AMs to
respond to oxidative stress improved(367).
Long term treatment with oral NAC (200mg tds) in healthy smokers resulted in
reduced levels of lactoferrin (LF), anti-chymotrpysin and chemotatic activity of
neutrophils in BAL. In plasma from the same individuals, concentrations of
myeloperoxidase and elastase were reduced(368). Low dose NAC (600mg od) in
patients with COPD over a twelve month period resulted in reduced levels of
hydrogen peroxide in exhaled breath condensate after 9 and 12 months of
treatment, but not after 6 months, versus placebo. This medication did not have
any impact on levels of TBARS in plasma(369).
Gerrits et al performed a retrospective analysis studying the impact of the
introduction of NAC at first hospital presentation of exacerbation of COPD on
readmission with exacerbations in the first year of treatment. This demonstrated
that NAC appeared to reduce the risk of readmission by 33% after adjustment for
disease severity. This reduction appeared to be dose related. Although small
numbers received more than 200mg od of NAC (19 of the 97 patients studied)
relative risk for readmission was 0.55 compared with the group who did not receive
NAC (370).
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In contrast, acute administration of low dose NAC (600mg od) along with
conventional therapy at the time of presentation with an exacerbation of COPD did
not affect recovery from exacerbation in terms of length of stay, improvement in
lung function, breathlessness scores or oxygen saturations(371).
Although several interventional studies with NAC in patients with either COPD or
chronic bronchitis have been performed, individual results from these trials have
been inconclusive. Most recently the Bronchus trial, a large multicentre, double
blind placebo control trial of 600mg od of NAC over 3 years versus placebo, was
performed in 523 patients. No affect was noted on exacerbation rates or rate of
decline in FEV-|. Sub group analysis of steroid naive patients demonstrated a
relative risk reduction for exacerbation of 0.79, however no effect was
demonstrated on spirometry in this group (372).
A Cochrane database review of randomised, double blind, placebo controlled
studies with a variety of oral mucolytics, including n acetyl cysteine, was
performed. Trials included in the review were to be of at least two months therapy
in subjects with chronic bronchitis (21 papers) or COPD (2 papers). This
demonstrated a reduction in exacerbations of COPD compared with placebo. Six
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trial subjects required treatment with an oral mucolytic to prevent one exacerbation
in the study period (range 2 months to 24 months) compared with placebo(373).
A quantitative systematic literature review of the use of NAC specifically has also
been carried out. This review identified 11 randomised placebo controlled trials of
NAC, daily doses between 400mg and 600mg, in treatment of chronic bronchitis
over periods between 12 and 24 months. Nine of the 11 papers used exacerbation
rate as an end point. Overall a reduction in exacerbations was identified in NAC
versus placebo (30-60% vs 40-81%), with 5.8 patients requiring treatment for trial
duration to prevent one exacerbation. An improvement in symptoms of
breathlessness was also noted in the 5 trials which used this as an endpoint,
61.4% demonstrating an improvement in SOB score in NAC versus 34.6% in
placebo(374).
In conclusion oral NAC appears to play a role in the management of COPD. This is
most likely due to increasing intracellular reduced glutathione although the
chemical itself may also have direct anti-oxidant effect along with mucolytic
properties. Administration of NAC has demonstrated evidence of reduced oxidative
stress along with attenuated response to various agents related to oxidative stress.
However the response in clinical studies of oral NAC has been variable.
This variable response demonstrated in clinical studies may relate to the limited
bioavailability of N-acetyl-cysteine. As mentioned above, low dose NAC had no
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effect on glutathione in BAL. NAC is acidic, thus limiting its usefulness as inhaled
therapy due to bronchospasm and febrile reactions. This has led to the
development of Nacystelyn (NAL), the lysine salt of N-acetylcysteine
(C11H23N3O5S). Nacystelyn has a neutral pH, and is well tolerated when given by
inhalers in clinical studies in healthy adult smokers at doses up to 80 mg bd over
4.5 days(375, 376). Inhaled N-acetylcysteine or nacystelyn therapy may more
effectively improve antioxidant capacity in the lungs compared with oral treatment.
When the efficacy of NAL was studied in a cell free assay both NAC and NAL were
shown to inhibit hydrogen peroxide, but not superoxide, action comparable to
glutathione. Cultured A549 cells incubated with NAC results in an increase in levels
of total glutathione. This increase is significantly greater (two fold) after culture with
NAL. NAC and NAL have both been shown to reduce hydrogen peroxide release
from PMN cells of smokers with COPD by around 45%. Activation of phagocytic
cells by serum induced zymosan and sudsequent ROS generation as measured by
luminal enhanced chemiluminescence is inhibited by 50% by NAL at lower
concentrations than either NAC or captopril(377). The pH of NAC is 3.6 and of NAL
6.4(378).
When nacystelyn comes into contact with mucus fluid it dissociates into the two
base compounds, lysine and N-acetylcysteine. These compounds are then either
incorporated into the host cells or excreted without accumulation or retention(379-
382). Administration of NAL using a mono dose inhaler and gelatine capsules has
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an in-vivo lung deposition of 30% nominal dose in healthy subjects(383) and 23.5%
in adults with CF(384).
Previous studies have been performed examining the role of Nacystelyn in human
lung disease. Subjects with cystic fibrosis were administered NAL in a phase II,
multicentre, clinical trial(385). This demonstrated a dose dependent reduction in
the primary study rheological endpoint, log G*, a measure of sputum viscosity, at
all time points. This improvement in sputum rheology appeared to correlate with
clinical improvement as reflected in a reduction in the number of respiratory
infections, the increase in time to first respiratory infection, and a reduction in the
number of days of absence from work or school.
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1.7 Conclusion
Chronic Obstructive Pulmonary Disease is a common condition which is increasing
in prevalence and has a major impact in terms of morbidity and mortality on
individuals and society.
COPD is strongly, but not exclusively, associated with cigarette smoking. Several
other factors, including diet, socioeconomic status and air pollution affect the
development of this disease. There is evidence that COPD pathogenesis is
associated with increased levels of oxidative stress in the lungs, leading to
inflammation and tissue damage. Treatment with anti-oxidant therapy may play a
role in the management of COPD.
Several methods of monitoring non-invasive biomarkers of inflammation and
oxidative stress have been identified which may be of use in furthering our
understanding of the pathogenesis of this disease.
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1.8 Hypothesis and Aims
The hypotheses of this thesis are as follows:
• Oxidative stress and subsequent airways inflammation are major factors in
the pathogenesis of COPD;
• Non invasive biomarkers of oxidative stress and airways inflammation can
be measured in the exhaled breath condensate and induced sputum of
subjects with COPD and controls;
• Measurement of these biomarkers is reproducible during three visits in a
four week period;
• The level of oxidative stress and inflammation measured with these
biomarkers relates to severity of disease;
• Treatment with inhaled anti-oxidant reduces the level of oxidative stress and
inflammation resulting in reduced levels of biomarkers and improved health
status.
The aims ofthis thesis were as follows:
• Identify which biomarkers can be measured in induced sputum and exhaled
breath condensate;
• Assess the reproducibility of these biomarkers;
• Relate levels of inflammation and oxidative stress to severity of COPD;





Chapter 2 Materials and Methods
The study protocols, method of statistical analysis and ethical approval for each
individual study are discussed at the start of the appropriate chapter.
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2.1 Standard Operating Procedures for sample collection
2.11 Exhaled Breath Condensate Collection
Exhaled Breath Condensate was collected using a Jaeger EcoScreen device. The
mouthpiece, collection port, collection tube, saliva trap and breathing valve were
sterilised between each individual use.
Exhaled carbon monoxide was assessed immediately prior to the test to exclude
acute smoking. Subjects were asked to rinse their mouth with water prior to the test
and to wear nose clips. They were then asked to perform normal tidal breathing for
10 minutes.
If there was a build up of saliva during collection, subjects were asked to stop the
test and remove this. Subjects were allowed to stop collection during the test for up
to one minute.
Once collection was completed samples were stored on ice and placed in a -80-
°C freezer within 30 minutes of collection. Samples were stored as 0.25ml aliquots.
(Appendix 2.1)
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2.1.2 Induced Sputum Collection
Induced sputum was obtained from subjects after baseline FEV-i post
bronchodilator was measured. Those subjects whose FEVt was less than 1 litre
were reviewed by a member of medical staff prior to continuing with the procedure.
Subjects were asked to rinse their mouth and expectorate any spontaneous
sputum which was then discarded. Hypertonic saline (5mls of 3% saline) was then
inhaled via a Sonix 2000 nebuliser. After nebulisation subjects were asked to clear
their nasal passages, rinse their mouth then attempt expectoration. Sputum
obtained was inspected macroscopically and, if felt to be suitable, the procedure
stopped.
If no suitable sputum was obtained, spirometry was repeated. If there was a less
than 10% fall in FEVi from baseline, 4% nebulised saline was given. If there was a
fall between 10% and 20% in FEN^ from baseline, then hypertonic saline at the
same concentration (3%) was administered. If a fall greater than 20% from
baseline FEVi was demonstrated the procedure was abandoned and nebulised
bronchodilator administered.
If no suitable sputum was obtained with 4% saline, the procedure was repeated
with 5% saline.
In all subjects at the end of the procedure FEVi was checked. Nebulised
bronchodilator was given if a greater than 10% fall from baseline FEVi was noted,
and subjects remained in the unit until FEV-i had returned to >90% baseline.
(Appendix 2.2)
2.1.3 Induced Sputum Processing
All sputum samples were processed within 2 hours of production by the method of
Popov et al(386). In summary, sputum plugs were separated from contaminating
saliva by macroscopic examination, and the weight measured.
A freshly prepared solution of 0.1% dithiothreitol (DTT: from a stock 1% in sterile
distilled water) in phosphate buffered saline (PBS), which was 4 times the weight of
the selected sputum was added, vortexed for 30 seconds and mixed on ice for 15
minutes to homogenise the mucus. A volume of PBS equivalent to the DTT
volume was then added, and the sample filtered through 48 pm nylon gauze to
remove mucus and debris, but not the cells.
The cells were centrifuged at 1200 rpm for 10 minutes at 4°C. The supernatant
was decanted, centrifuged at 2500 rpm for 8 minutes at 4°C, and stored in aliquots
at -70°C. The cells were washed with PBS, and centrifuged at 1000 rpm for 8
minutes at 4°C. The total cell count, viability (exclusion of trypan blue), and
percentage squamous cell contamination was assessed using a Neubauer
haemocytometer. Cytospins were made in a Shandon Cytospin 3 by centrifugation
at 300rpm for 3 minutes. (Appendix 2.3)
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2.1.4 Blood and Urine Sampling
Blood samples were taken after exhaled breath condensate collection.
Venesection was performed using a Vacutainer system. Plasma was collected in a
9ml Lithium Heparin and a 5ml EDTA tube whilst 5ml of serum was obtained in an
anti-coagulant free tube.
Once plasma was collected it was centrifuged then aliquoted. Plasma was stored
at -80°C until analysis was performed. Serum samples were allowed to clot at room
temperature for twenty minutes then centrifuged, aliquoted and stored at -80°C.
Urine was collected in a Sterilin tube and stored at -80°C. (Appendix 2.4)
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2.1.5 Spirometric Assessment
Spirometry was measured using a Vitalograph spirometer which was calibrated
prior to use.
FEVi and FVC were measured first. Subjects were asked to take a full inspiration
then exhaled as hard, as fast and as long as possible into the Spirometer
mouthpiece. At least three measurements were calculated. A satisfactory result
was obtained if there was less than 5% variation between the best test and two
other results.
Slow Vital Capacity was also calculated. Subjects were asked to complete a full,
steady, non-forced exhalation after a full inspiration. The higher of the two vital
capacities measured, Forced Vital Capacity or Slow Vital Capacity was taken as
the accurate measure.
Reversibility to bronchodilator was then assessed. Patients were given 2.5mg
nebulised salbutamol. Lung function was repeated between 15 and 30 minutes
after nebulisation. (Appendix 2.5)
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2.2 Protocols for Sample Measurement
2.2.1 Exhaled Breath Condensate Assays
2.2.1.1 8-lsoprostane and Leukotriene B4 measurement
8-lsoprostane was measured in exhaled breath condensate using a commercially
available enzyme immunoassay kit from Cayman Chemicals, AnnArbour, US . In
brief, the sample or standard was added to a coated well along with anti-serum
specific for 8-lsoprostane and 8-lsoprostane linked to tracer. The plate was then
incubated at room temperature overnight. Free 8-isoprostane and 8-lsoprostane
linked to tracer completively bind to the anti-serum. The anti-serum binds to the
mouse monoclonal antibody which is coated on the well.
The following day, after 18 hours incubation, wells were washed and Ellman's
reagent added to the wells. This reagent reacts with the tracer producing a yellow
colour. The intensity of this colour is measured spectrophotometrically at a
wavelength of between 405 and 420nm. The intensity of colour is proportional to
the amount of 8-lsoprostane linked to tracer and therefore inversely proportional to
the amount of free 8-lsoprostane.
Standard curves were plotted and concentration of 8-lsoprostane in samples
calculated.
Leukotriene B4 was measured using a similar kit also available from Cayman
Chemicals. (Appendix 2.6)
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2.2.1.2 Hydrogen Peroxide Assay
Hydrogen peroxide was measured spectrophotometrically using the method
devised by Gallati and Pracht. In brief horseradish peroxidase was added to
tetramethylbenzidine dissolved in citrate buffer at a pH of 3.8. 110pL of this
solution was added to 100pL of sample or standard in a sterile 96 well plate. These
two solutions react producing a blue colour. The concentration of hydrogen
peroxide was related to the colour intensity. The reaction was terminated using
sulphuric acid after 20 minutes resulting in the fluid in the wells changing to yellow.
The intensity of this colour was measured spectrophotometrically at 450nm.
Standard curves were then plotted and comcentration of hydrogen peroxide in
samples calculated. (Appendix 2.7)
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2.2.1.3 Nitrotyrosine Assay
Nitrotyrosine levels in exhaled breath condensate was calculated using a
commercially available kit from Assay Designs Chemicals.
In brief, sample or standards were added to precoated wells. Wells were incubated
for one hour then washed and nitrotyrosine antibody added and incubated for one
hour. Plates were then washed and streptavidin peroxidase added. After a further
hour plates, were washed and TMB substrate added to the wells and incubated for
30 minutes in darkness. The reaction was stopped by sulphuric acid and intensity
of yellow colour measured spectrophotometrically at 450nm.
Standard curves were plotted and sample concentration calculated. (Appendix 2.8)
2.2.2 Induced Sputum Assays
2.2.2.1 Cytokine measurement in Induced Sputum Supernatant
The cytokines IL-1I2>, IL-6, IL-8, TNF-a and VEGF were all measured using a
commercially available kit from R+D Chemicals. Kits were supplied with capture
antibody and detection antibody specific for the cytokine to be measured.
To summarise, sterile 96 well plates were incubated overnight with capture
antibody. The wells were then washed and blocked for one hour. Samples and
standard were then added to the wells and incubated for two hours. The
appropriate cytokine would bind to the capture antibody. Plates were then washed
and detection antibody added to bind to this complex. Plates were incubated for a
further two hours. Streptavirdin horseradish peroxidase, which binds to detection
antibody, was then added to the sample, incubated and washed. TMB was added
to the wells producing a reaction which was stopped using sulphuric acid after 30
minutes.
The sample solution is yellow in colour, the intensity of yellow being dependant on
the amount of streptavirdin-HRP in the wells which in turn reflects the
concentration of cytokine in the well. This was measured spectrophotometrically at
450nm, standard curve plotted and sample concentration calculated. (Appendix
2.9)
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2.2.3 Blood Sampling Assays
2.2.3.1 C-Reactive Protein Measurement
High sensitivity C-Reactive Protein was measured using a commercially available
ELISA kit from ImmunDiagnostiks.
In brief, CRP standard or samples were added to wells precoated with polyclonal
capture antibodies to CRP and incubated for one hour. Plates were then washed
and CRP antibody, labeled with peroxidase, added and incubated. Plates were
then washed again and TMB substrate added which reacts with peroxidase. This
reaction was stopped with sulphuric acid and the intensity of yellow colour
measured spectrophotometrically at 450nm. A standard curve was then plotted and
sample concentration calculated. (Appendix 2.10)
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2.2.3.2 Thiobarbituric Acid Reactive Substance Measurement
Thiobarbituric Acid Reactive Substances were measured in plasma based on the
method of Conti et al(387).
In brief, TCA was added to plasma then incubated at 95°C for 30 minutes.
Supernatant was removed and Thiobarbitutric Acid added to the samples.
Tetramethoxypropane was used as a standard. Sodium Dodecyl Sulphate and
acetic acid were also added to this solution. Samples solutions were incubated for
60 minutes at 95°C. TBA reacts with aldehydes and lipid perxoxides, known as
Thiobarbituric Acid Reactive Substances (TBARS), producing a pink colour. The
intensity of this colour is dependant on the concentration of TBARS. N-butanol was
added to the solution, centrifuged and the organic layer removed. The intensity of
colour was read flurometrically at 515nm, standard curve plotted and sample
concentration calculated. (Appendix 2.11)
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Reproducibility of Biomarkers of
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Measured in Exhaled Breath Condensate




Reproducibility of Biomarkers of Inflammation and Oxidative
Stress Measured in Exhaled Breath Condensate and Induced
Sputum in Subjects with COPD and Controls
3.1 Introduction
The pathogenesis of Chronic Obstructive Pulmonary Disease is not yet fully
understood. As mentioned in Chapter 1, oxidative stress leading to pulmonary and
systemic inflammation may play a significant role in the development of this
disease. Non-invasive measurement of molecules which relate to this process may
aid our understanding of the disease. Several published papers have
demonstrated significant differences in cross sectional studies when the levels of a
variety of biomarkers in both exhaled breath condensate and induced sputum of
subjects with COPD are compared with healthy controls. These data are discussed
in further detail in Chapter 1.
COPD is a heterogeneous disease with a large variation in the level of disability
and in the rate of progression of the disease process. Longitudinal monitoring of
biomarkers of oxidative stress and inflammation may help identify subjects with
aggressive disease who may benefit from intensive treatment. Furthermore,
measurement of biomarkers may be of use in assessing response to treatment in
interventional studies.
117
Interpretation of data from longitudinal or interventional studies is dependant on the
reliability of the biomarkers measured. There is little information in the published
literature on the reproducibility of non-invasive biomarkers. This chapter describes
two methodology studies to assess the variability of biomarkers in induced sputum
and exhaled breath condensate.
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3.2 Reproducibility of Differential Cell Counts, Total Cell Counts
and Inflammatory Cytokines in Induced Sputum in subjects
with COPD and controls.
3.2.1.1 Study Population
Subjects were recruited from local COPD clinics, GP practices and by local
advertisment. Subjects were asked to give written informed consent to the trial
prior to participation.
COPD subjects were required to have a documented diagnosis of COPD, had to
be over 40 years of age and be either a current or ex-smoker (defined as no
tobacco consumption for 6 months) with a minimum of 10 pack years tobacco
exposure. One pack year was defined as the equivalent of 20 cigarettes per day for
one year. A clinical diagnosis of COPD had to be supported by spirometric
evidence of airflow limitation, with post bronchodilator FEVi less than 80%
predicted and with FEVt/FVC ratio less than 70%. Subjects with significant
improvement after bronchodilator, defined as greater than 12% improvement in
FEVi, or complete reversal of airflow limitation were excluded from the trial.
Study visits were only performed on clinically stable patients, defined as no
exacerbation in the last month or no exacerbation requiring hospital admission in
the last 2 months. Subjects who had experienced more than two exacerbations of
COPD in the last 6 months were excluded from the trial. An exacerbation was
defined as a change in baseline dyspnoea, cough and / or sputum production
sufficient to merit a change in management. (Appendix 3.1.1-3). Symptoms of
cough, sputum production and wheeze were scored as either zero (no symptoms),
1 (symptoms present but not constant) or 2 (symptoms present throughout day)
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Control subjects were recruited from local GP practices and by local advertising.
Subjects were over the age of 40. Current and Ex-Smokers were required to have
a smoking history of at least 10 pack years. Ex-Smokers must have abstained for
at least 6 months. Non-smokers had to be either lifelong non-smokers or have a
smoking history of less than 1 pack year. All subjects were to be free from any
clinically significant documented disease which the study doctor felt may either
compromise the subject's safety during the trial or interfere with the study results.
Controls were required to have normal lung volumes on spirometry, defined as
both FEVi and FVC greater than 80 percent predicted with no significant
reversibility and FEV^FVC ratio greater than 70%. (Appendix 3.1)
A number of exclusion criteria were used in this study and applied to both COPD
patients and healthy controls. These included current or previous history of atopy,
sinusitis, respiratory disease other than COPD, unexplained respiratory symptoms,
any recent upper or lower respiratory tract infection and non-respiratory
inflammatory disease. (Appendix 3.1) Subjects with significant symptoms of peptic
ulcer disease or gastro-oesophageal reflux were excluded from the trial.
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3.2.1.2 Study Visits
Prior to study attendance, subjects were asked to abstain from smoking and
caffeine for a minimum of 8 hours. Inhaled corticosteroids and bronchodilators
were withheld on the morning of clinic attendance. Trial participation was deferred
if subjects had received any antibiotics within the last 4 weeks or oral
corticosteroids within the last 8 weeks. Subjects who reported significant variation
in their respiratory symptoms over the past 4 weeks had trial entry deferred.
Subjects who demonstrated significant between-visit variation in post
bronchodilator FEV-i, defined as out with the range of 90-115% of initial FEVi, were
excluded from the trial.
On the day of the study, after informed consent to participate in the trial had been
obtained, clinical history was reviewed to ensure suitability for trial participation.
Past medical history, drug history, occupational history and family history was
recorded. Smoking history was noted including the time of the last cigarette.
Height, weight, body mass index, blood pressure, oxygen saturation and pulse
were measured. Exhaled carbon monoxide level was measured and exhaled
breath condensate collection was undertaken if there was no evidence of acute
cigarette smoke exposure.
Lung spirometry was then measured using a standardised procedure (Appendix
2.5). Induced sputum was then obtained, analysed and supernatant stored as per
the study protocol (Appendix 2.2,2.3). Sputum specimens were frozen at -80 °C
and analyzed in batches using standard assay protocols (Appendix 2.9).
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After the initial study visit, subjects were asked to return in a further 14 (±3) days at
the same time of day, within one hour, of previous clinic attendance. On the second
study visit, a brief medical review was performed to ensure no significant change in
respiratory symptoms over the last two weeks and spirometry was repeated to
ensure post bronchodiiator FEVi remained within 90-115% of the previous
measurement. Induced sputum samples were then collected. A further study visit
was then arranged 14 (±3) days from visit 2. The same protocol was followed at
visit 3.
3.2.1.3 Statistical Analysis
Analysis between groups was performed using Tukey One Way Analysis of
Variance (ANOVA). Contingency tables were analyzed using Fisher's Exact Test.
Intra subject variability was assessed using the concordance correlation co¬
efficient. This coefficient quantifies the precision and accuracy of paired
observations. One set of measurements are plotted on the y axis and the other on
the x axis. The concordance correlation coefficient relates how close the plotted
line is to 45°. A value of 1.00 is equivalent to a group of paired observations being
exactly the same(388). Intra subject variability was plotted using a Bland Altman
Plot of mean level between measurements versus difference between
measurements where 95% of plots should lie within the 95% confidence intervals
(±1.96 xSD).
3.2.1.4 Ethics Approval
Ethical approval for this study was obtained from the ethics committee of Lothian
Acute Hospitals NHS Trust. Prior to trial participation, subjects were issued with
written information regarding the study and given a minimum of 24 hours to digest
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Study Details and Demographics
Study Details
A total of 57 subjects were recruited for the reproducibility study. Twenty seven of
the subjects had COPD and 30 were controls. Twelve of the COPD subjects were
current smokers. Six of the controls were current smokers, 12 ex-smokers and 12
non-smokers.
Forty seven of the 57 patients completed the trial. Twenty one subjects with COPD,
eight of whom were current smokers, and 26 control subjects, 4 smokers, 10 ex-
smokers and 12 non-smokers completed. Eight subjects withdrew as a result of
respiratory illness, one through non-respiratory illness and one withdrawal was for
social reasons.
The demographics of the trial population are discussed below. These data describe
the subjects who completed the trial.
3.2.2.2 Demographics
The mean age of subjects who were lifelong non-smokers without respiratory
disease was lower (52.1 years ± 7.8) than smokers with COPD (69.9 years ± 5.6,
p<0.001), ex-smokers with COPD (72.2 years ± 7.8, p<0.001) and control ex-
smokers (63.2 years ± 9.4, p<0.05). No other significant differences in mean ages
were noted between the groups, table 3.1.
There was no significant difference in smoking pack years between the four groups
with a smoking history. There was no significant variation in the gender, body mass
index or level of co-morbidity between the 5 study groups, table 3.1.
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Smokers and ex-smokers with COPD had significantly lower FEV-i, FVC and
FEVi/FVC ratio compared with the three control groups. There was no significant
difference in spirometric parameters between the two COPD groups or between
the three healthy control groups, table 3.2.
There was no significant variation in terms of therapy, health status, exacerbation













Number 8 13 4 10 12
Age
meanistdev
69.9±5.6 72.2±7.8 61.3±13.9 63.2±9.4 52.1±7.8
Sex (m/f) 3/5 10/3 3/1 6/4 5/7
BMI
Meanistdev
24.2±2.8 27.2±6.6 26.2±3.8 26.7±4.3 24.7±2.8
Pack Years
Meantstdev
48.5±27 48.6±24 40±18 24.7±9 0.4±1.4
IHD 0 3 1 0 0
HBP 1 2 0 3 0
Diabetes 0 1 0 0 0
Table 3.1 Patient Demographics
BMI= Body mass index, FFM= Fat Free Mass, IHD= Ischaemic Heart Disease,













FEVi Post BD (L)
Mean ± stdev
1.2 ±0.3 1.2 ±0.4 2.6 ± 0.3 3.0 ±0.6 3.2 ± 0.6
FVC Post BD (L)
Mean ± stdev
2.3 ± 0.9 2.5 ± 0.8 3.7 ± 0.3 4.0 ±0.8 4.1 ± 0.9
FEVi/FVC Ratio
Mean ± stdev




52.7 ± 12 46.5 ± 15 89 ± 6 110 ± 12 106 ± 12
%change post BD
Mean ± stdev
7 ± 6 11 ± 11 4 ± 6 3 ± 3 1± 3
Vol.Change postBD
Mean ± stdev
99±87 111 ±101 95±152 84±107 36±89
Table 3.2 Spirometry Results per Study Group
FEV^Forced Expiratory Volume in 1 sec, FVC=Forced Vital Capacity,
BD=bronchodilator
127
Group COPD Smoker COPD Ex Smoker
Number 8 13
MRC Chronic Bronchitis
Mean ± St Dev
0.9 ± 0.4 0.5 ± 0.5
MRC Dyspnoea
Mean ± St Dev
3.0 ± 1.1 3.4 ±1.0
Cough (0-2)
Mean ± St Dev
1.4 ±0.7 1.1 ± 1.0
Sputum (0-2)
Mean ± St Dev
1.9 ± 0.4 1.2 ±0.8
Wheeze (0-2)
Mean ± St Dev
1.1 ± 0.8 0.7 ± 0.6
Exac Freq
Mean ± St Dev
1.8 ± 1.3 1.4 ± 1.5









Mean ± St Dev
68.7 ±17.8 60.4±21.9
SGRQ Activity
Mean ± St Dev
64.5±21.4 77.3±18.5
SGRQ Impact
Mean ± St Dev
36.0±22.0 40.3 ± 16.6
SGRQ Total
Mean ± St Dev
50.4±18.6 55.1±15.5















Table 3.5 COPD Treatment in Current and Ex Smoking Groups
SABA= short acting R> agonist, LABA= long acting R> agonist, SAAC= short acting
anti-cholinergic, LAAC= long acting anti-cholinergic, ICS= Inhaled Corticosteroid
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3.2.3 Reproducibility of Biomarkers in Induced Sputum
3.2.3.1 Sputum Production in Trial Completers
Forty seven subjects completed the trial. Twenty three of these subjects (49%)
were able to provide sufficient sputum for analysis on all three visits. A further six
patients (13%) were able to provide sputum on two of the three study visits. Three
subjects (6%) provided sputum on one of the visits whilst 15 (32%) were unable to
provide sputum on any of the study visits. Table 3.6
There was a significant difference in the ability to provide sufficient sputum for
analysis between subjects with COPD and non smoking controls. Eighteen of the
21 (86%) subjects with COPD were able to provide sputum for analysis on all three
study visits whilst the other three subjects (14%) provided sputum on two of the
three visits.
In contrast only 2 of the 10 ex-smokers (20%) and none of the 13 lifelong non-
smokers provided sputum on all three study visits. Three ex-smokers (30%)
provided sputum on one or two of the study visits and five (50%) failed to provide
sputum on all three visits. Three non-smokers (23%) provided one or two sputum
samples, 10 non-smokers (77%) were unable to produce induced sputum during
the trial. The three control smokers who completed the trial were all able to provide
sputum on the three study visits. Statistical analysis confirms that subjects with
COPD were more likely to provide sputum on at least two visits when compared
with ex or non smoking controls (p<0.001). Table 3.6. Reproducibility analysis was













No Sputum 0 0 0 5 10
Sputum on 1 visit 0 0 0 1 2
Sputum on 2 visits 2 1 0 2 1
Sputum on 3 visits 6 12 3 2 0
Table 3.6 Sputum Production during trial per study group
Subjects with COPD were more likely to produce sputum on at least two visits (21
of 21) during the trial when compared with control non and ex-smokers (5 of 23),
p<0.001.
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3.2.3.2 Reproducibility of Differential Cell Counts
3.2.3.2.1 Reproducibility of Total Cell Counts
Total cell counts in induced sputum did not vary significantly between the five
groups. The reproducibility of total cell count in study subjects is expressed as the
concordance correlation. Overall the concordance of total cell counts in induced
sputum between visits was 0.65, p=0.0002 (95% confidence interval 0.35 to 0.85).
Figure 3.1
3.2.3.2.2 Reproducibility of Differential Neutrophil Counts
Subjects with COPD had a higher mean percentage neutrophils in the sputum
when compared with controls, 88.9% ± 11.2% versus 76.4% ± 13.3%, p=0.026.
The overall concordance correlation coefficient of differential neutrophil cell counts
was 0.26, p=0.21 (95% confidence interval -0.14 to 0.60). Separate analysis of the
COPD population demonstrated improved reproducibility in this group, with a
concordance correlation of 0.45 although this did not reach statistical significance,
p=0.09 (95% confidence interval 0 to 0.75). Figure 3.2
3.2.3.2.3 Reproducibility of Differential Macrophage Counts
Subjects with COPD had a significantly lower mean percentage of macrophages in
sputum (7.9%±6.9%) compared with control subjects (22.0%±12.7%), p=0.0015.
The concordance correlation coefficient for this group was 0.58, p=0.0007(95%
confidence interval 0.29 to 0.78). Figure 3.3
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3.2.3.2.4 Reproducibility of Differential Eosinophil Counts
There was no significant difference between the percentage of eosinophils in the
differential counts in the COPD population compared with healthy controls.
Furthermore serial differential counts did not correlate well with a concordance
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Figure 3.1 Bland Altman Plot Total Cell Counts
Dot plots represent the mean of study visits for each individual subject in the x axis against
the difference between study visits in the y axis. The dashed line represents the bias
between visits (-0.4 cells per ml) and the solid lines the limit of agreement of the test, -8.4
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Figure 3.2 Bland Altman Plot Differential Neutrophil Cell Counts
Dot plots represent the mean of study visits for each individual subject in the x axis against the
difference between study visits in the y axis. The dashed line represents the bias between visits
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Figure 3.3 Bland Altman Plot Differential Macrophage Cell Counts
Dot plots represent the mean of study visits for each individual subject in the x axis against
the difference between study visits in the y axis. The dashed line represents the bias
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Figure 3.4 Bland Altman Plot Differential Eosinophil Cell Counts
Dot plots represent the mean of study visits for each individual subject in the x axis against
the difference between study visits in the y axis. The dashed line represents the bias
between visits (0% eosinophils) and the solid lines the limit of agreement of the test, -3.5 to
3.5 % eosinphils.
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3.2.3.2 Reproducibility of Cytokines in Induced Sputum
Supernatant
3.2.3.3.1 Reproducibility of IL-1 ft
Levels of IL-1 ft were measured in the sputum supernatant of the 29 subjects who
provided induced sputum. Only 19 of these samples were within the detection limit
of the assay, with 9 samples being lower than the limit of detection of the assay
(4pg/ml). The level of IL-1 ft in the one remaining sample was above the limit of
detection of the assay (500pg/ml), insufficient sputum supernatant was available to
repeat this assay after diluting the sample.
No significant differences were noted in the levels of IL-1 ft measured in induced
sputum between the COPD and control groups. Concordance correlation
coefficient between study visits was 0.06, p=0.08 (95% confidence interval -0.3 to
0.4). Figure 3.5
3.2.3.3.2 Reproducibility of IL-6
Levels of the cytokine IL-6 were measured between the limits of detection of the
assay in 22 of the 29 samples obtained, with 7 samples being below the limit of
detection. There was no significant difference in the levels of IL-6 measured
between the COPD and control groups.
Concordance correlation coefficient between study visits was 0.24 , p=0.30 (95%
confidence interval -0.22 to 0.62). Figure 3.6
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3.2.3.3.3 Reproducibility of IL-8
IL-8 was detected in 25 of the 29 sputum samples obtained on visit 1. Four
samples were greater than the limit of detection for the assay (>1000pg/ml). There
was no significant difference in levels of IL-8 in the COPD and control groups.
Concordance correlation was 0.43, p=0.04 between study visits with 95%
confidence interval 0.02 to 0.7. Figure 3.7
3.2.3.3.4 Reproducibility of VEGF
VEGF levels were detected in twenty five of the 29 subjects in the trial with four
samples below the limit of detection of the assay (<15pg/ml). There was no
significant difference between the control and COPD groups.
Concordance correlation was 0.67 between study visits, p<0.001 (95% confidence



























Figure 3.5 Bland Altman Plot IL-1 li measurement in Induced Sputum
Dot plots represent the mean of study visits for each individual subject in the x axis against the
difference between study visits in the y axis. The dashed line represents the bias between visits (-
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Figure 3.6 Bland Altman Plot IL-6 measurement in Induced Sputum
Dot plots represent the mean of study visits for each individual subject in the x axis against the
difference between study visits in the y axis. The dashed line represents the bias between visits



























Figure 3.7 Bland Altman Plot IL-8 measurement in Induced Sputum Dot plots
represent the mean of study visits for each individual subject in the x axis against the difference
between study visits in the y axis. The dashed line represents the bias between visits (-50 pg/ml).
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Figure 3.8 Bland Altman Plot VEGF measurement in Induced Sputum
Dot plots represent the mean of study visits for each individual subject in the x axis
against the difference between study visits in the y axis. The dashed line
represents the bias between visits (25 pg/ml) and the solid lines the limit of
agreement of the test, -560pg/ml to 610 pg/ml.
140
3.2.3 Conclusion
Obtaining induced sputum for analysis in subjects without COPD was problematic,
particularly in control non or ex-smokers. Interpretation of the reproducibility of
induced sputum in this population is therefore not possible.
Sputum induction was more successful in the COPD population with all subjects
able to provide sputum on at least two occasions.
The total cell counts obtained appeared reproducible in the study population with a
concordance coefficient of 0.65 during the trial (p<0.001). The percentage of
macrophages in the differential cell counts also correlated (0.58) between subjects
during the trial, p<0.001.
In contrast the percentage of neutrophils and eosinophils counted in sputum did
not closely correlate between subject visits, although neutrophils differential counts
were close to significance in the COPD population (p=0.09).
The cytokines IL-18 and IL-6 were not reproducible in the supernatant of induced
sputum. In contrast measurements of levels of IL-8 (correlation coefficient 0.43,
p=0.04) and VEGF (correlation coefficient 0.67, p<0.001) in sputum were
reproducible during the trial.
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3.3 Reproducibility of Biomarkers of Oxidative Stress Measured
in Exhaled Breath Condensate in Subjects with COPD and
Controls
3.3.1.1 Study Population
Subjects were recruited from local COPD clinics, GP practices and by local
advertisement. Subjects were asked to give written informed consent to the trial
prior to participation.
COPD subjects had to meet the same criteria used in the induced sputum trial,
again study visits were only performed on clinically stable patients.
Control subjects were recruited by local advertising. Control subjects were not
matched for either age or smoking history. All subjects were to be free from any
clinically significant disease which was felt may either compromise the subject's
safety during the trial or interfere with the study results.
Clinical and spirometric inclusion and exclusion criteria were similar to the induced
sputum trial, (appendix 3.1)
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3.3.1.2 Study Visits
Study visits followed the same protocol as in the Induced Sputum reproducibility
trial mentioned above. Exhaled breath condensate was collected from the subjects
using a standardised procedure (Appendix 2.1). Spirometry was then measured
using a standardised procedure. EBC specimens were frozen at -80 °C and
analyzed in batches using standard assay protocols (appendix 2.6, 2.7).
After the initial study visit subjects were asked to return in a further 14 (±3) days at
the same time of day (within one hour) of previous clinic attendance. On the
second study visit a brief medical review was performed to ensure no significant
change in respiratory symptoms over the last two weeks and spirometry was
repeated to ensure post-bronchodilator FEVi remained within the 90-115% range.
Exhaled breath condensate collection was then repeated.
3.3.1.3 Statistical Analysis
Analysis between groups was performed using Tukey One Way Analysis of
Variance (ANOVA). Intra subject variability was assessed using the concordance
correlation co-efficient. Intra subject variability was plotted using Bland Altman Plot
of mean level between measurements versus difference between measurements.
3.3.1.3 Ethical Approval
Ethical approval for this study was obtained from the ethics committee of Lothian
Acute Hospitals NHS Trust. Prior to trial participation, subjects were issued with
written information regarding the study and given a minimum of 24 hours to digest
this information. Written informed consent was given and signed prior to trial
recruitment.
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3.3.2 Study Details and Demographics of Study Population
A total of twenty three subjects participated in the trial. Five of the subjects were
control smokers, five control life long non-smokers and thirteen had Chronic
Obstructive Pulmonary Disease.
Twenty one of the subjects completed the trial. One of the COPD subjects had an
exacerbation of her disease between visits one and two and one of the healthy non
smoking controls discovered that she was pregnant during the trial. Demographic
data below discusses the subjects who completed the trial.
The control populations were not age matched with the COPD group. The mean
age of the control group was 29.2 ± 6.4 for the control smokers and 29.8 ± 5.4
years for the control non-smokers. The mean age of the COPD group was 67.7 ±
6.4 years. Three of the ten control group were male and ten of the thirteen COPD
patients male. Table 3.7
Four of the COPD subjects were current smokers and nine ex-smokers. Average
pack years for the control smokers was 9.5 ± 5.0 pack years and 52.2 ± 37.1 for
the COPD subjects. The mean St Georges Flealth Questionnaire Total score was
57.8 ± 15.4 points. Table 3.7
All subjects in the control group had normal lung volumes and FEVt /FVC ratio. All
COPD subjects had airflow obstruction on spirometry with a mean FEN^ of 1.2±0.7










Age mean±stdev 67.7±6.4 29.2±6.4 29.8±5.4
Sex (m/f) 10/3 1 14 2/3
Pack Years mean+stdev 52.2±37 9.5±5.0 0
FEVi Post BD (L)
Mean ± stdev
1.2 ± 0.7 3.3 ± 0.4 3.7 ± 0.7
FEVi Post BD (%Pred)
Mean ± stdev
40.8 ±21.7 104 ± 12.2 98.2 ± 10.3
FEV^FVC Ratio
Mean ± stdev





Table 3.7 Demographics of COPD and Control Groups EBC Reproducibility Study
FEV^Forced Expiratory Volume in 1 sec, FVC=Forced Vital Capacity,
BD=bronchodilator
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3.3.3 Reproducibility of Biomarkers in Exhaled Breath Condensate
Exhaled breath condensate was obtained on both visits in all 22 subjects. 8-
Isoprostane was measured in all 44 samples. Hydrogen peroxide levels were
measured on both visits in fourteen of the trial participants, 4 non-smokers, 5
healthy smokers and 5 patients with COPD.
3.3.3.1 Reproducibility of 8-lsoprostane
Levels of 8-lsoprostane were detected in the majority of samples. Two of the
twenty two samples on visit one, five of the twenty two on visit two were below the
limit of detection for the assay (1,9pg/ml). Levels of 8-lsoprostane measured in the
remaining samples were also low with 16 of the remaining 20 samples less than
10pg/ml on visit one, 14 of 17 below 10pg/ml on visit two. There was no significant
difference in the levels of 8-isoprostane measured in the three study groups.
The 8-lsoprostane measured did not demonstrate Gaussian distribution when
tested using the Kolmorogov and Smirnov method (p<0.05) and was skewed to the
left for both visits. Figure 3.9a,b. After data was transformed to the log it had
normal distribution, Kolmorogov and Smirinov >0.1. Reproducibility analysis was
carried out on log transformed data.
Reproducibility of log 8-lsoprostane levels comparing between visits is expressed
as the concordance correlation with 95% confidence intervals. There was a just
significant correlation between log 8-lsoprostane levels at visit 1 and at visit 2 for
the study population as a whole, correlation co-efficient 0.28, 95% confidence
interval 0.02 to 0.50, p=0.034. Figure 3.10
146
_ O-m-CDD
□ o inn □ □ o
0.00 10.00 20.00 30.00 40.00 50.00












0.00 10.00 20.00 30.00 40.00 50.00 60.00 70.00
8-lsoprostane Visit 2 (pg/ml)
Figure 3.9b
Figure 3.9 Dot Plot Representation of 8-lsoprostane levels measured at
Visit 1 (3.9a) and Visit 2 (3.9b)
Plots represent 8-lsoprostane levels per individual for visit 1 and visit 2 of the trial.
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Figure 3.10 Bland Altman plot log 8-lsoprostane levels in Exhaled Breath
Condensate- COPD, smokers and non-smokers
Plots represent the mean log 8-lsoprostane levels of the two visits for individuals
compared to the difference between the two measurements. The dashed line represents
the bias between visits (0.12 pg/ml) and the solid lines the limit of agreement of the test, -
0.83 pg/ml to1,07pg/ml.
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3.3.3.2 Reproducibility of Hydrogen Peroxide
Hydrogen peroxide levels were measured in exhaled breath condensate (EBC) in
14 individuals on two occasions, five smokers, 4 non-smokers and 5 subjects with
COPD. Twelve of the 14 subjects had levels of hydrogen peroxide above the lower
limit of detection of the assay (0.78umol/L) on visit 1. At visit 2 again 12 of the 14
subjects had detectable hydrogen peroxide in EBC, although it was not the same
individuals who did not have detectable levels when compared to visit 1. Hydrogen
peroxide levels measured in EBC in this study demonstrated Gaussian distribution,
Kolmorogov and Smirnov p>0.1. Figure 3.12
There was no significant difference in the mean levels of hydrogen peroxide
measured in the three treatment groups.
The correlation coefficient for between visit measurements of hydrogen peroxide in
the study population was 0.48 with a range from 0.00 to 0.77. This correlation failed
to reach statistical significance with a p value of 0.057. Statistical analysis repeated
after values below the limit of detection of the assay had been removed did not
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Figure 3.12 Dot Plot Representation of Hydrogen Peroxide levels measured
during study
Plots represent Hydrogen Peroxide levels per individual during trial. Dashed
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Figure 3.13 Bland Altman plot Hydrogen Peroxide Levels in Exhaled Breath
Condensate during study
Dot plots represent the mean of study visits for each individual subject in the x axis against
the difference between study visits in the y axis. The dashed line represents the bias




Levels of both biomarkers of oxidative stress were measurable in exhaled breath
condensate from the majority of patients.
8-lsoprostane levels did not display Gaussian distribution with the majority of
measurements being on or close to the lower limit of detection of the assay. The
study was not designed to compare levels between the treatment groups and the
numbers studied were small. It should be noted however that there was no
significant difference in levels of 8-lsoprostane between the groups.
There was a statistically significant between-visit correlation in log 8-lsoprostane
levels in this study population. Hydrogen peroxide levels were normally distributed
although levels were not detectible in a minority of cases. As with 8-lsoprostane,
there was no significant difference in levels between the study groups.
Hydrogen peroxide levels did demonstrate a trend toward correlation between
study visits however this failed to reach statistical significance.
The results of this chapter are discussed in detail in Chapter 6.2.
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Chapter 4
Relationship between Exhaled Breath Condensate
Biomarkers and Lung Function, Health Status and Smoking
Status in Subjects with COPD and Healthy Controls
4.1 Introduction
Several biomarkers of inflammation and oxidative stress have been identified
which may potentially be of use in the study of the Exhaled Breath Condensate
(EBC) of patients with COPD. Published data regarding this are discussed in
Chapter One of this thesis. The reliability of 8-lsoprostane and Hydrogen Peroxide
in Exhaled Breath Condensate when measured by our group is discussed in
Chapter Four. In this chapter, comparison is also made between levels of these
biomarkers in EBC in five subject groups; COPD smokers, COPD Ex-smokers,
Control Smokers, Control Ex-Smokers and Control Non-Smokers. The relationship
between these biomarkers and a variety of parameters of health in subjects with
COPD is also discussed. Samples obtained in this study were also used to identify
novel biomarkers in EBC which may be of use in clinical studies.
4.1.1 Study Population
Subjects were recruited from local secondary care clinics, GP practices and from
local advertisements. Subjects were asked to give written informed consent to the
trial prior to participation.
Prior to trial recruitment COPD subjects required a documented diagnosis of
COPD, had to be over 40 years of age and be either a current or ex-smoker
(defined as no tobacco consumption for 6 months) with a minimum of 10 pack
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years tobacco exposure. A clinical diagnosis of COPD had to be supported by
spirometric evidence of airflow obstruction with post-bronchodilator FEVi less than
80% predicted and FE\A/FVC ratio less than 70%. Subjects with significant
improvement after bronchodilator, defined as greater than 400ml or reversal of
airflow obstruction were excluded from the trial.
Study visits were only performed on clinically stable patients, defined as no
exacerbation in the last month or no exacerbation requiring hospital admission in
the last 2 months. An exacerbation was defined as a change in baseline dyspnoea,
cough and / or sputum production sufficient to merit a change in management.
Control subjects were recruited from local GP practices and by local
advertisements. Subjects were over the age of 40. Current and ex-smokers
required a smoking history of 10 pack years. Ex-smokers must have abstained for
at least 6 months. Non-smokers had to be either lifelong non-smokers or have a
smoking history of less than 1 pack year. All subjects were to be free from any
clinically significant disease which was felt may either compromise the subject's
safety during the trial or interfere with the study results.
Healthy volunteers were required to have normal spirometry, as defined by both
FEVi and FVC greater than 80 percent predicted with no significant reversibility
and FEVi/FVC ratio greater than 70%. A number of exclusion criteria were used in
this study and applied to both COPD patients and healthy controls. These included
current or previous history of atopy, sinusitis, respiratory disease other than COPD,
unexplained respiratory symptoms, any recent upper or lower respiratory tract
infection and non-respiratory inflammatory disease (appendix 4.1) .
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4.1.2 Study Visits
Prior to study attendance, subjects were asked to abstain from smoking and
caffeine for a minimum of 8 hours. Inhaled corticosteroids and bronchodilators
were withheld on the morning of clinic attendance. Trial participation was deferred
if subjects had received any antibiotics in the last 4 weeks or oral corticosteroids in
the last 8 weeks.
On study attendance, clinical history was reviewed to ensure suitability for trial
participation. Past medical history, drug history, occupational history and family
history were recorded. Smoking history was noted including the time of the last
cigarette. COPD subjects were asked to complete a St Georges Respiratory
Questionnaire (appendix 5.3) and MRC Dyspnoea Score (appendix 4.2).
Symptoms of cough, sputum production and wheeze were scored as either zero
(no symptoms), one (intermittent symptoms during day) or 2 (constant symptoms
throughout day). The presence or absence of ankle oedema and nocturnal
symptoms were recorded and annual exacerbation rate noted along with date of
last exacerbation.
Height, weight, body mass index, blood pressure, oxygen saturation and pulse rate
were measured. Exhaled carbon monoxide level was measured and exhaled
breath condensate collection was only undertaken if there was no evidence of
acute cigarette smoke exposure.
Exhaled breath condensate collected using a standardised procedure (Appendix
2.1). Specimens were frozen at -80 °C and analysed in batches using standard
assay protocols (Appendix 2.6,2.7). Lung spirometry was then measured, again
using a standardized procedure (Appendix 2.5).
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4.1.3 Statistical Analysis
The method of statistical analysis was dependant on the distribution of the data.
Results with more than two data sets with a parametric distribution were analyzed
using Tukey One Way Analysis of Variance (ANOVA). Analysis between two data
sets with a parametric distribution used paired t-test. Non parametric data were
analyzed using the Dunn Formula for groups and the Mann-Whitley test for two
data sets.
4.1.4 Ethical Approval
Ethical approval for this study was obtained from the ethics committee of Lothian
Acute Hospitals NHS Trust. Prior to trial participation, subjects were issued with
written information regarding the study and given a minimum of 24 hours to digest




A total of 139 subjects participated in the trial. Seventy eight of these subjects had
COPD and 61 were controls. Thirty seven of the subjects with COPD were current
smokers, 41 ex-smokers. Thirteen of the control subjects were current smokers, 23
ex-smokers and 25 lifelong non-smokers.
All trial participants were over forty; however the groups were not age matched.
Subjects with COPD were significantly older (p<0.001) when compared with
controls. Seventy six of the subjects were male. There were statistically more
males in the COPD ex-smoker group compared with the control smokers and
control non-smoker groups.
COPD ex-smokers were older than current smokers (p<0.01). COPD subjects had
a significantly higher smoking pack year history compared with healthy smokers,
p<0.001. There was no difference in the pack years between COPD ex and current
smokers. Equally there was no difference in pack years between control ex or
current smokers.
There was no statistically significant difference in body mass index between the
groups. The COPD groups had significantly higher levels of cardiovascular disease
compared with the control group. Fourteen of the 78 subjects with COPD also had
ischaemic heart disease compared with 3 of the healthy controls, p<0.05. Twenty
four COPD subjects had hypertension compared with six of the 61 healthy controls,
p<0.05. Table 4.1
Subjects with COPD had significantly lower FEVi (p<0.001) compared with
controls, with no differences between the two COPD groups or between the three
158
control groups. Control ex-smokers (p<0.01) and non-smokers (p<0.05) had higher
mean FVC compared with COPD subjects. There was no difference between
COPD subjects and current smokers and no difference between the two COPD
groups.
COPD subjects had a lower FEVVFVC ratio compared with controls, p<0.001.
There was no difference between the two COPD groups or between the three
control groups. COPD current smokers demonstrated more reversibility to
bronchodilator, 155ml ±167 when compared with healthy non-smokers, 48ml ±93,
p<0.05, there was no difference between the other groups in terms of reversibility.
Table 4.4
COPD ex-smokers had statistically lower total St Georges Respiratory
Questionnaire score compared with COPD current smokers, 42.7 points ± 20.0
versus 58.2 points ±15.9, p<0.001. All components of the SGRQ score were lower
in the ex-smoking group.
Current smokers with COPD were more likely to report symptoms of chronic
bronchitis (80% versus 30%, p<0.001) and had higher mean cough scores (1.5±0.6
versus 1.1 ±0.8, p<0.05) compared with COPD ex-smokers. There were no
differences in symptoms of breathlessness, wheeze or exacerbation frequency.
There was no difference in the use of any form of bronchodilator between the two
groups. COPD ex-smokers were more likely to be on inhaled corticosteroids, 32
out of 41 compared with19 of 37 COPD current smokers, p<0.05.
Group
COPD COPD Healthy Healthy Healthy
Smoker Ex Smoker Ex Non
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Number 37 41 13 23 25
Age
meantsd
64.6±8.4 72.1 ±6 55.6±9.3 59.7±10.2 54.0±9.0
Sex (m/f) 21/15 32/9 4/8 11/11 8/17
BMI
meantsd
24.2±4.2 26.8±5.8 27.9±3.4 27.1 ±4.2 27.0±4.6
FFM
Mean±sd
46.7±10.5 55.2±10.4 49.1±13.7 51,7±10.6 50.6±9.0
Pack Years
mean+sd
49.5±23.7 45.8±18.8 26.9±12.7 23.9±10.8 0.3±1.1
IHD 7 7 1 2 0
HBP 10 14 1 4 1
High
Cholesterol
2 1 1 2 2
Diabetes 1 2 0 0 1
Table 4.1 Patient Demographics














FEVi Post BD (L)
Mean ± sd
1.3 ± 0.6 1.4 ± 0.6 2.8 ± 0.6 3.0 ± 0.6 3.1 ± 0.7
FVC Post BD (L)
Mean ± sd
3.0 ± 3.1 2.9 ±1.0 3.6 ± 0.9 4.0 ± 0.8 3.8 ± 1.0
FEVi/FVC Ratio
Mean ± sd




52.3 ± 22 53.0 ±21 100 ± 15 104 ± 14 108 ± 12
%change post BD
Mean ± sd
15 ± 15 13 ± 12 3 ± 7 3 ± 5 2± 3
Vol.Change postBD
Mean ± sd
155±167 137±120 68±153 95±158 48±93
Table 4.2 Spirometry Results per Study Group
FEV^Forced Expiratory Volume in 1 sec, FVC=Forced Vital Capacity,
BD=bronchodilator
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0.8 ± 0.4 0.3 ± 0.5
MRC Dyspnoea
Mean ± Sd
3.0 ± 0.9 2.8 ±1.0
Cough (0-3)
Mean ± Sd
1.5 ± 0.6 1.1 ± 0.8
Sputum (0-2)
Mean ± Sd
1.6 ± 0.6 1.7 ±0.7
Wheeze (0-2)
Mean ± Sd
1.2 ± 0.8 0.9 ± 0.7
Exac Freq
Mean ± Sd
1.8 ± 1.3 2.1 ±2.3
Table 4.3 Health Status Results per study group
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58.2 ±15.9 42.7 ±20.0
SGRQ Symptoms
Mean ± Sd
73.5 ± 18.3 55.0 ±23.1
SGRQ Activity
Mean ± Sd
72.5 ± 19.5 59.5 ±23.4
SGRQ Impact
Mean ± Sd
45.1 ± 18.6 28.9 ±20.7






symptoms activity impact total symptoms activity impact total
COPD Smokers COPD Ex Smokers
Figure 4.1 St Georges Health Questionnaire in COPD Smokers and Ex-smokers.
White Histograms represent COPD current smokers, black histograms COPD Ex-smokers.
Higher mean scores were recorded in current smokers for symptoms (p<0.001), activity
(p<0.001) and impact (p<0.001) component scores. Total mean score was significantly














Table 4.5 COPD Treatment in Current and Ex Smoking Groups
SABA= short acting fi agonist, l_ABA= long acting li agonist, SAAC= short acting anti¬
cholinergic, LAAC= long acting anti-cholinergic, ICS= Inhaled Corticosteroid
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4.3 Measurement of Biomarkers in Exhaled Breath Condensate Relationship
with COPD and Smoking
No significant difference was demonstrated in mean levels of 8-lsoprostane
measured in exhaled breath condensate between subjects with COPD and
controls. There were also no significant differences between groups dependant on
current smoking status. Figure 4.2
Mean hydrogen peroxide levels in EBC were higher in ex-smokers with COPD
(3.5pmol/L ± 0.9) compared with current smokers with COPD (2.0 pmol/L ± 0.5),
p=0.007. Mean hydrogen peroxide levels in current smokers with COPD were
similar to the three healthy control groups. Ex-smokers with COPD had higher
levels than healthy non-smokers (3.5pmol/L ± 0.9 versus 1.1pmol/L ± 0.2,
p=0.0003) but not healthy smokers or ex-smokers. Figure 4.3
Ex-smokers with no evidence of respiratory disease had elevated hydrogen
peroxide levels compared with control non-smokers (2.0pmol/L ± 0.4 versus
1.1pmol/L ± 0.2, p=0.048). Current smokers without respiratory disease had lower
levels than ex-smokers. However this was not statistically significant (p>0.05).
Overall, independent of current smoking habit, subjects with COPD had higher
mean hydrogen peroxide levels (2.8[imol/L ± 0.5) compared with subjects without
COPD (1.5pmol/L ± 0.2), p=0.04. Figure 4.4
When current smoking intake was analysed independent of respiratory disease,
ex-smokers had higher levels of hydrogen peroxide (3.0pmol/L ± 0.6) compared
with current smokers (1.9pmol/L ± 0.4), p=0.0134 and lifelong non-smokers
(1.1 pmol/L ± 0.2), p=0.0007. Figure 4.4
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A variety of other biomarkers were identified as being potentially measurable in
COPD. These included Leukotriene B4, Prostaglandin E2, pH, Myeloperoxidase,
Tumour Necrosis Factor a and Interleukins 6,8 and 10. Of these biomarkers only
Prostaglandin E2 (PGE2) and pH could be readily detected in EBC on a regular
basis.
Prostaglandin E2 levels did not significantly vary between the two COPD groups.
Levels in the control smokers and ex-smokers groups were similar to those in the
COPD groups. Control non-smokers had significantly lower mean levels of PGE2
(9.6pg/ml ± 1.0, p=0.03) compared with current smokers (12.2pg/ml ± 0.7) and
healthy ex-smokers (12.4pg/ml ± 0.8, p=0.03). Subjects with COPD, independent
of current smoking habit, had similar PGE2 levels (11.7pg/ml ± 0.5) when
compared with healthy current or ex-smokers (12.2pg/ml ± 0.8). The mean levels
of PGE2 in healthy non-smokers was significantly lower than both these groups
(both p values =0.04). Figures 4.5, 4.6. No significant variation was seen in the pH

















COPD Smoker COPD Ex Control Smoker Control Ex Control Non
Figure 4.2 Levels of 8-lsoprostane measured in Exhaled Breath Condensate per Study
Group. Histograms represent Box and whisker plots of quartiles of 8-lsoprostane levels
(pg/ml). No significant difference is noted between the five study groups.
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Figure 4.3 Levels of Hydrogen Peroxide measured in Exhaled Breath Condensate per
Study Group
Histograms represent Box and whisker plots of quartiles of hydrogen peroxide levels
(pmol/L) for the five study groups. Significantly higher mean levels of hydrogen peroxide in
COPD Ex-smokers compared with COPD current smokers, p=0.007(**), and control non-
smokers, p=0.0003(###). Control ex-smokers had higher levels of hydrogen peroxide
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Figure 4.4 Hydrogen Peroxide levels in Exhaled Breath Condensate in subjects with
COPD compared with controls and in Current, Ex Smoking and Non Smoking Groups
Independent of Respiratory Disease.
Histograms represent Box and whisker plots of quartiles of hydrogen peroxide levels (pmol/L) for
the subjects with and without COPD independent of smoking status and for smokers, ex-smokers
and lifelong non-smokers independent of respiratory disease. Significantly higher levels of hydrogen
peroxide were measured in subjects with COPD compared with those without, p=0.04(*). Ex-
smokers had higher hydrogen peroxide levels than non-smokers, p=0.0007(+++) with a trend
towards higher levels compared with current smokers, p=0.013.
Figure 4.5 PGE2 levels in Exhaled Breath Condensate per study group
Histograms represent Box and whisker plots of the four quartiles of PGE2 levels (pg/ml) in EBC.
Significantly higher levels were seen in COPD smokers, p=0.03, (*) and control Ex-smokers, p=0.03
(+) compared with non smoking controls.
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COPD Current / Ex Smoker Non Smoker
Figure 4.6 PGE2 levels in Exhaled Breath Condensate per study group
Histograms represent Box and whisker plots of the four quartiles of PGE2 levels (pg/ml) in
EBC. Significantly higher levels were seen in COPD patients, p=0.04 (*), and Control
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Figure 4.7 pH of Exhaled Breath Condensate per study group
Histograms represent Box and whisker plots of the four quartiles of EBC pH. No significant
variation is demonstrated between the five study groups.
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4.4 Relationship between biomarkers and Co-Morbidity other than
COPD
Section 4.3 demonstrated that levels of many of the biomarkers were similar in
subjects with COPD compared with the control population. One possible
explanation for this is that the control population has a significant degree of non¬
respiratory co-morbidity which may contribute to elevated levels of exhaled breath
condensate biomarkers.
To further investigate this possibility, the control population was divided into those
subjects with or without significant non respiratory disease. Twenty of the 61
subjects in the control group had no significant co-morbidity, compared with 41 with
non-respiratory co-morbidity. Co-morbidities of the trial participants are listed in
appendix 4.3. There was no significant difference in smoking status between
control subjects with and without co-morbidity. Table 4.6
Analysis of the 4 biomarkers was performed comparing control subjects with no co¬
morbidity to subjects with any co-morbidity including COPD. Further analysis was
performed comparing subjects with a non respiratory co-morbidity to subjects with
COPD.
4.4.1 pH and Co-Morbidity
No significant differences in mean levels of pH in EBC were noted between
subjects with and without significant co-morbidity. Figure 4.8
4.4.2 PGE2 and Co-Morbidity
Prostaglandin E2 levels in EBC of subjects with no co-morbidity (9.8 pg/ml ± 0.9)
demonstrated a trend towards lower mean levels compared with subjects with any
co-morbidity including COPD (11.6 ± 0.4, p=0.08) and non COPD co-morbidity
(12.1 pg/ml ± 0.9, p=0.08). Mean levels in the COPD group as a whole also
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demonstrated a trend towards higher levels (11.6pg/ml ± 0.5, p=0.07) compared
with controls having no co-morbidity. The difference when compared with the
control group without co-morbidity was statistically significant in current smokers
with COPD (12.2pg/ml ± 0.7, p=0.04) Figure 4.10
4.4.3 Hydrogen Peroxide and Co-Morbidity
There was no significant difference between hydrogen peroxide levels in EBC of
controls with no co-morbidity to all of the other subject groups. Figure 4.9
4.4.4 8-lsoprostane and Co-Morbidity
8-lsoprostane levels were significantly lower in control subjects with no co¬
morbidity (3.4pg/ml ± 0.5) compared with subjects with any co-morbidity (5.9 pg/ml
± 0.4, p=0.02) and subjects with non COPD co-morbidity (7.0pg/ml ± 0.7, p=0.001).
There was no significant difference between control subjects with no co-morbidity
and subjects with COPD. There was however a trend towards higher levels in
current smokers with COPD (5.6pg/ml ± 0.8) compared with the group with no co¬
morbidity, p=0.09. Figure 4.11
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Control COPD
No Comorbidity Co morbidity
Current Smoker 4 9 37
Ex Smoker 7 16 41
Non Smoker 9 16
Total 20 41 78
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Figure 4.8 pH levels in EBC compared withSubject Co-Morbidity Histograms
represent Box and whisker plots of quartiles of pH levels in trial subjects. No significant
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Figure 4.9 Hydrogen Peroxide Levels in EBC per Co-Morbidity
Histograms represent Box and whisker plots of the quartiles of EBC hydrogen peroxide
levels per subject co-morbidity. No significant difference was seen between subjects with












Figure 4.10 PGE2 Levels in EBC compared withSubject Co-Morbidity
Histograms represent Box and whisker plots of the quartile of PGE2 levels in EBC for the
trial subjects dependant on co-morbidity. Subjects with no co-morbidity had significantly
lower levels of PGE2 (9.8pg/ml ± 0.9) compared with Current Smokers with COPD
(12.2pg/ml ± 0.7) p=0.04 (*).
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Figure 4.11 8-lsoprostane levels in EBC per Subject Co-morbidity
Histograms represent Box and whisker plots of the quartiles of 8-isoprostane levels in EBC
per co-morbidity. Levels of 8-lsoprostane in EBC were significantly higher in subjects with
all causes of co-morbidity (5.9pg/ml ± 0.4, p=0.02) and non COPD co-morbidity (7.0pg.ml
± 0.7, p=0.001, ***). 8-lsoprostane levels in COPD current smokers demonstrated a trend
towards higher levels (5.6pg/ml ± 0.8) compared with healthy controls, p=0.09.
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4.5 Relationship between EBC, Spirometry and Health Status in
Current Smokers with COPD.
Exhaled breath condensate was collected in 37 current smokers with COPD. The
levels of Hydrogen Peroxide, 8-lsoprostane, Prostaglandin E2 and pH measured in
these samples were compared with a variety of markers of health status. These
included current respiratory symptoms, St Georges Health Questionnaire, COPD
therapy, pack year history and lung function. Nutritional status, age and sex were
also compared with EBC biomarker measurement. Listed below are the markers of
health status which were compared with exhaled breath condensate biomarkers.
In summary, there were no relationships demonstrated between symptom score,
past medical history, spirometry and St Georges Respiratory Questionnaire and
any EBC biomarkers. Inhaled corticosteroid use was the only treatment which
demonstrated a relationship to EBC, with lower levels of 8-lsoprostane in smokers
with COPD compared with smokers with COPD not taking ICS. BMI was the only
demographic parameter which appeared to affect biomarker measurement with
higher levels in those subjects with BMI higher or lower than normal.
4.5.1 Relationship with Biomarkers and BMI in Smokers with COPD
Subjects with a normal Body Mass Index (BMI), between 20 and 25, demonstrated
a trend towards lower mean levels of 8-lsoprostane compared with subjects with a
BMI greater than 25, 3.8pg/ml ± 3.0 versus 7.1pg/ml ± 6.1, p=0.10. There was no
difference between subjects with a low BMI and those with a normal BMI. Figure
4.12
Hydrogen peroxide levels also demonstrated a trend toward lower levels in those
subjects with a normal BMI. With this biomarker those subjects with a BMI less
than 20 had higher mean levels, 3.7pmol/L ± 4.5 compared with those with a
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normal BMI, 1.0 pmol/L ± 0.9, although this was not statistically significant, p=0.10.
Figure 4.13. No relationship was demonstrated between levels of PGE2 or pH in
Exhaled Breath Condensate and BMI.
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<20 20-25 >25
Figure 4.12 EBC 8-lsoprostane Levels in COPD Smokers Related to BMI
White Histograms represent BMi<20, Hatched BMI 20-25 and Black BMI >25. Error Bars
represent standard deviation. No statistically significant differences were demonstrated
although a trend towards higher mean 8-lsoprostane levels with BMI > 25 compared with
BMI 20-25 was noted, p=0.1.
Figure 4.13 EBC Hydrogen Peroxide Levels in COPD Smokers Related to BMI
White Histograms represent BMI<20, Hatched BMI 20-25 and Black BMI >25. Error bars
represent standard deviation. No statistically significant difference was demonstrated
although a trend towards higher mean hydrogen peroxide levels with BMI <20 compared
with BMI 20-25, p=0.1.
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4.5.2 Relationship between Biomarkers and Inhaled
Corticosteroids in Smokers with COPD
Current smokers with COPD who were not taking inhaled corticosteroids on a
regular basis had higher mean levels of 8-lsoprostane (7.4 pg/ml ± 6.0) compared
with patients using ICS (3.9 pg/ml ± 3.0). This difference was statistically
significant, p<0.05. Figure 4.14
A similar relationship was demonstrated in levels of PGE2 with mean levels higher
in steroid naive subjects, 13.5 pg/ml ± 4.5 compared with those subjects using ICS,
10.8 pg/ml ± 2.6. This relationship was close to statistical significance, p=0.056.
Figure 4.15
No relationships were demonstrated between levels of hydrogen peroxide and pH
in EBC and inhaled corticosteroid use. There was no relationship between other




Figure 4.14 Inhaled Corticosteroid Use and EBC 8-lsoprostane levels in COPD
Smokers Dot plots represent each individual 8-lsoprostane level in current smokers with
COPD. Statistically higher mean 8-lsoprostane level in COPD Smokers not on ICS
(7.4±6.0pg/ml) compared with subjects on ICS (3.9±3.0pg/ml). p<0.05.
Figure 4.15 Inhaled Corticosteroid Use and EBC PGE2 levels in COPD Smokers Dot
plots represent each individual 8-lsoprostane level in current smokers with COPD. Trend
towards higher PGE2 levels in COPD Smokers not on inhaled corticosteroids
(13.5±4.5pg/ml) compared with subjects taking ICS (10.8±2.6pg/ml), p=0.056
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4.6 Relationship between EBC Biomarkers and Symptoms,
Health Status, Therapy, Demographics, Past Medical
History and Spirometry in Ex-smokers with COPD
In contrast to current smokers with COPD, when the various parameters of health
in ex-smokers with COPD were compared with biomarkers of oxidative stress and
inflammation in exhaled breath condensate, several relationships were noted.
Exhaled Breath Condensate biomarkers did not relate to patient demographics,
past medical history or treatment. Several relationships were noted however
between health status, symptom score and spirometry measurement with 8-
Isoprostane levels in EBC. Hydrogen peroxide related to some measurements of
lung function. There was no relationship between PGE2 and pH measurement and
any of the parameters of health used.
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4.6.1 Relationship between 8-lsoprostane in EBC and St Georges Respiratory
Questionnaire in Ex-smokers with COPD
8-isoprostane levels in EBC did not display Gaussian distribution, with levels being
skewed to the left, figure 4.16. Comparison of levels of oxidative stress in EBC and
health status was therefore carried out by dividing the subjects by 8-lsoprostane
quartile and then comparing the health status in the four groups.
Symptom score in subjects with the lowest quartile of 8-lsoprostane levels had
significantly lower mean scores when compared with those subjects from the
highest quartile. 42.1 points ± 5.3 versus 69.7 points ± 5.3, p=0.007, Figure 4.17.
Mean SGRQ activity scores were also higher in the highest quartile of 8-
Isoprostane compared with the lowest quartile, 74.1 points ± 5.3 versus 50.0 points
± 6.4, p=0.02. Figure 4.18
A similar relationship was also shown between Impact scores and 8-lsoprostane
levels, 21.7 points ± 4.9 in the lowest 8-lsoprostane quartile compared with 43.0
points ± 6.4, p=0.02. Figure 4.19
In keeping with the three components of the SGRQ health questionnaire relating to
levels of 8-lsoprostane in EBC, the mean total SGRQ score was significantly
higher in those subjects with the highest 8-lsoprostane levels (57.0 points ± 6.0)
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Figure 4.16 Distribution of 8-lsoprostane measurement in EBC
Level of 8-lsoprostane measured in EBC in ex-smokers with COPD during trial. Each dot





Figure 4.17 SGRQ Symptoms Score per EBC 8-lsoprostane Quartile in
COPD Ex-smokers
Histograms represent the mean SGRQ symptom score per Quartile of EBC 8-
Isoprostane. Error bars represent standard error of mean. Subjects from the first 8-
Isoprostane Quartile had lower mean SGRQ symptom score (42.1 ±5.3) compared
with quartile 4 (69.7±5.3). **p=0.0074 Q1 compared with Q4.
Figure 4.18 SGRQ Activity Score per 8-lsoprostane Quartile in COPD
Ex-smokersHistograms represent the mean SGRQ activity score per
Quartile of EBC 8-lsoprostane. Error bars represent standard error of mean.
Subjects from the first 8-lsoprostane Quartile had lower mean SGRQ activity score



















Figure 4.19 SGRQ Impact Score per 8-lsoprostane Quartile in COPD Ex-smokers
Histograms represent the mean SGRQ impact score per Quartile of EBC 8-lsoprostane. Error bars
represent standard error of mean. Subjects from the first 8-lsoprostane Quartiie had lower mean
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Figure 4.20 SGRQ Total Score per 8-lsoprostane Quartile in COPD Ex-smokers
Histograms represent the mean SGRQ total score per Quartile of EBC 8-lsoprostane. Error bars
represent standard error of mean. Subjects from the first 8-lsoprostane Quartile had lower mean
SGRQ total score (33.9±4.5) compared with quartile 4 (57.0±6.0). **p=0.007 Q1 compared with Q4.
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4.6.2 Relationship between 8-lsoprostane in EBC and symptom
scores in Ex-smokers with COPD
Mean symptom scores were related to 8-lsoprostane quartiles in EBC. No
relationship was demonstrated between levels of oxidative stress in EBC and any
of the following; MRC Dyspnoea Score, Wheeze score, the presence of ankle
oedema and the presence of nocturnal symptoms. Exacerbation frequency related
to 8-lsoprostane quartiles whilst cough, wheeze and chronic bronchitis scores
demonstrated trends towards an association with 8-lsoprostane in EBC.
Subjects from the lowest quartile of 8-lsoprostane levels had a significantly lower
mean annual exacerbation frequency (0.7 ± 0.3 exacerbations per year) compared
with the highest quartile, (3.8 ±1.1 exacerbations per year), p=0.03. Figure 4.23
Fewer of the subjects in the lowest quartile of measured 8-lsoprostane in EBC
reported symptoms of chronic bronchitis (2 out of 10) compared with those in the
4th quartile, 5 out of 9. This trend was not statistically significant, p=0.10. Figure
4.21.
A similar trend was noted between the cough score and 8-lsoprostane levels.
Subjects from the 1st quartile had a mean cough score of 0.8 points ± 0.2
compared with 1.4 points ± 0.2 in the 4th quartile. Again this trend failed to reach
statistical significance, p=0.074. Figure 4.21a
A further trend towards higher reported sputum production scores was noted. The
mean score in the highest quartile of the 8-lsoprostane group was 1.4 points ± 0.2
compared with the 0.9 points ± 0.2 in the lowest quartile. This was not statistically
significant, p=0.13. Figure 4.22. No relationship was demonstrated between any of
the symptom scores and levels of pH, PGE2 and hydrogen peroxide in EBC.
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Figure 4.21 Chronic Bronchitis Score per Quartile EBC 8-lsoprostane in COPD Ex-
smokers Histograms represent the percentage of patients in each EBC 8-lsoprostane Quartile with
symptoms of chronic bronchitis. Error bars represent standard error of mean. Trend towards higher
percentage of patients with chronic bronchitis in Quartile 4 (56%) vs Quartile 1 (20%) p>0.05
Figure 4.21a Cough score per Quartile EBC 8-lsoprostane in COPD
Ex-smokers Histograms represent the mean cough score in each quartile EBC 8-
Isoprostane. Error bars represent the standard error of mean. Patients in the first quartile had
demonstrated a trend towards lower cough scores (0.8±0.2) when compared with quartile four
(1.4±0.2). This was not quite statistically significant, p=0.076
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Figure 4.22 Sputum Score per EBC 8-lsoprostane Quartile in
COPD Ex-smokers Histograms represent the mean sputum score in each quartile
EBC 8-lsoprostane. Error bars represent the standard error of mean. Patients in the first
quartile demonstrated a trend towards lower sputum scores (0.9±0.2) when compared with
quartile four (1.4±0.2). This was not statistically significant, p=0.13
Figure 4.23 Annual Exacerbations Frequency per EBC 8-lsoprostane
Quartile in COPD Ex-smokers Histograms represent the mean annual exacerbation
frequency in each quartile EBC 8-lsoprostane. Error bars represent the standard error of
mean. Patients in the first quartile had lower annual exacerbation frequency (0.7±0.3)
when compared with quartile four (3.8±1.1), p=0.03.
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4.6.3 Relationship between 8-lsoprostane and Lung Spirometry in Ex-
smokers with COPD
Post bronchodilator FEVi, FVC, FEVi/FVC ratio and the degree of reversibility
were compared with the 8-lsoprostane levels in EBC. Both absolute lung volumes
in litres and percentage predicted values were analysed. The ex-smoking COPD
group was divided into quartiles dependant on the level of 8-lsoprostane levels.
Mean values for the lung function parameters mentioned above were then
calculated and between quartile analyses performed.
The highest quartile of 8-lsoprostane levels in EBC had a significantly lower mean
percentage predicted FEV-i post bronchodilator (37.6% ± 3.5) compared with the
lowest quartile of 8-lsoprostane (60.7% ± 6.5). This difference was statistically
significant, p=0.009. Figure 4.24
The mean ratio of FEVi/FVC was also significantly lower in subjects from the
quartile with the highest levels of 8-lsoprostane in EBC, 39.1% ± 3.0, compared
with the lowest quartile group with mean levels of 54.7% ± 4.7. p=0.017. Figure
4.25
No significant difference was demonstrated between 8-lsoprostane quartiles and
any absolute dynamic lung measurement. The degree of reversibility and the
percentage predicted FVC did not relate to EBC measurement of 8-lsoprostane.
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Figure 4.24 Percentage Predicted FENAi post Bronchodilator per EBC 8-lsoprostane
Quartile Histograms represent the mean percentage predicted FEVt measured post
bronchodilator in each quartile of 8-lsoprostane measurement in EBC. The error bars
represent the standard error of mean. Subjects in the lowest quartile of EBC 8-lsoprostane
had statistically significant higher FE\A, (60.7%±6.5) when compared with Quartile 4
(37.6%±3.5), **p=0.009.
Figure 4.25 Ratio of FEV^FVC post bronchodilator per EBC 8-lsoprostane Quartile in
COPD Ex-smokers.Histograms represent the mean FEV^FVC ratio measured post
bronchodilator in each quartile of 8-lsoprostane measurement in EBC. The error bars
represent the standard error of mean. Subjects in the lowest quartile of EBC 8-lsoprostane
had statistically significant higher FEV-i/FVC ratio (54.7%±4.7) when compared with
Quartile 4 (39.1%±3.0), *p=0.017.
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4.6.4 Relationship between Hydrogen Peroxide in EBC and Lung
Spirometry in Ex-smokers with COPD
Hydrogen peroxide levels in Exhaled Breath Condensate were divided into
quartiles. The mean levels of the dynamic lung function tests mentioned in the
previous section were then calculated for each quartile and between groups
comparisons were made.
The mean absolute FEVi post bronchodilator was lower in the 4th quartile of
hydrogen peroxide EBC (1.05 L ± 0.1) compared with both the first quartile (1.67 L
± 0.23, p=0.046) and the second quartile (1.68 L ± 0.19, p=0.001). Figure 4.26.
The absolute levels of Forced Vital Capacity post bronchodilator were also
associated with hydrogen peroxide levels. Subjects with the highest levels of H2O2
had significantly lower mean FVC (2.4 L ± 0.19) compared with those from the
lowest quartile (3.34 L ± 0.32), p=0.02. Mean FVC levels in the second quartile (3.2
L ± 0.32) were close to statistical significance compared with4th quartile, p=0.053.
Figure 4.27
Percentage predicted FEV1 post bronchodilator was also associated with hydrogen
peroxide levels. Subjects with the highest levels of hydrogen peroxide had lower
mean FEV1 (39.7% ± 4.2) compared with subjects from the second quartile (66.0%
± 6.3), p=0.003, whilst subjects from the lowest quartile had a trend towards higher
mean FEV-| post BD (54.3% ± 6.3) compared with the 4th quartile, p=0.068. Figure
4.28. There was no relationship between reversibility to salbutamol or post
bronchodilator percentage predicted FVC and hydrogen peroxide levels.






Figure 4.26 Post Bronchodilator (L) per Hydrogen Peroxide Quartile in COPD Ex-
smokers Histograms represent the mean FEVt (L) post bronchodilator in each of the
quartiles of hydrogen peroxide EBC levels. Error bars represent standard error of mean.
Subjects from the first quartile and second quartiles of hydrogen peroxide EBC levels had
higher mean FENA, (1.67±0.23 and 1.68±0.19 respectively) when compared with quartile
four (1.05±0.1), *p=0.046 Q1 vs Q4, **p=0.001 Q2 vs Q4
Figure 4.27 Post Bronchodilator FVC (L) per Hydrogen Peroxide Quartile in COPD Ex-
smokers. Histograms represent the mean FVC (L) post bronchodilator in each of the quartiles of
hydrogen peroxide EBC levels. Error bars represent standard error of mean. Subjects from the first
quartile of hydrogen peroxide EBC levels had a higher mean FVC (3.34±0.32) when compared with
quartile four (2.40±0.19), *p=0.02 Q1 vs Q4. Mean FVC levels (3.20±0.33) in the second quartile





Figure 4.28 Post Bronchodilator Percentage Predicted FEN^ per Hydrogen Peroxide
Quartile in COPD Ex-smokers. Histograms represent the mean percentage predicted FEV!
post bronchodilator in each of the quartiles of hydrogen peroxide EBC levels. Error bars
represent standard error of mean. Subjects from the second quartile of hydrogen peroxide
EBC levels had a higher mean %pred FE\A| (66.0±6.3) when compared with quartile four
(39.7±4.2), **p=0.003 Q2 vs Q4. Mean %pred FEVi levels (54.3±6.3) in the first quartile
was close to a statistically significant difference when compared with quartile 4, p=0.068.
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4.6 Conclusions
The study populations were not age matched. Prostaglandin E2 and pH were
measurable in the Exhaled Breath Condensate of subjects with COPD and healthy
controls. 8-lsoprostane and hydrogen peroxide were also detectable in the majority
of trial subjects. However these measurements were often close to the limit of
detection of the assay.
There was no major variation in the pH of breath condensate or levels of 8-
Isoprostane found in breath condensate between patients with COPD and controls
without respiratory disease. Furthermore current smoking habit did not appear to
affect levels of these two biomarkers.
Ex-smokers, both subjects with COPD and controls, had higher mean levels of
hydrogen peroxide in EBC compared with control non-smokers and current
smokers. Subjects with COPD had higher mean levels of hydrogen peroxide
compared with controls.The majority of subjects in the control group had significant
non respiratory co-morbidities. Subjects with co-morbidity appeared to have
elevated levels of PGE2 and 8-lsoprostane when compared with controls with no
co-morbidities. This observation is made without fully categorising the non
respiratory co-morbidities. No similar trend was demonstrated in the pH level or
hydrogen peroxide measurements in EBC. Levels of PGE2 and 8-lsoprostane were
similar in the group with COPD compared with the group with non respiratory co¬
morbidity.
Levels of the four biomarkers in EBC did not appear to relate to age, sex,
nutritional status or lung function in the control subjects. In a similar fashion, PGE2
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and pH in EBC in the COPD group bore no relation with any of the identified
parameters of disease.
In the group of COPD current smokers a relationship was demonstrated between
levels of 8-lsoprostane and ICS use, with a trend towards a similar result in PGE2.
No other relationship was identified with any of the health parameters applied. In
contrast, 8-lsoprostane levels in the EBC of ex-smokers with COPD were
significantly related to health status, with higher levels associated with worsening
health status, exacerbation frequency and symptom scores. Higher 8-lsoprostane
levels were also related to a reduced FEV-|. Hydrogen peroxide levels also
appeared to be inversely correlated with airflow limitation.
In conclusion, none of the four biomarkers studied appear to be useful in
differentiation of COPD from patients without respiratory disease. Non respiratory
co-morbidity appears to affect measurement of inflammation and oxidative stress in
EBC.
EBC measurement in current smokers with COPD did not appear to help
characterise the disease process. In contrast, in the group of subjects with COPD
who were ex-smokers, 8-lsoprostane levels, and to a lesser extent hydrogen
peroxide, were related to a variety of health parameters. The number of subjects in
each quartile of the two COPD groups was small.
The positive results demonstrated in section 6.4 should therefore be interpreted
with caution. A repeat study, with a larger sample size, would be required to
support these initial results.
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Assessment of EBC Oxidative Stress in subjects with COPD who are not currently
smoking may be of use in classifying the extent of ongoing disease activity.




Impact of Inhaled Nacystelyn on Patients
with Chronic Obstructive Pulmonary
Disease
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Chapter 5 Impact of Inhaled Nacystelyn on Patients
with Chronic Obstructive Pulmonary Disease
5.1 Introduction
Chapter One of this thesis describes the oxidative stress hypothesis for Chronic
Obstructive Pulmonary Disease. In this hypothesis, subjects with COPD have
higher levels of oxidative stress in the lungs along with an impaired anti-oxidant
defence system. This results in direct damage to the lung together with increased
inflammation and cellular influx. These processes result in further tissue damage
and the development of COPD.
The major extracellular anti-oxidant in the lung is glutathione. Glutathione and
cysteine, the immediate precursor of glutathione, have poor bio-availability, limiting
their clinical usefulness as a therapy. N-Acetylcysteine is a precursor of cysteine.
When administered orally it is readily metabolised by the liver to produce
glutathione. The majority of this glutathione produced is consumed in the liver,
limiting the effect it will have on glutathione levels in the lung. N-Acetylcysteine is
acidic and not tolerated when inhaled.
Nacystelyn is the lyseine salt of N-Acetylcysteine, has a neutral pH and is tolerated
by inhalation. Inhalation of Nacystelyn (NAL) may increase the levels of glutathione
in the lung. As discussed in chapter 1, improved pulmonary anti-oxidant defences
may reduce the level of oxidative stress in subjects with COPD. Reduced oxidative




Inhaled antioxidant therapy will improve health status, lung function
and biomarkers of inflammation and oxidative stress in patients with
COPD
5.3 Study Objectives
The primary objective was to determine if the efficacy of NAL 20 mg bd and
NAL 40 mg bd was superior to that of placebo in a 2 centre, randomised, double-
blind, placebo-controlled, Phase I la study of patients with moderate to severe
COPD after 12 weeks administration. Health status measured using the St.
George's Respiratory Questionnaire (SGRQ) was the primary endpoint (appendix
5.3).
Secondary objectives were to evaluate the efficacy of NAL 20 mg bd and NAL
40 mg bd compared with that of placebo using a variety of parameters, including
non-invasive biomarkers of oxidative stress and inflammation, diary card




Subjects were recruited after clinical and spirometric confirmation of their
diagnosis. An initial two to four week run-in period was followed by twelve weeks of
treatment of one of the three arms of the study, randomised in a double blind
manner on a 1:1:1 ratio. Subjects were assessed during the study, immediately at
the end of trial and two weeks after trial completion.
5.4.2 Trial Subject Selection
Informed consent was obtained prior to assessing subjects' suitability for trial
participation. Subjects with a firm clinical diagnosis of COPD were recruited into
the trial. Confirmation of the diagnosis was made from clinical history, physical
examination, spirometric assessment and review of case records.
To participate in the study subjects were required to be over 40 years of age, be
either current or ex-smokers with at least 10 pack years and have a confirmed
clinical diagnosis of COPD. Subjects were also required to have spirometric
confirmation of irreversible airflow limitation, have chronic symptoms of
breathlessness and have had at least one exacerbation of their condition in the last
year. Subjects were required to be clinically stable, as defined by no exacerbation
in the previous month, (appendix 5.2)
The population studied is prone to exacerbations; one such exacerbation requiring
steroids and/or antibiotics during the trial would not result in withdrawl from the
trial. Failure to recover from this exacerbation or a subsequent exacerbation during
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the trial period would indicate that the subject's disease was too unstable to allow
continued trial participation.
Subjects were excluded from the trial if they had a clinical diagnosis of asthma or
any other active lung diseases. Subjects with unstable non-respiratory conditions
or a history of malignancy in the previous five years were also excluded, (appendix
5.2)
5.4.3 Spirometric Assessment
Clinical suspicion of COPD was confirmed by spirometric testing. As mentioned in
the GOLD definition, subjects with COPD demonstrate airflow limitation which is
not fully reversible. For the purpose of this study we recruited patients who
demonstrated moderate to severe airflow limitation defined as a Forced Expiratory
Volume! (FEVi) between 30-70% predicted with a FEVi to Forced Vital Capacity
(FVC) ratio of less than 70%. Reversibility of airflow obstruction was then assessed
twenty minutes after administration of 2.5mg nebulised salbutamol. Significant
reversibility was defined as greater than 200ml increase absolute FEVi and greater
than 15% increase percent predicted FEVi. Subjects who demonstrated this
degree of reversibility were excluded from the trial (appendix 2.5).
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5.4.4 Therapy during Trial
Administration of medications was assessed prior to trial participation and
monitored for the duration of the trial. Attempts were made to minimise alterations
to medications during the course of the trial. No alterations were made to non¬
respiratory medications.
Inhaled |B2-agonists, both short-acting (e.g. salbutamol) and long-acting
(e.g. salmeterol) were allowed during the study as were inhaled short acting
anticholinergics (e.g. ipratropium bromide). Inhaled long acting anticholinergics
(e.g. tiotropium) were not permitted during the trial; subjects on this medication
were excluded from trial entry. Oral mucolytics and theophyllines were also
prohibited during the trial and subjects on these medications were excluded from
trial entry.
Inhaled corticosteroids (ICS) are widely used in the management of COPD. To
ensure that administration of ICS did not lead to bias in the trial it was decided to
ensure that all patients were on regular ICS for a minimum of 4 weeks prior to trial
entry, and that all subjects were taking the same type, dose and device of ICS.
Subjects who were not already on an ICS were commenced on Fluticansone
Accuhaler 250 pg bd 4 weeks prior to randomisation. Those already on an ICS
were changed to Fluticansone Accuhaler 250 pg bd. Subjects on other ICS therapy
were asked to discontinue this therapy. Subjects on combination ICS and long
acting R> agonist therapy were asked to discontinue this medication and were
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issued with an appropriate long acting R> agonist along with the standard ICS used
in this study. Subjects using different delivery systems of Fluticasone were asked
to discontinue these and take an accuhaler.
Administration of one course of oral corticosteroids for an exacerbation of COPD
was permitted at a dose of 30 mg prednisolone per day for a maximum of two
weeks. Antibiotics were allowed if given for less than 2 weeks during a single
respiratory exacerbation or for reasons other than a respiratory exacerbation.
5.4.5 Screening Demographics prior to trial entry
The following screening demographic information was obtained; age, sex, race,
weight, height, body mass index, alcohol intake, smoking status and smoking pack
years.
All relevant medical history was recorded. Active medical history, defined as
medical conditions that were ongoing at start of study, was to be summarised
separately.
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5.4.6 Trial Subject Participation
The trial consisted of a 2-4 week run-in period, a 12 week treatment period and a 2
week follow up period with a total of 6 study visits, (appendix 5.1)
5.4.6.1 Run-in Period Visit 1 (Week -A to -2)
After consent was confirmed, clinical assessment including spirometry was
performed. Each patient was then instructed how to use the study medication
inhaler device (appendix 5.5). Patients were issued with placebo capsules, 50mg
anhydrous p-lactose 4 capsules bd, to be taken along with Fluticasone Accuhaler
250 pg bd.
Subjects were issued with a diary card (appendix 5.4) and asked subjectively to
record daily their symptoms of cough, wheeze, breathlessness, sputum production
and colour, nocturnal symptoms along with the impact of disease on activities of
daily living. Subjects were also encouraged to record any new or changing
symptoms which they experienced during the duration of the trial.
Plasma sampling was performed; measurement was made of renal and liver
function including glucose, creatinine, total protein, alanine aminotransferase,
aspartate aminotransferase, gamma-glutamyl transferase, total bilirubin, uric acid,
alkaline phosphatase, sodium, potassium, phosphate, albumin and calcium. Full
blood count was also measured including haemoglobin concentration, haematocrit,
platelet, red blood cell count, mean cell volume, white blood cell and differential
counts. Samples were also taken to allow measurement of systemic oxidative
stress and inflammation (appendix 2.4)
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Subjects were then asked to return after 2 weeks if they were currently on ICS and
after 4 weeks if they were steroid naive.
5.4.6.2 Randomisation - Visit 2 (Week 0)
At Visit 2 (Week 0), subject's willingness to participate in the trial was confirmed.
Repeat clinical status was assessed; any significant change from previous
attendance was recorded. Health status was measured using St Georges
Respiratory Health Questionnaire (SGRQ). Diary cards were reviewed and
medication returned, capsules counted to ensure compliance, consumption of 80%
of study medication considered to be good compliance.
Exhaled breath condensate was obtained, subjects were asked to breathe for ten
minutes into a Jaeger Ecosystem, exhaled breath condensate was then aliquoted
and frozen at -80°C (appendix 2.1). Plasma sampling was performed followed by
spirometry pre and post nebulised 2.5mg salbutamol. Finally sputum induction was
carried out, samples obtained were then processed within 4 hours of collection
(appendix 2.3). Subjects were then randomised and issued with study medication
along with a fresh diary card.
Patients were randomised in a 1:1:1 ratio to receive NAL 20 mg bd, NAL 40 mg bd
or placebo along with Fluticasone. Randomisation was performed using a validated
system that automates the random assignment of treatment groups to
randomisation numbers. The randomisation scheme was held by authorised
personnel not actively involved in the study and locked by them after approval.
204
Selection And Timing Of Dose For Each Patient
Group NAL 20 mg bd NAL 40 mg bd Placebo


































Doses were to be taken twice daily, administered using the MIAT monodose DPI,
allowing the powder to be inhaled through the mouth. The 20 mg dose group took
two active nacystelyn capsules and two placebo capsules, the 40 mg dose group
took four active nacystelyn capsules, and the placebo group took four placebo
capsules in the morning and in the evening. Dosing was to be 12 hours apart.
In addition to their study medication all patients were to take a fixed daily dose of
inhaled fluticasone (250 pg bd) to standardise the inhaled corticosteriod treatment
for all patients.
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5.4.6.3 Trial Monitoring Visit 3 (Week 2)
At Visit 3, clinical assessment including spirometry was performed. Any significant
changes in symptoms were recorded. Compliance with therapy was assessed.
Diary cards were reviewed and a new diary card was issued.
5.4.6.4 Trial Monitoring Visits 4 (Week 4) and 5 (Week 12)
At Visit 4 (Week 4) and Visit 5 (Week 12), clinical assessment including spirometry
was performed, along with review of diary cards. Any significant change in
symptoms or new symptoms was recorded. Health status was again assessed
using SGRQ. Treatment compliance was confirmed by counting medications
returned. EBC, plasma and induced sputum were obtained and stored for analysis.
At Visit 4 subjects were issued with further medication and diary cards. At Visit 5 all
medication was collected and it was ensured that subjects had a supply of their
previous inhaled therapy, at which stage trial participation was ceased.
5.4.6.5 Trial Follow-Up - Visit 6 (Week 14)




Measurement of health status was assessed using health questionnaires and
symptom diary cards. Objective analysis of response to therapy was carried out
using spirometric measurement of lung function along with non-invasive
biomarkers from exhaled breath condensate, induced sputum and plasma.
5.5.1 St Georges Respiratory Health Questionnaire (appendix 5.3)
Initially published in 1991 the St Georges Respiratory Health Questionnaire is a
well validated assessment of health status in COPD. Subjects are asked to
respond to 72 questions. The responses are then applied to a formula which
generates a total score. The scores range from 0, no effect on health status, to
100, maximal effect. This total score can then be subdivided into three component
scores (symptoms, activities and impact) each of which again range from 0-100. An
improvement of 4 units has been shown to be associated with a clinically
significant improvement(389).
5.5.2 Diary Cards (appendix 5.4)
Subjects were asked to keep a daily diary. They were asked to record scores for
cough (0=no cough to 3=cough throughout day), breathlessness (0=no
breathlessness to 4=breathlessness at rest), sputum production (0=no sputum to
3=sputum throughout day), sputum colour (0=no sputum to 4 dark green/ yellow
sputum), number of night awakenings, time off work, time unable to carry out
household tasks and any changes in medications. They were also encouraged to
record any new or changing symptoms which they experienced during the course
of the trial.
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5.5.3 Spirometry (appendix 2.5)
Lung function was assessed using a Vitalograph Spirometer. Subjects were
requested to abstain from short acting (i-agonists and anticholinergics for 8 hours
and long acting G-agonists for 24 hours.
Subjects were requested to inhale fully then exhale as hard and fast as possible
into a mouthpiece until their lungs emptied. Each test was repeated until three
recordings had been obtained with a variation of less than 5%
Subjects were then given 2.5mg of nebulised salbutamol and lung function was
repeated fifteen minutes later.
Percentage predicted lung volumes, dependant on age, height, sex and race were
calculated using the following formula:-
(4.3 x height) - (0.029 x age) - 2.49 for males
(3.95 x height) - (0.025 x age) - 2.60 for females
5.5.4 Non Invasive Biomarkers
The utility of biomarkers of airways inflammation and oxidative stress is discussed
in Chapter 1 of this thesis. The following biomarkers were selected for
measurement during this trial on the basis of previous published studies. Exhaled
Breath Condensate was collected using a standard operating protocol (appendix
2.1) and levels of Hydrogen Peroxide, 8-lsoprostane, Leukotriene B4 and
Nitrotyrosine measured (appendix 2.6, 2.7,2.8). Induced Sputum was collected
(appendix 2.2, 2.3), differential cell counts calculated and supernatant analysed for
levels of IL-1G, IL-6, IL-8 and TNF-a(appendix 2.9).
Plasma samples were collected and differential cell counts, high sensitivity CRP
and Thiobarbituric acid reactive substances measured (appendix 2.10, 2.11).
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5.6 Ethical Approval
Ethical permission for this study was obtained from the Ethics Committee of
Lothian Acute Hospitals NHS Trust prior to study commencement. Written
information regarding this study was provided to all subjects at least 24 hours prior
to trial recruitment. Written informed consent was signed before study participation
5.7 Statistical Analysis
Analysis of the baseline characteristics of the study groups was performed using
Tukey One Way Analysis of Variance (ANOVA), Fisher's Exact Test and Non
Paired T-Tests. Exacerbations rates and side effects during the trial were
compared using Fisher's Exact Test and non-paired T-test. Spirometric data, which
had a parametric distribution, was analysed using Tukey One Way Analysis of
Variance (ANOVA). Within-group analysis comparing changes from baseline to a
study visit was performed using paired t-test.
Data obtained from the St Georges Health Questionnaire, diary cards and non¬
invasive biomarker measurement was of a non-parametric distribution. Group
analysis was therefore performed using the Dunn version of ANOVA. Comparison
within groups of two points in the trial was performed using Wilcoxon matched
pairs.
This study was conducted over an 18 month time period. A power calculation prior
to trial commencing indicated that in the region of 100 patients would be required in
each study arm sufficiently to power the SGRQ results in the study, 300 patients in
total. It was understood prior to trial commencement that we would be unlikely to
recruit this number of patients. This was the first clinical study of this therapy in
COPD. The study was run as a "proof of principle" and to observe tolerance of the
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treatment with the appreciation that it may be insufficiently powered to answer the
primary endpoint of health status change.
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5.8 Demographics
A total of 58 patients participated in the trial. There were 19, 20 and 19 patients in
the 40mg bd, 20mg bd and placebo groups respectively. The patients were
predominately males (36M, 22F) with no significant variation between the three
arms. Mean age was 66.5 (±8.8), range 48-94, BMI 26.1 (±5.2) range 15.8-41.4,
neither of these parameters varied significantly between the treatment groups.
(Table 5.1)
Twenty-six of the 58 (45%) patients were current smokers. The placebo (12/19)
and 40mg bd (9/19) groups had more current smokers than the 20mg bd group
(5/20), although these differences were not statistically significant (p>0.05).
Average smoking history was 47(±21.5) pack years, range 15-120 pack years.
There were no statistically significant differences in pack years between the
groups.
Thirty-eight of the 58 (66%) patients participating in the trial were on inhaled
corticosteroids prior to trial entry. Sixteen of the 20 (80%) patients in the 20mg bd,
13 of the 19 (68%) in the placebo group and 9 of the 19 (47%)in the 40mg bd
having recently been on ICS. 59% of patients were on long acting bronchodilators
prior to trial entry.
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Trial subjects' health status, as assessed by St Georges Respiratory
Questionnaire, demonstrated wide variation between individuals, but did not differ
significantly between the three treatment arms prior to trial entry. The SGRQ will be
discussed in more detail in the results section.
Lung function prior to study commencement demonstrated moderate to severe
airflow limitation, mean absolute FEN^ post bronchodilator 1.301 (SD 0.461), range
0.42-2.841, mean percentage predicted FEVi post bronchodilator 49% predicted
(SD 12.1%), range 28-77%.
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Table 5.1 Patient demographics prior to trial commencement per treatment
group. BMI=body mass index, ICS=inhaled corticosteroids, LABD=long acting
bronchodilator, FEVi= forced expiratory volume in 1 second post bronchodilator,
SGRQ=St Georges Respiratory Questionnaire.
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5.9 Study Details
The study ran from the 6th of January 2003 until the 18th of August 2004. A total of
58 patients were randomised into the study. Overall 44 of the 58 (74.1%)
completed the study. Fourteen patients (24.1%) did not complete the study. Only
one clinically significant exacerbation of COPD defined, according to ERS/ATS
guidelines, as "an acute change in a patient's baseline breathlessness, cough
and/or sputum beyond day-to-day variability sufficient to warrant a change in
therapy", was allowed during the trial. As mentioned in section 5.4.2, the trial
protocol stated that failure to recover from the first exacerbation or a further
exacerbation would be felt to indicate clinically unstable disease and would result
in withdrawl from the trial. Two subjects (1 in the 40mg bd NAL, 1 in the 20mg bd
NAL) were withdrawn from the study due to recurrent exacerbations of COPD.
Eleven of these 14 patients withdrew because of side effects. None of these side
effects were classified as major eg. life threatening or requiring hospitalisation,
urgent medical review or change in medication. Two subjects withdrew solely due
to worsening respiratory symptoms other than recurrent exacerbations of COPD.
Four withdrew because of a combination of side effects from respiratory and other
systems. Five withdrew because of symptoms not originating from the lower
respiratory tract. Other systems involved included neurological (3), cardiovascular
(2), musculoskeletal (2), genitourinary (1) and dermatological (1). There was no
significant difference in the number of subjects withdrawing from the trial due to
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side effects between the three treatment arms. One subject in the 40mg bd NAL







Randomised 19 (100) 20(100) 19(100)
Completed 15 (79) 16(80) 13 (68)
Withdrawn 4(21) 4(20) 6 (32)
Adverse Event 4(21) 3(15) 4(21)
Recurrent Exac 0(0) 1 (5) 1 (5)
Withdrew Consent 0(0) 0(0) 1 (5)
Table 5.2 Subject trial completion per treatment arm and reason for withdrawal.
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5.10 Side Effects and Adverse Events
A total of 155 side effects were reported during the course of the study. Side
effects which occurred frequently (>5% of side effects in study population) within
the groups are described below.
The most frequent adverse event in each treatment group was an exacerbation of
COPD. A total of 23 exacerbations affected 21 subjects participating in the trial.
Fewer patients had exacerbations in the 20mg bd NAL group compared with
placebo (p=0.048). No statistical difference was seen between the 40mg bd NAL
group and placebo or between the 20mg bd NAL group and the 40mg bd NAL
group. Figure 5.1.
Side effects other than exacerbations of COPD were frequently reported during the
trial. Subjects in the 40mg bd NAL and 20mg bd NAL were more likely to report
symptoms of sore throat or cough compared with placebo, and less likely to report
symptoms of headache, muscle cramp, upper respiratory tract infection or dry
mouth. None of the differences between groups was statistically significant.
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Placebo 20 mg bd 40mg bd
Figure 5.1 Clinically significant exacerbations during trial
Number of clinically significant exacerbations during trial per treatment group
relative to the number of patients in each group (black histograms) expressed as
the number of exacerbations (hatched histograms) and as the number of subjects








Randomised 19 (100) 20 (100) 19 (100)
Exacerbations 10 (53) 5(25) 8(42)
Table 5.3 Exacerbations during trial per treatment group.
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Figure 5.2 Number of Side Effects Noted During Trial. Number of patients reporting the
most commonly reported side effects experienced during the trial in each treatment group, 20mg bd
(hatched histograms) and 40mg bd (white histograms), compared with placebo (black histograms).
No statistically significant difference in reported side effects is noted between the three groups.
Placebo NAL 20mg bd NAL 40mg bd
n (%) n (%) n (%)
Randomised 19 (100) 20(100) 19 (100)
Sore Throat 0(0) 4(20) 4(21)
Cough 1 (5) 4(20) 3(16)
Headache 4(21) 3(15) 0(0)
URTI 3(16) 2(10) 1 (5)
Muscle Cramp 4(21) 0(0) 1 (5)
Dry Mouth 3(16) 0(0) 0(0)
Table 5.4 Side Effects during trial per treatment group
Number and percentage of patients who experienced the most frequently reported adverse events
during the trial per treatment group
5.11 Spirometry
Spirometry was performed on all patients to assess suitability for trial entry. Post
bronchodilator FEVi and FVC was assessed at baseline and after 4 and 12 weeks
of trial therapy.
Results discussed below relate to those subjects who completed the trial. Results
are expressed as absolute post bronchodilator FEVi in litres and also percentage
predicted post bronchodilator FEVi. A wide range in FEVi was noted for each
treatment arm prior to trial commencement with no significant difference between
the three treatment arms.
Mean absolute FEV in the placebo group dropped by 60ml from 1.411 to 1.351
during the duration of the trial, however this was not statistically significant
(p>0.05).
A small improvement in FEV-i (60ml) was demonstrated in the 20mg bd NAL group
at week 4 of the trial which was statistically significant when compared with
baseline (p=0.022). A trend towards improvement (40ml) was noted at the end of
trial compared with baseline, but this did not achieve statistical significance
(p=0.10)
40mg bd NAL produced a small improvement in FEVi(l) at week 4 of trial therapy
(60ml) which was statistically significant (p=0.021) compared with baseline levels.
There was no statistical difference between baseline levels and trial completion
FEVi for this group.
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Analysis between treatment arms did not demonstrate any significant changes in
FEVi.
In summary there was evidence of small changes in the FEVi within the treatment
groups at week four of the study. However this was not demonstrated at trial











Figure 5.3 Post Bronchodilator FEVi during trial in each treatment group.
Histograms represent the mean and error bars the SEM. Black histograms
represent week 0 of trial, hatched histograms week 4 and white histograms trial
completion. * = p<0.05 when compared with 20mg bd baseline.+=p<0.05















placebo 20mg bd 40mg bd
Figure 5.4 Post Bronchodilator FEV1 percentage predicted during trial in each
treatment group. Expressed as mean for each group at each stage of the trial, error
bars express standard error of mean. Black histograms represent week 0 of trial,
hatched histograms week 4 and white histograms trial completion.
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Placebo n=15 20mg bd n=14 40mg bd n=13
Wk of tial Post Bronchodilator FEVt (L) (MEAN ± SEM)
0 1.41±0.16 1.23±0.08 1.29±0.16
4 1.37±0.16 1.29±0.08 1.35±0.16
12 1.35±0.17 1.28±0.08 1.33±0.16
Placebo 20mg bd 40mg bd
Post Bronchodilator Percentage Predicted FEVi (MEAN ± SEM)
0 50.21±3.27 47.73±3.57 47.31±3.54
4 48.79±3.70 49.87±3.24 49.54±3.56
12 48.36±3.76 49.40±2.98 47.69±3.56
Table 5.5 Post bronchodilator FEV1 in litres and percentage predicted during
course of trial for each treatment group. Values expressed as mean and standard
error of mean
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5.12 St Georges Respiratory Questionnaire
St Georges Respiratory Questionnaire (SGRQ) was completed at commencement
of trial therapy (week 0), after 4 weeks of therapy and at trial completion. Patients
who withdrew from the trial had an Early Termination visit (ET) at which a SGRQ
was collected where possible.
SGRQ was available from all 58 participants at baseline. Ten patients withdrew
prior to week 4, 8 of whom completed a SGRQ. 48 questionnaires were completed
at week 4. Five subjects who withdrew between week 4 and week 12, 1 completed
a SGRQ. SGRQ was obtained for 43 patients at trial completion. A breakdown of
the SGRQ per treatment arm is listed below.
Review of response to treatment
5.12.1a Total Scores
Analysis of SGRQ changes in response to treatment was carried out only in those
patients who provided SGRQ at Week 0, 4 and 12. Total scores and component
scores were analysed. Analysis between the groups was carried out using ANOVA.
Changes within treatment arms were analysed using Wilcoxon Matched Pairs
analysis.
Prior to trial commencement, there were no significant differences between the
treatment arms for any component of the SGRQ (table 5.6). Initial analysis of the
changes was made between health status in the two treatment arms compared
with placebo. Additional analysis of changes within the treatment arms was carried
out.
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SGRQ total score improved during the trial in the placebo group from 55.7(±13.5)
at trial commencement to 51,6(±14.9) at week 4 and 50.3(±14.8) at trial
completion, although this change was not statistically significant, p=0.09.Table 6.6,
Figure 5.5d
The NAL 20mg bd produced a 6 point improvement in total score from 54.3 (±18.8)
to 48.3 (±22.0) in total SGRQ score at week 4 of the trial compared with baseline.
However this change was not statistically significant (p=0.08). At trial completion
the total score was clinically and statistically improved when compared with
baseline measurements, from 54.3 (±18.8) to 46.6 (±18.2), p=0.02. Table 5.6,
Figure 5.5d
NAL 40mg bd group produced an improvement in the total SGRQ from 51.45
(±13.38) at baseline to 40.37 (±13.63), at week 4,p=0.0012. At trial termination,
week 12, the SGRQ total score was 49.05 (±15.07) which was not statistically or
clinically different from trial commencement, 51.45 (±13.38). Table 5.6, Figure
5.5d.
The improvements in the SGRQ Total Score demonstrated in the 20mg bd group at
week 12 and the 40 mg bd group at week 4 were statistically significant when
compared with the baseline levels for these groups. However when scores were
compared with placebo no statistically significant changes were noted. This may
relate to the small sample size.
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5.12.2 Component Scores
The SGRQ symptom component did not change during the trial in the placebo
group. In contrast, an improvement of symptom score was seen at trial completion
in the 20mg bd (-12.2 points, p=0.01) and at week 4 in the 40mg bd (-13.8 points,
p=0.001) groups. At these two time points changes in symptom scores had the
largest effect on total health status. A 12.3 point drop in symptom score in the
20mg bd group was noted at week 4 of the trial which was close to significance
(p=0.09). Table 5.6, Figure 5.5a, 5.6a.
SGRQ Activity component changes were noted in the 40mg bd group at week 4 (-
9.9 points, p=0.034). No other statistically significant changes were noted at any
time during the trial although the 5.4 point improvement in the placebo group at
completion was close to statistical significance, p=0.07. Table 5.6, Figure 5.5a,
5.6a.
The impact component of the SGRQ improved by 10.8 points in the 40mg bd group
at week 4 of the trial, p=0.008. An improvement was also seen in the placebo
group at week 4, (-8.6 points, p=0.015). At trial completion the improvement of 7.1
points in the impact score in the 20mg bd group was statically significant, p=0.049,
whilst the improvement in the placebo group, also 7.1 points was close to
significance (p=0.065). In contrast the 40mg bd group impact score returned to
near baseline levels.
In summary the improvement in health status that was noted in the 40mg bd group
at week 4 of the trial was related to all three components of the SGRQ. These
changes were statistically significant when compared with baseline 40mg bd levels
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but not when compared with placebo. In the 40mg bd treatment arm health status
scores returned to baseline levels at trial completion.
Treatment with 20mg bd NAL improved total score at trial completion with the
symptoms component making the main contribution to this change. This was
statistically and clinically significant when compared with the baseline levels in the
20mg bd group. However the changes in the 20mg bd group were not statistically
significant when compared with the placebo group.
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5.5c 5.5d
Figure 5.5 St Georges Respiratory Questionnaire scores during the trial for the
three treatment groups. Scores are expressed as mean and SEM. Black
histograms represent week 0 of trial, hatched histograms week 4 and white
histograms trial completion. The three components of the SGRQ; symptoms (a),
activity (b) and impact (c) of disease along with total scores (d) during the trial for
the three treatment groups. *=p<0.05 vs 20mg bd baseline,+=p<0.05 vs 40mg bd
baseline, ++=p<0.01 vs 40mg bd baseline, +++=p<0.001 vs 40mg bd baseline,




























Symptoms 0 59.1 ±6.4 61.6±5.0 54.61 ±6.4
4 58.5±6.5 0.900 49.3±6.0 0.090 40.80±4.5 0.001
12 58.4±6.0 0.700 49.4±5.2 0.010 52.28±6.7 0.400
Activity 0 74.2±3.7 68.2±4.6 66.22±5.5
4 75.0±3.7 0.900 61,6±7.2 0.150 56.33±6.3 0.034
12 68.8±4.3 0.070 62.4±6.8 0.430 65.82±6.1 0.900
Impact 0 44.3±4.6 44.2±5.7 41.50±3.7
4 35.9±4.1 0.015 40.3±5.8 0.190 30.75±4.1 0.008
12 37.1 ±3.9 0.065 37.1±5.3 0.049 38.19±4.9 0.274
Total 0 55.7±3.5 54.3±4.9 51.45±3.6
4 51,6±3.8 0.060 48.3±5.7 0.080 40.37±3.6 0.012
12 50.3±3.8 0.090 46.6±4.7 0.022 49.05±4.0 0.330
Table 5.6 St Georges Respiratory Questionnaire score during trial for each
treatment group. Figures are expressed as mean of group and standard error of
mean. Total SGRQ score is expressed along with symptom, activity and impact
component of score. The p value is expressed for each stage of the trial compared
with the baseline for that group. Significant p values are in bold.
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5.6c 5.6d
Figure 5.6 SGRQ Symptom (a), Activity (b), Impact (c) and Total Scores (d).
Change from Baseline at Weeks 4 and 12 of trial for the three treatment groups.
Mean SGRQ score was calculated for each treatment group at each of the three
study visits; baseline, after 4 weeks and 12 weeks of therapy. The baseline score
was then subtracted from the mean score at weeks 4 and 12 of the trial for each
treatment group. The three components of the SGRQ are expressed along with the
total score. Histograms represent the mean changes from baseline for placebo
(black), 20mg bd NAL (hatched) and 40mg bd (white).
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5.13 Symptom Diary Cards
5.13.1 Symptom Diary Cards Overview
All subjects who participated in the trial completed a daily diary of symptoms
throughout the trial. Full sets of diary card responses were obtained for thirteen
subjects in the 40mg NAL bd group, 15 of the 20mg NAL bd subjects and 15 of the
placebo subjects.
Trial participants were asked to record scores for cough (0=no cough to 3=cough
throughout day), breathlessness (0=no breathlessness to 4=breathlessness at
rest), sputum production (0=no sputum to 3=sputum throughout day), sputum
colour (0=no sputum to 4 dark green/ yellow sputum), number of night awakenings,
time off work, time unable to carry out household tasks and any changes required
in medications. They were also encouraged to record any new or changing
symptoms which they experienced during the course of the trial. An example of the
daily diary card is found in appendix 5.4.
The mean of symptom scores for each week of the trial were calculated for each
individual. The average score for each treatment arm per week of the trial was then
calculated. Comparisons were then made between baseline and trial completion
within treatment groups and between placebo and active treatment for the duration
of the trial.
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Baseline scores were taken as the average score for the two weeks prior to trial
commencement. Diary card scores were recorded for breathlessness, cough,
sputum production and sputum colour. Further analysis was performed to calculate
of the number of days per week with no or mild symptoms for breathlessness,
cough, sputum production, sputum colour and night time awakenings.
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5.13.2 Diary Card Breathlessness Score
Subjects were asked to record daily breathlessness score from 0, no
breathlessness to 4, breathless at rest (appendix 5.4). Mean breathlessness score
per treatment arm per week prior to trial commencement was 1.8 (±1.3) for 40mg
bd NAL, 1.8 (±1.0) for 20mg bd NAL and 2.0 (±0.9) for Placebo with no significant
difference between the three groups.
Analysis within treatment arms did not show any statistically significant change in
breathlessness scores from trial commencement to completion for the 40mg bd
NAL or the placebo group. A statistically significant improvement in breathlessness
score was noted in the NAL 20mg bd group of between 0.3 and 0.5 at weeks 8
(p=0.004), 10 (p=0.004), 11 (p=0.04) and 12 (p=0.04) of the trial. The mean score











Figure 5.7 Mean Breathlessness score for each treatment group during the trial.
Histograms represent the mean weekly breathlessness scores for all individuals who completed the
trial in each of the treatment groups during the trial, placebo (black histograms), 20mg bd (hatched
histograms) and 40mg bd (white histograms) Error bars express the standard error of mean.
Significant improvement in the 20mg bd group compared with baseline levels was noted at weeks 8,
10,11 and 12 of the trial. No significant change was noted in the 40mg bd group or the placebo












Figure 5.8 Change from baseline levels mean breathlessness score for the three
treatment arms, 40mg bd NAL (diamond), 20mg bd NAL (square) and placebo (triangle).
Mean Breathlessness Score at week 0 is subtracted from the breathlessness score for each week
of the trial, negative figures indicate improvements in mean score during trial. Error bars represent
standard error of mean. Breathless score significantly improved from baseline at weeks 8, 10, 11
and 12 of the trial in the 20mg bd group. * p<0.05 compared with 20mg bd NAL baseline levels.
**p<0.005 compared with 20mg bd NAL baseline levels.
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5.13.3 Number of Days with Mild or No Breathlessness
The impact of treatment on subject reporting of breathlessness was also expressed
as the mean number of days per week subjects in each treatment arm experienced
mild or no breathlessness, equivalent to diary card score 0 or 1.
The 40mg bd and placebo groups did not show any change in the average number
of days per week with mild or no breathlessness throughout the study period. The
mean number of days per week with mild or no breathlessness in the 20mg bd NAL
treatment arm steadily increased during the trial from 2.9 (±3.3) days per week
prior to trial commencement to 5.1 (±3.0) days per week at trial completion. A
statistically significant difference between 20mg bd and placebo was noted at
weeks 4, 6 and 8-12 of the trial. Figures 5.9, 5.10
These data suggest that treatment with low dose NAL (20mg bd) significantly
improves the number of days per week with no or mild symptoms of
breathlessness compared with placebo.
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Figure 5.9 Mean Number of Days perWeek with Mild or No Breathlessness per Treatment
Arm. Histograms represent the mean number of days per week with diary card reporting of
mild or no breathlessness in the three treatment groups during the trial, placebo (black
histogram), 20mg bd (hatched histogram) and 40mg bd (white histogram) for each week of
the trial. Error bars represent the standard error of mean. Significant improvement in the
20mg bd compared with placebo was noted at weeks 4, 6,8, 10-12 of the trial.* p<0.05 vs
placebo for week 4 and 6 of the 20mg bd group and **p<0.005 vs placebo for weeks 8-12
of the trial group.
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Week of trial
Figure 5.10 Change from baseline in the mean number of days with mild or no
breathlessness in the treatment groups. Mean number of days with mild or no
breathlessness for each week of the trial are subtracted from baseline levels,
negative value indicates increasing number of days with breathlessness. Error bars
represent the standard error of mean. Number of days per week with mild or no
breathlessness significantly improved compared with placebo at weeks 4, 6,8, 10-
12 of the trial. *=p<0.05,**=p<0.005
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5.13.4 Cough Score
Diary card responses for cough score ranged from 0, no cough to 3, cough
throughout day, appendix 6.4. Treatment with NAL 40mg bd or placebo did not
affect the reporting of cough in the patient diary cards. NAL 20mg bd demonstrated
a statistically significant improvement of between 0.35 and 0.45 from baseline at
weeks 4, 7, 8 and 12 of the trial, Figure 5.11, 5.12.
These changes noted in the 20mg bd group were not statistically significant when
compared with placebo.
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Figure 5.11 Mean Cough Score during trial per treatment group. Average cough
scores were calculated for each treatment group at each week of the trial.
Histograms represent the mean weekly cough scores for all individuals who
completed the trial in each of the treatment groups during the trial, placebo (black
histograms), 20mg bd (hatched histograms) and 40mg bd (white histograms). Error
bars represent the standard error of mean. Significant improvement in the 20mg bd
group compared with baseline levels was noted at weeks 4, 7, 8 and 12 of the trial.
No significant change was noted in the 40mg bd group or the placebo group. *
p<0.05 compared with 20mg bd NAL baseline levels. **p<0.005 compared with
20mg bd NAL baseline levels.
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Week of trial
Figure 5.12 Change from baseline levels mean cough score for the three treatment
arms, 40mg bd (diamond), 20mg bd (square) and placebo (triangle). Mean Cough
Score at trial commencement was subtracted from the cough score for each week
of the trial, negative figures indicate improvements in mean score during trial. Error
bars represent standard error of mean. Cough score significantly improved from
baseline at weeks 4, 7, 8 and 12 of the trial in the 20mg bd group. * p<0.05
compared with 20mg bd NAL baseline levels. **p<0.005 compared with 20mg bd
NAL baseline levels.
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5.13.5 Number of days per week with mild/ no cough
The effect of treatment on patient diary card recording of cough was also
expressed as the number of days per week with no or mild cough equivalent to
cough score 0 or 1.
Average weekly cough score did not change significantly in any group during the
trial. A comparison of changes with the active treatment and the placebo was also
not significant
Analysis of the 20mg bd group data separately did demonstrate that the change
from baseline was close to statistical significance at week 8 of the trial (p=0.057).
Figure 5.13,5.14
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Figure 5.13 Number of Days per Week with Mild or No Cough per Treatment Arm.
Histograms represent the mean number of days per week with diary card reporting of mild or no
cough in the three treatment groups, placebo (black histogram), 20mg bd (hatched histogram) and
40mg bd (white histogram) for each week of the trial. Error bars express the standard error of mean.
No significant improvement is seen between the treatment groups during the trial.
Figure 5.14 Change from baseline levels mean number of days with no or mild cough for
the three treatment arms, 40mg bd (diamond), 20mg bd (square) and placebo (triangle).
Mean number of days with no or mild cough at trial commencement was subtracted from the
number of days with no or mild cough for each week of the trial, postive figures indicate
improvements in mean score during trial. Error bars represent standard error of mean.
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5.13.6 Sputum Production
Subjects were asked to score daily sputum production, ranging from 0, no sputum,
to 3, sputum throughout the day. There was a wide variation between individuals in
the levels of sputum production before the start of the study. Despite this, and the
small numbers in the trial, trends towards improvement in sputum production were
seen for both treatment groups.
There was no significant change in the sputum production scores in the placebo
arm of the study. In the 20mg bd group there was a trend towards a fall in sputum
production during the trial. This was statistically lower than the 20mg bd baseline
levels at week 9 of the trial, p=0.027. The 40mg bd NAL group demonstrated a non
significant trend towards improved sputum production score at weeks 3, 4 and 7.
There were no significant differences in sputum production comparing placebo
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Figure 5.15 Mean Sputum Production score for each treatment group during the trial.
Histograms represent the mean weekly sputum production scores for all individuals who completed
the trial in each of the treatment groups during the trial, placebo (black histograms), 20mg bd
(htched histograms) and 40mg bd (white histograms). Error bars represent the standard error of
mean. Significant improvement in the 20mg bd group compared with baseline levels was noted at
week 9 the trial. No significant change was noted in the 40mg bd group or the placebo group. *
p<0.05 compared with baseline levels.
Figure 5.16 Change from baseline levels mean sputum production score for the three
treatment arms, 40mg bd (diamond), 20mg bd (square) and placebo (triangle). Mean score
at trial commencement was subtracted from the score for each week of the trial, negative figures
indicate improvements in mean score during trial. Error bars represent the standard error of mean.
Sputum production score significantly improved from baseline at week 9 of the trial in the 20mg bd
group. * p<0.05 compared with baseline levels.
5.13.7 Number of days with mild or no sputum production
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Sputum production is also expressed as the number of days per week with mild or
no sputum production, equivalent to sputum scores 0 or 1. These results run in
parallel with the sputum production scores.
A trend towards improvement from baseline was seen in the 40mg bd and 20mg bd
groups. Again this improvement was most marked early in the trial with the 40mg
bd treatment arm, a 1.0 improvement at week 4 in the number of days with mild or
no sputum production, and later in the 20mg bd group with a 1.6 improvement in
the number of days with mild or no sputum production at week nine. The average
number of days with mild or no sputum production tended to fall from baseline in
the placebo group.
At week 4 of the trial the increase in the number of days with mild or no sputum for
those subjects taking 40mg bd NAL was statistically significant (p<0.05) compared
with placebo. No other statistically significant differences were found. Figure 5.17,
5.18.
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Figure 5.17 Mean Number of Days per Week with Mild or No Sputum Production in
each treatment group during the trial. Histograms represent the mean scores for all
individuals who completed the trial in each of the treatment groups during the trial, placebo
(black histograms), 20mg bd (hatched hsitograms) and 40mg bd (white histograms). Error
bars represent the standard error of mean. Significant improvement in the 40mg bd group
compared with placebo was noted at week 4 of the trial. No significant change was noted
in the 20mg bd group or the placebo group. * p<0.05 compared with baseline levels.
Week of trial
Figure 5.18 Change from baseline levels mean number of days with mild or no sputum
production for the three treatment arms, 40mg bd (diamond), 20mg bd (square) and
placebo (triangle). Mean Score at trial commencement was subtracted from the score for
each week of the trial, positive figures indicate improvements in mean score during trial.
Error bars represent the standard error of mean. The number of days with mild or no
sputum production significantly improved from baseline at week 4 of the trial in the 40mg
bd group. * p<0.05 compared with baseline levels.
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5.13.8 Daily sputum colour
The 40mg bd treatment group demonstrated a trend towards improvement in
sputum colour scoring throughout the trial. This was most marked in the early
stages of the trial, and was close to statistical significance compared with placebo
at weeks 2 and 4 of the trial. Compared with other parameters measured in the
40mg group, the change demonstrated in sputum colour score did not return to
baseline as the trial progressed.
In contrast a similar trend towards improvement in sputum colour was not shown in
the 20mg bd NAL treatment group. Figure 5.19, 5.20
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Figure 5.19 Mean Sputum Colour score for each treatment group during the trial.
Histograms represent the mean weekly scores for all individuals who completed the trial in each of
the treatment groups during the trial, placebo (black histograms), 20mg bd (hatched histograms)
and 40mg bd (white histograms). Error bars represent the standard error of mean. No significant
improvement was noted during the trial.
Figure 5.20 Change from baseline levels mean sputum colour score for the three
treatment arms, 40mg bd (diamond), 20mg bd (square) and placebo (triangle). Mean Score
at trial commencement was subtracted from the score for each week of the trial, negative figures
indicate improvements in mean score during trial. Error bars represent the standard error of mean.
No significant changes were noted during the trial.
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5.13.9 Average number of days per week with colourless/ no
sputum
These data are similar to those for the sputum colour scores. A trend towards
improvement in the number of days with no or colourless sputum is seen in the
40mg treatment arm, which is not statistically significant (p=0.058 at week 4)
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Figure 5.21 Mean Number of Days perWeek with Colourless or no sputum for each
treatment group during the trial. Histograms represent the mean weekly scores for all individuals
who completed the trial in each of the treatment groups during the trial, placebo (black histograms),
20mg bd (hatched histograms) and 40mg bd (white histograms). Error bars represent the standard
error of mean. No significant improvement was noted during the trial
Figure 5.22 Change from Baseline levels mean Number of Days perWeek with
Colourless or No Sputum for the three treatment arms, 40mg bd (diamond), 20mg bd
(square) and placebo (triangle). Mean Score at trial commencement was subtracted from the
score for each week of the trial, positive figures indicate improvements in mean score during trial.
Error bars represent the standard error of mean. No significant changes were noted during the trial.
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5.13.10 Diary Card Summary
In summary, analysis of diary card scores indicated that the 20mg NAL bd
treatment arm showed a significant improvement in the reporting of breathlessness
when compared with placebo. A similar change was shown early in the trial for
40mg bd NAL but this was not sustained throughout the trial. Trends towards
improvement in cough were seen. No improvement was demonstrated in terms of
sputum production or colour nor any improvement in activities.
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5.14 Plasma
Plasma samples were obtained at trial entry (week -4 or -2), week 4 and week 12,
trial completion.
5.14.1 Thiobarburic Acid Reactive Substances
A wide range of Thiobarbituric Acid Reactive Substance (TBARS) levels in plasma
was noted in each of the treatment arms prior to trial commencement, with no
significant differences in the levels between the three treatment groups. This
between-subject variation was noted for the duration of the trial.
A statistically significant (p=0.049) drop in the levels of TBARS measured in the
placebo group was noted from baseline to trial completion, 2.11pmol/l ±3.2 versus
0.74pmol/l ±1.38. Average plasma levels of TBARS in the 20mg bd group
decreased from a baseline of 1.9pmol/l ±3.49 to 1.15pmol/l ±2.8 at week 12. There
was no significant change in TBARs levels in the 40mg bd group. When between
treatment arm analysis was performed there was no statistically significant



















Figure 5.23 Plasma TBARS levels in the three treatment groups. Plasma was obtained
at baseline and weeks 4 and 12 of the trial. Histograms represent the mean in three
treatment groups, placebo (black bars), NAL 20mg bd (hatched bars) and NAL 40mg bd
(white bars). Error bars represent the standard error of mean. A significant drop was
demonstrated in plasma TBARS in the Placebo and 20mg bd groups between baseline
and week 12. *p<0.05
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Figure 5.24 Change from baseline mean plasma TBARS. Histograms represent the means
measured at weeks 4 and 12 of the trial after subtraction of the baseline levels. Negative
values represent a decrease in the level of TBARS measured during the trial. Black
histograms represent placebo, hatched 20mg bd and white 40mg bd. Error bars express
standard error of mean. A statistically significant fall in the plasma TBARS was shown at
week 12 of the trial compared with baseline in the placebo and 20mg bd groups.*=p<0.05
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5.14.2 C-Reactive Protein (CRP)
A wide variation in the level of CRP measured in plasma was noted within each of
the treatment arms at the start of trial. No significant variation was noted between
treatment arms at trial commencement and no significant change was noted in
levels of CRP between treatment arms during the course of the trial. Inhaled NAL
had no effect on plasma CRP during the trial. Furthermore prior use of ICS did not
affect plasma levels of CRP.
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Figure 5.25 Plasma CRP levels in plasma during trial. Plasma was obtained at baseline
and weeks 4 and 12 of the trial. Histograms represent the mean CRP (mg/ml) measured in
plasma in the three treatment groups, placebo (black bars), NAL 20mg bd (hatched bars)
and NAL 40mg bd (white bars) during the trial. Error bars represent the standard error of
mean. No significant change was demonstrated in plasma CRP in the three treatment
groups.
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Figure 5.26 Change from baseline plasma CRP during trial.
Histograms represent the mean CRP measured at weeks 4 and 12 of the trial after
subtraction of the baseline mean, positive values represent an increase in the level of CRP
measured compared with baseline. Black histograms represent placebo, hatched 20mg bd
and white 40mg bd. Error bars represent standard error of mean.
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5.15 Induced Sputum
Absolute and differential cell counts were obtained from induced sputum and
sputum supernatant was analysed for the cytokines IL-6, IL-8, TNF-a, IL-I3. and
VEGF.
5.15 Sputum Production
47 of the 58 (81%) patients recruited into the trial were able to provide sputum for
analysis on at least one occasion. 34 of the 43 (79%) patients who completed the
trial were able to provide sputum on one occasion. 24 of the 43 (56%) patients who
completed the trial provided sputum for analysis on all three visits. Table 5.6
40 mg bd 20 mg bd Placebo
Sputum production of




9/13 (69%) 12/15 (80%) 13/15 (87%)
Full sputum set of
subjects completing
trial
5/13 (39%) 10/15 (67%) 9/15 (60%)
Table 5.6 Sputum production during trial. The majority of patients who were
recruited into the trial were able to provide sufficient sputum for analysis at trial
entry. The majority of those subjects who completed the trial were able to provide
at least one sputum sample for analysis. The proportion of patients who were able
to provide sufficient sputum for analysis on all three trial visits was lower in
comparison, this drop was most marked in the 40mg bd group.
5.15.1 Induced Sputum IL-8
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A wide variation was noted in the levels of IL-8 measured in induced sputum prior
to trial commencement. There was no significant difference in IL-8 levels measured
between the three treatment groups prior to trial commencement.
In the 40mg bd group and placebo there were no significant differences in the IL-8
levels measured during the trial.
There was a fall in levels of IL-8 measured in sputum supernatant in the 20mg bd
group from 1108±597pg/ml at trial commencement to 1026±561 pg/ml at week 4
and 853±550pg/ml at trial completion. Changes from baseline to week 12 of the
trial were close to statistical significance, p=0.0646.
When changes between treatment arms are compared by ANOVA no statistically




















Figure 5.27 IL-8 Levels in induced sputum during the trial in the three treatment groups.
No statistically significant difference was demonstrated between the three groups during
the trial although changes from baseline to week 12 of the trial in the 20mg bd group were
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Figure 5.28 Change in IL-8 levels in induced sputum from baseline during trial. Histograms
represent the level of IL-8 measured at weeks 4 and 12 of the trial after subtraction of the
baseline values. Positive values represent an increase in the level of IL-8 measured during
the trial. Black histograms represent placebo, hatched 20mg bd and white 40mg bd. Error
bars represent standard error of mean.
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5.15.2 Induced Sputum IL-1B
There were no significant changes in levels of IL-113. measured during the trial,


















Figure 5.29 IL-1B in induced sputum during the trial in the three treatment groups. No





Figure 5.30 Change from baseline levels of induced sputum IL-1IS measured during trial.
Histograms represent the level of IL-1IJ measured at weeks 4 and 12 of the trial after
subtraction of the baseline levels, positive values represent an increase in the level of IL-
1li measured during the trial. Error bars represent standard error of mean.
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5.15.3 Induced Sputum IL-6
The placebo group demonstrated a statistically significant increase in the levels of
IL-6 measured from trial commencement 34.8±35.6 pg/ml to 103.8±139.0 at trial
completion, p=0.039. Mean levels of IL-6 measured in induced sputum in the 20mg
bd and 40mg bd groups did not change significantly during the trial. Between group
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Figure 5.31 Induced Sputum IL-6 Levels during the trial in the three treatment groups. A
statistically significant increase in the levels of IL-6 measured in the placebo group at trial






























Figure 5.32 Change from baseline levels of induced sputum IL-6 during trial. Histograms
represent the level of IL-6 measured at weeks 4 and 12 of the trial after subtraction of the baseline
levels, positive values represent an increase in the level of IL-6 measured during the trial. Black
histograms represent placebo, hatched 20mg bd and white 40mg bd. Error bars represent standard
error of mean. A statistically significant increase in the levels of IL-6 measured in the placebo group
at trial completion compared with baseline was noted, *p<0.05.
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5.15.4 Induced Sputum TNF-a
A wide variation in the levels of TNF-a was noted prior to trial commencement. A
higher average level was present in the 20mg bd group compared with placebo
and 40mg bd however this was not statistically significant. The mean TNFa levels
















Figure 5.33 Induced Sputum TNF-a Levels during the trial in the three treatment groups.
No statistically significant change was noted in the levels of TNF-a measured in induced sputum
during the trial in the three groups.
Placebo 20mg bd 40mg bd
Figure 5.34 Change from baseline levels of induced sputum TNF-a during trial. Histograms
represent the level of TNF-a measured at weeks 4 and 12 of the trial after subtraction of the
baseline levels, positive values represent an increase in the level of TNF-a measured during the
trial. Error bars represent standard error of mean. No statistically significant change was noted in
the levels of TNF-a measured in induced sputum during the trial in the three groups.
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5.15.5 Induced Sputum VEGF
A wide variation in levels of VEGF measured was noted in all three treatment arms.
The average levels of VEGF in the 40 mg bd group were lower than the 20mg bd
and placebo groups at trial commencement. However this was not statistically
significant. There was no significant variation in the levels of VEGF measured in














Figure 5.35 Induced Sputum VEGF Levels during trial in the three treatment groups. No
statistically significant change was noted in the levels of VEGF measured in induced












Figure 5.36 Change from baseline levels of Induced Sputum VEGF during trial. Columns
represent the level of VEGF measured at weeks 4 and 12 of the trial after subtraction of
the baseline levels, positive values represent an increase in the level of VEGF measured
during the trial. Error bars represent standard error of mean. No statistically significant
change was noted in the levels of VEGF measured in induced sputum during the trial in
the three groups.
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5.16 Exhaled Breath Condensate
Exhaled breath condensate was measured at trial commencement, after 4 weeks
of therapy and after 12 weeks of therapy. Three biomarkers of oxidative stress,
hydrogen peroxide, 8-lsoprostane and 3-nitrotyrosine were measured along with
Leukotriene B4 as a marker of inflammation. A wide variation was seen in levels of
all biomarkers measured prior to trial commencement with no significant variation
between groups. Treatment with inhaled NAL had no effect on levels of any of the
selected exhaled biomarkers during the trial.
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5.16.1 8-lsoprostane
A wide variation was noted in the levels of 8-lsoprostane at baseline for all three
groups from 1,5pg/ml to 275pg/ml with no significant variation between the groups.
A wide variation in levels of 8-lsoprostane was again noted during the trial in all
three treatment groups without any statistically significant changes.
Figure 5.37 Exhaled breath condensate 8-lsoprostane levels during the trial in the
three treatment groups. No statistically significant difference was demonstrated
between the three groups during the trial.
267
5.16.2 Hydrogen Peroxide
A wide range of hydrogen peroxide levels measured in EBC at baseline were noted
from 0.04pM/ml to 15.43pM/ml. Mean levels of hydrogen peroxide did not vary




























Figure 5.38 Exhaled Breath Condensate Hydrogen Peroxide Levels during the trial
in the three treatment groups. No statistically significant difference was
demonstrated between the three groups during the trial.
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5.16.3 3-Nitrotyrosine
3-Nitrotyrosine was below the detection limits of the assay in two thirds of the EBC
samples obtained. There did not appear to be any significant variation within
treatment arms in terms of level of nitrotyrosine or numbers detectable, either prior






















Figure 5.39 Exhaled Breath Condensate Nitrotyrosine Levels during the trial in the
three treatment groups. No statistically significant difference was demonstrated
between the three groups during the trial.
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5.16.4 Leukotriene B4
As per the project protocol, LTB-4 was last to be analysed. The amount of EBC
available from each individual varies. This resulted in only 35 of the 58 trial
participants having sufficient EBC available for analysis of LTB-4. Therefore less
data was available for this biomarker.
There was no variation in the mean levels of LTB-4 measured in EBC as the trial


























Figure 5.40 Exhaled Breath Condensate LTB-4 Levels during the trial in the three
treatment groups. No statistically significant difference was demonstrated between




Inhaled Nacystelyn appeared to be well tolerated during the trial although there
was an increase noted in oropharyngeal pain and discomfort in the two treatment
arms compared with placebo. Subjects taking the higher dose nacystelyn showed
a significant improvement in health status after 4 weeks of trial therapy. However
this was not sustained. Low dose nacystelyn demonstrated less substantial but
clinically significant improvement, in health status at trial completion along with
improvements in diary card reporting of symptoms of cough and breathlessness. A
small placebo effect was also observed.
The improvements in health status noted in the two treatment groups were
statistically significant as individual data could be paired with baseline levels,
strengthening the statistical power. However there were no significant changes
when compared to placebo. With the data available the study was insufficiently
powered to prove that the changes noted in health status in the treatment arms
were statistically different from placebo. A crossover study would have improved
the power of the study.
Biomarkers were not effective in demonstrating the action of nacystelyn. A large
amount of variation was noted in the majority of biomarkers prior to trial
commencement. This may reflect either a wide variation in the amount of oxidative
stress and inflammation in the population studied or demonstrates that the use of
the non-invasive biomarkers selected is not useful in assessing minor changes in




Chapter 6 Discussion and Conclusions
This chapter discusses the results of the studies described in the previous three
chapters and compares these results to previous published work. When possible
conclusions are drawn and possible direction of future research identified. The
results of each study will be summarised before discussing each study.
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6.1 Reproducibility of Exhaled Breath Condensate
Biomarkers
Levels of both hydrogen peroxide and 8-lsoprostane were measurable in exhaled
breath condensate from most patients. The majority of 8-lsoprostane
measurements were close to the limit of detection of the assay. There was a
statistically significant between-visit correlation in measurement of 8-lsoprostane
levels in this study population. Hydrogen peroxide levels were normally distributed
although levels were not detectable in a minority of cases. Hydrogen peroxide
levels did demonstrate a trend toward correlation between study visits. However
this failed to reach statistical significance.
The results of the exhaled breath condensate reproducibility study were similar to
previous publications. In the majority of subjects there was either low level of
biomarkers measured or none detected. Occasionally a high measurement would
be noted. A high level measured on one visit did not guarantee a high level on the
second visit. During the trial subjects were assessed at each visit and if there was
any clinically significant change in their symptoms or signs then they were
withdrawn from the study. These high measurements were therefore independent
from any discernable change in their disease process.
There are several factors which may impact on the variability of exhaled breath
condensate collection. Previous studies have shown that the time of day of
collection(276), the rate of breathing and subsequent volume collected(390), the
use of nose clips(391) and saliva contamination(392) all influence the
reproducibility of breath condensate.
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Other factors which may influence the variability but which have not yet been
studied include time to storage at -80°C, current smoking status and time from last
cigarette, time of last meal and caffeine intake. Factors related to COPD itself
which may influence variability include the FEV^time from last exacerbation and
current inhaled therapy. Again there are no published studies regarding these
factors.
For the purpose of this study we developed a standard operating procedure
following the recommendations of the recent ERS/ATS task force(239), in an
attempt to control for some of these factors. The time of day on which EBC was
obtained was similar for both study visits. All subjects were asked to wear nose
clips and to stop collection if there was a build up of saliva during the collection
process. The duration of collection was limited to 10 minutes; however, no attempt
was made to limit the rate of breathing. It should be noted that the volume of
condensate collected in that time varied from less than 0.5mls to greater than 2mls.
Although the concentration of hydrogen peroxide and 8-lsoprostane was measured
rather than the absolute amount, the volume collected may have had a significant
impact on final results. Further work may be required to assess if controlling the
rate of breathing impacts on the reproducibility in EBC.
Several other measures were employed to try and limit the impact which
individual's habits and lifestyle may have on the reproducibility. Current smokers
were asked to abstain from smoking from the night before the day of collection and
all subjects were asked to withhold caffeine intake on the morning of the test.
Subjects were not, however, asked to fast prior to the study visit. COPD subjects
were asked to withhold inhaled therapy on the day of study visit to attempt to
minimise the effect of these drugs on reproducibility. There is no strong evidence
regarding the impact of inhaled therapy or caffeine on EBC measurements. A
pragmatic approach was adopted in developing our Standardised Operating
Procedure, aiming to minimise the impact of study participation on the individual
whilst controlling for factors which may or may not have an impact.
Study entry was deferred if they had experienced an exacerbation in the previous
month. It is unclear if 4 weeks is sufficient to allow recovery from an exacerbation.
Biernacki et al have shown that 8-lsoprostane levels were elevated at the time of
an exacerbation when compared with two weeks and two months after the
exacerbation. However, it is unclear from this study if these levels had returned to
baseline at that stage(305).Our reproducibility study trial protocol meant that a
subject could have serial measurements at four, six and eight weeks after an
exacerbation. Biomarker levels may vary as a result of the exacerbation, in turn
influencing the repeatability of these measurements.
Thirty seven of forty four (84%) samples obtained in our study had detectable 8-
Isoprostane levels. This compares favourably with the previous published
reproducibility study on 8-lsoprostane where the authors were only able to
measure 8-lsoprostane in 36% of the samples(393). In the majority of cases low
levels were detected (below 10pg/ml). Between sample reproducibility of log 8-
Isoprostan levels was statistically significant although the concordance correlation
co-efficient was low at 0.28.
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Hydrogen peroxide measurement was less promising. Twenty four of the 28
samples (86%) obtained for hydrogen peroxide measurement had detectable
levels, however between visits concordance was lower than in the 8-lsoprostane
study and did not reach statistical significance. This is in keeping with previous
EBC studies. Van Beurden et al measured hydrogen peroxide in EBC of 20
subjects with COPD and 20 healthy controls on 5 occasions over a 3 week period.
The co-efficient of variation in this study was 45% for the COPD group and 43% for
the controls. This study also showed a significant variation in hydrogen peroxide
levels when measured at different time points on the same day.(276)
One possible explanation for this is that, whilst both H202and 8-lsoprostane are
stable end products of oxidative stress, hydrogen peroxide may be metabolised
more rapidly than 8-lsoprostane. Previous unpublished study by this group
indicated that the acute effects of smoking on hydrogen peroxide levels in EBC
returned to baseline 5 hours after smoking. The impact of acute smoking on 8-
Isoprostane appeared more complex with elevated levels in some subjects 24
hours after acute smoking. These data indicate that 8-lsoprostane may be present
in the lung longer than hydrogen peroxide after excess oxidative stress. Thus over
night abstinence may not be sufficient in 8-lsoprotsane measurement in EBC.
The between visit variation of hydrogen peroxide measurement was higher in
COPD subjects when compared with controls independent of smoking status. This
may reflect ongoing acute intermittent oxidative stress, with subsequent variation in
hydrogen peroxide production. There were however only 5 subjects in the COPD
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sub-group and this result should be interpreted with caution. There was no similar
difference between the control subjects and COPD in 8-lsoprostane measurement.
As mentioned earlier, there are other factors which may influence biomarker
variability which were not controlled during the trial. Measurement of hydrogen
peroxide in 7 atopics and 8 controls demonstrated that mean hydrogen peroxide
levels were influenced by the rate of flow of exhaled air, with mean concentration at
a flow rate of 48ml/sec 0.32±0.03pmol/L compared with 0.13±0.02pmol/L at
140ml/sec, p<0.001. In this study EBC was collected on different days. The mean
co-efficient of variation was high independent of the flow rate, 68% (range 28-
193%) at a rate of flow of 140ml/sec and 82% (range 17-930%) at a flow rate of
48ml/sec(394). A further study has shown that the volume of expired air correlates
with the volume of EBC collected(390). It may therefore be that rate of breathing
has a significant influence on the volume of EBC produced, thus influencing
biomarker levels and variability.
Another possible factor influencing the repeatability is sub clinical infection during
the trial. Although subjects were screened for significant change in illness between
study visits, a minor viral illness between visits may not have been noted. A recent
study has shown that hydrogen peroxide levels were acutely elevated in twenty
healthy individuals with the common cold 0.20pmol/L, range 0.03 to 1,2pmol/L
compared with 0.09pmol/L, range <0.01 to 0.4pmol/L, 2 weeks later,
p=0.006(395). This may be another factor influencing the variability of EBC
measurement.
In conclusion, our study corrected for several factors which may influence
biomarker variability. The reproducibility of 8-lsoprostane measurement was
improved when compared with previous studies, possibly as a consequence of
these corrections. Current smoking, despite overnight abstinence appeared to
have a detrimental effect on 8-lsoprostane reproducibility.
Hydrogen peroxide measurement was less reliable, especially in subjects with
COPD. Hydrogen peroxide in EBC appears to be a more acute marker of oxidative
stress. Minor illness or simply the day to day variation in disease activity may
cause significant changes in hydrogen peroxide measurement.
This study indicates that 8-lsoprostane is a more reproducible biomarker when
compared with hydrogen peroxide. Further work on this biomarker may further
improve the reliability of these measurements. The impact of smoking abstinence
acutely on current smokers merits further investigation. The time course of
elevated 8-lsoprostane after an exacerbation may also be of interest. The impact of
the severity of COPD on reproducibility has not been studied. Subjects with COPD
who have very variable disease, with higher exacerbation rates, may have worse
reproducibility than those with more stable disease. The disease severity may also
affect reproducibility. Finally, another area of study is the role of tidal volume and





6.2 Reproducibility of Induced Sputum Biomarkers
Obtaining induced sputum for analysis in subjects without COPD was problematic,
particularly in control non or ex-smokers. The total cell counts obtained and the
percentage of macrophages appeared reproducible in the study population. In
contrast the percentage of neutrophils and eosinophils counted in sputum did not
closely correlate between subject visits.
The cytokines IL-1I3> and IL-6 were not reproducible in the supernatant of induced
sputum. In contrast measurements of levels of IL-8 and VEGF were reproducible
during the trial.
Exhaled Breath Condensate was successfully obtained in all subjects on each
study visit. This reflects the non-invasive nature of the procedure which was well
tolerated by all individuals, even those with severe COPD. In contrast obtaining
induced sputum was more problematic, although there were no major side effects
from the procedure.
Induced sputum production was low specifically in the control subjects who were
not current smokers. Only two of the twenty three subjects (9%) in these groups
were able to provide sufficient sputum for analysis on all three occasions. This
differs from previous studies. For example Spanevello et al(396) were able to
obtain induced sputum in 96 out of 114 healthy non smoking volunteers. It was
unclear from the Spanevello paper if the ability to produce induced sputum was a
selection criterion.The induction protocol differed from our study. In the Spanevello
study 4.5% hypertonic saline was used sequentially for 1,2,4,8 then 16 minutes, a
total of 31 minutes maximum or until sputum was obtained. This procedure was
tolerated well with no significant drop in FEVi(396). In comparison, in our study 3%
nebulised saline was administered for 5 minutes, followed by 4% then 5% for five
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minutes if subjects failed to proved sputum, a total of 15 minutes maximum. The
higher success rate with sputum induction may in part relate to the more prolonged
induction protocol.
Sputum induction was more successful in the COPD group in our study. Eight-six
percent of subjects provide sufficient sputum for analysis on all three visits,
compared with 95% in a reproducibility study by Brightling et al (314) and 100% in
a similar study by Beeh et al(311).
The majority of initial work on reproducibility of induced sputum concentrated on
subjects with asthma and cystic fibrosis along with healthy controls. A study of the
reproducibility of induced sputum in 31 healthy controls by Purokivi et al showed
that 18 were able to produce sputum on two occasions two days apart. The intra
class correlation coefficient (ICC) for percentage neutrophils was 0.76, for IL-6 0.57
and for TNFa 0.66(397). These figures are significantly better than our study with
ICC of 0.26 for % neutrophils and 0.24 for IL-6. A different protocol was used for
sputum induction in the Purokivi study with healthy subjects inhaling 4% saline for
15-20 minutes prior to sputum induction. There was no difference in the sputum
processing or sample anaylsis. There is no comment made in this paper regarding
the smoking habits or other subject characteristics. The superior reproducibility in
the Purokivi paper may be as a result of prolonged saline administration or may
reflect that sampling was performed on two consecutive days.
Measurement of levels of TNFa, IL-8 and neutrophil differential counts in 17
subjects with cystic fibrosis on two days of the same week showed good
reproducibility with intra-class correlation 0.93, 0.82 and 0.82 respectively.(398)
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Reproducibility of neutrophils differential counts measured in induced sputum of 21
asthmatics on two visits at least two days apart demonstrated an intra class
variation of 0.57(309). In a separate study 29 asthmatics had differential cell counts
measured on two visits on two consecutive days and showed an intra class
correlation of 0.85(399).
Previous studies of reproducibility in COPD demonstrate better reproducibility
when compared with our study although results have not been as encouraging as
in other airway disease processes. This may in part reflect the diverse disease
activity in subjects with COPD.
The superior reproducibility in other studies may be as a result of the selection
criteria of the studies. Beeh et al recruited only COPD subjects who were ex-
smokers (311), in comparison 8 of the 21 COPD subjects studied in our group were
current smokers. Furthermore the COPD subjects in this study had a GOLD level 2
disease, all subjects having FEVi between 40% and 70% predicted where as our
study recruited patients with FEVi ranging from 24% to 80%. The intra-class
correlation in the Beeh et al paper was 0.66 for %neutrophils and 0.50 for sputum
IL-8, compared with 0.45 for %neutrophils and 0.43 for IL-8 in our study.
Brightling et al were able to obtain sufficient induced sputum for analysis in 116 of
122 subject visits with COPD. The selection criterion for this study was very similar
to our study as were the patient characteristics although fewer patients were
current smokers(314). Intra class correlation in this study was 0.57 for %
neutrophils.
It may be that current smoking habit has a significant effect on the reproducibility of
induced sputum, although there are too small numbers in the study groups to allow
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further comment on this. Several other factors may influence the reproducibility of
induced sputum such as the time from last exacerbation, with other papers having
a longer time from last exacerbation than our study, and the use of inhaled
corticosteroids. Both the other studies discussed exclusively studied steroid naive
patients.
In conclusion our study has shown that obtaining induced sputum in healthy
controls was difficult using our protocol. This may improve with more prolonged
sputum induction methods. The sputum induction success rate in subjects with
COPD was comparable with previous studies. The reproducibility of %neutrophils
and pro-inflammatory cytokines was inferior when compared with other airways
diseases. Repeatability in previous studies of COPD was also superior compared
with our study, although it does appear that overall induced sputum in COPD is
less reliable than in other diseases. Several factors such as time from last
exacerbation, current smoking and drug therapy may impact on the reproducibility
of the process and merit further study.
Factors relating to the individual subject's disease process, which have not been
commented on in previous papers, such as exacerbation frequency, severity of
cough, sputum volume and character, degree of airflow limitation and airways
lability may all also impact on the reproducibility of induced sputum in COPD.
Controlling for some of these factors may improve reproducibility.
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6.3 Cross Sectional Study of Biomarker
Measurement in Exhaled Breath Condensate
None of the four biomarkers studied appear to be useful in differentiation of COPD
from patients without respiratory disease. Non respiratory co-morbidity appears to
affect measurement of inflammation and oxidative stress in EBC. Breath
condensate measurement in current smokers with COPD did not appear to help
characterise the disease process. In contrast, in the group of subjects with COPD
who were ex-smokers, 8-lsoprostane levels, and to a lesser extent hydrogen
peroxide, were related to a variety of health parameters. Prostaglandin E2 and pH
measurement did not appear to be of any use in characterising the subjects
studied.
Oxidative stress results in generation of free radicals. Cell lipid membranes can be
damaged by these free radicals, a process which is known as lipid
peroxidation(400). 8-lsoprostane is one of these stable end products and is thought
to be biologically active, possibly as a cell mediator(247, 265).
Previous studies have shown that 8-isoprostane is a reliable marker of lipid
peroxidation in vitro(249) and in animal models(245, 250, 251). 8-lsoprostane is
elevated in the urine of patients with COPD when compared with healthy smoking
controls(252). Urine 8-isoprostane correlates inversely with FEVi and Pa02(266).
Initial studies measuring exhaled breath condensate in COPD were encouraging.
Montuschi et al demonstrated increased levels of 8-isoprostane in the EBC of 40
patients with COPD when compared with healthy controls, 12 smokers and 10 non-
smokers. 8-lsoprostane levels were elevated in smokers compared with non
smokers in the healthy control groups. Furthermore acute smoking led to a rise in
8-lsoprostane in healthy controls(260).
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Levels of 8-lsoprostane in EBC of 21 patients with COPD increased during
exacerbations, taking up to two months to return to baseline levels(401). A further
study confirmed elevated 8-lsoprostane in EBC of 30 patients with COPD during
exacerbations. In the same paper 10 subjects with stable COPD were given the
antioxidant carbocysteine which resulted in a fall in EBC 8-isoprostane(402).
Supplemental oxygen increased levels of 8-lsoprostane in the EBC of 23 patients
with COPD, along with 23 healthy subjects(403).
Subsequent published measurements of 8-lsoprostane have been less successful.
Kostikas et al have shown that whilst 8-lsoprostane levels were elevated in the
EBC of 30 subjects with COPD compared with 10 controls, these measurements
did not relate to disease severity, inhaled corticosteroid use or induced sputum
differential cell counts, unlike hydrogen peroxide in exhaled breath condensate
which demonstrated relationships with these endpoints(404). Van Hoydonck et al
collected EBC of 12 smokers three times over a one week period and were only
able to measure 8-lsoprostane in 36% of the samples resulting in major concerns
over reproducibility of this technique(393).
Our study has again shown that 8-lsoprostane could not always be detected in
COPD. 8-lsoprostane was not measured in forty five of the 138 subjects studied
(32%). Twenty four of the 138 (17%) had levels below the accepted Limit of
Detection of the assay whilst 21 of the 138 (15%) provided samples which were not
replicated. The levels of 8-lsoprostane measured were low with only 16 of the 138
subjects having levels greater than 10pg/ml. The proportion of subjects with levels
below the limit of detection did not vary between the five populations studied.
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No significant difference in mean 8-lsoprostane levels was shown between the
groups studied. This may simply reflect the fact that 8-lsoprostane as a biomarker
does not differentiate between COPD and controls.
Another possible explanation is that levels of 8-lsoprostane in EBC reflect the
degree of systemic and pulmonary oxidative stress independent of the disease
process. Whilst subjects with significant pulmonary disease or inflammatory
processes were excluded from the trial, subjects with other disease processes
including cardiovascular and cerebrovascular disease were not excluded. Indeed
only 20 of the 60 (33%) control subjects had no significant co-morbidity. This
reflects the fact that we were attempting to recruit control subjects who had a
significant smoking history and who were age matched to our COPD population.
Therefore these subjects would be expected to have a high incidence of co¬
morbidity.
8-lsoprostane levels in the control group who had no significant co-morbidity were
significantly lower than the subjects with any disease process, including COPD,
3.4pg/ml ± 0.5 versus 5.9 pg/ml ± 0.4, p=0.02. The other co-morbidities were not
strictly categorized and further interpretation of this data is limited.
Current smokers with COPD did not demonstrate any relationship between 8-
Isoprostane levels and markers of disease activity. Again this may indicate the
limited utility of 8-lsoprostane as a biomarker in COPD. Alternatively, given the
relationships demonstrated between ex-smokers with COPD and 8-lsoprostane, it
is possible that acute smoking, despite abstaining for 12 hours, may have a greater
influence on the level of 8-lsoprostane than the degree of chronic lung disease
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activity. The results do indicate however that measurement of 8-lsoprostane in
smokers with COPD does not reflect the severity or degree of disease.
Ex smokers with COPD show several relationships with disease activity. 8-
Isoprostane levels measured did not display Gaussian distribution. Subjects were
therefore divided into quartiles dependant on the level of 8-lsoprostane, including
those subjects with 8-lsoprostane levels below the limit of detection. Subjects in
the highest quartile had significantly higher exacerbation frequency and lower
health status and post bronchodilator percentage predicted FEVi when compared
with those in the group with the lowest levels of 8-lsoprostane. Non-statistically
significant trends were also noted in symptom scores for cough and
breathlessness. Levels in quartiles 2 and 3 did not significantly differ with either
quartile 1 or 4. The numbers in each quartile were small and these results should
be interpreted with caution.
To conclude, in our study, 8-lsoprostane levels in exhaled breath condensate did
not vary between subject groups according to the presence or absence of COPD or
current smoking status. The control groups in the study had significant co-morbidity
which may in part explain this observation.
Ex-smokers with COPD who had high levels of 8-lsoprostane demonstrated higher
exacerbation frequency, lower FEX^ and worse health status compared with
subjects with low levels. However the number of subjects in each group was small
and a larger, possibly multicentre, study would be required to confirm these initial
findings.These results suggest that 8-lsoprostane is of limited use in differentiating
COPD from control but may be of some benefit in assessing disease severity in ex-
smokers.
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Hydrogen peroxide, like 8-lsoprostane, is a product of oxidative stress. Superoxide
ion interacts with water to produce this molecule, a process catalysed by
superoxide dismutase. H202 is a stable product and can be measured in exhaled
breath condensate.
Emelyanov et al demonstrated elevated levels of hydrogen peroxide in EBC of 70
subjects with asthma compared with 17 healthy controls. Furthermore hydrogen
peroxide levels appeared to correlate to FEV-i and bronchial hyperactivity(272).
Loukides et al were able to demonstrate a similar pattern in bronchiectasis with
elevated hydrogen peroxide levels in 37 patients compared with 25 age matched
controls with evidence of correlation between hydrogen peroxide levels and airflow
limitation(273).
Several trials have shown elevated hydrogen peroxide levels in EBC of patients
with COPD. Dekhuijzen et al demonstrated elevated levels in 12 patients with
stable COPD compared with 10 healthy controls. Levels were further elevated
during exacerbations of COPD(90). Two conflicting trials have recently been
published regarding acute changes in exhaled breath condensate hydrogen
peroxide levels during exacerbations of COPD.
Gerritsen et al showed that treatment with high dose systemic corticosteroid
reduced levels of EBC hydrogen peroxide during the first 7 days of acute
exacerbations(274) whilst van Beurden et al did not demonstrate any significant
change in hydrogen peroxide levels in the first week after hospitalisation due to
lower respiratory tract infection in subjects with COPD(275).
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Levels of hydrogen peroxide in COPD patients along with healthy controls
demonstrate diurnal variation. Furthermore the coefficient of variation of hydrogen
peroxide over 21 days in COPD patients is 45%(276).
Hydrogen peroxide, as with 8-lsoprostane, did not appear to vary significantly
between the COPD population and the control group independent of current
smoking status. Furthermore ex-smokers with COPD had higher mean levels of
hydrogen peroxide when compared with current smokers with COPD. This is
despite the COPD current smoking group having worse health status when
compared with the ex-smokers. A similar trend was shown in control subjects with
ex smokers having higher hydrogen peroxide levels than current smokers.
These results may simply reflect the limited usefulness of hydrogen peroxide
measurement in EBC. Previous studies have shown that hydrogen peroxide is
stable at -20°C for one month(405). However it is possible that the duration of time
that samples were stored in the freezer may have impacted on the reproducibility of
these results.
An alternative explanation is that current smokers were asked to abstain from
smoking for at least 12 hours prior to trial visits. Inhaled cigarette smoke both
contains hydrogen peroxide(406) and generates further hydrogen peroxide in the
lung after inhalation(407). A variety of anti-oxidant systems in the lung exist to
metabolise H2C>2SUch as catalase and glutathione peroxidase(408). Acute
abstinence from cigarette smoke may result in excess activity of anti-oxidant
defence compared with levels of oxidative stress; this may result in acute reduction
in levels of hydrogen peroxide.
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In contrast to 8-lsoprostane, no significant trends were demonstrated between the
level of hydrogen peroxide and disease activity in ex smokers with COPD. The
most obvious conclusion to draw from this is that H2O2 in EBC does not relate to
disease activity in COPD.
In summary our study has failed to identify a relationship between the levels of
hydrogen peroxide and 8-lsoprostane in exhaled breath condensate and the
presence or absence of COPD in current and ex-smokers. 8-lsoprostane levels in
ex-smokers with COPD possibly relate to disease severity in these subjects.
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6.4 Effect of Inhaled Nacystelyn on Subjects with COPD
A variety of end points were measured in the Inhaled Nacystelyn study, including
measurement of health status, diary card reporting of symptoms and non-invasive
biomarkers. This section will discuss each end point separately.
6.4.1 Health Status
Health status assessment as a measurement of disease severity in COPD has
developed in recent years. This is in part due to the recognition that COPD is a
multi-factorial and systemic disease. Patients who suffer from this disease may
have symptoms and signs not directly related to airflow obstruction which can have
a significant impact on their health. Examples of this include exacerbation
frequency(409, 410), low BMI(41), depression(411) and respiratory muscle
weakness(412). Several of these factors are independent risk factors for mortality.
It has also been shown that FEV-i, despite being associated with mortality, does not
predict response to treatment with bronchosilator therapy(413), or risk of
hospitalisation(414).
The realisation that FEVi alone is not a sufficient marker of disease extent and
activity in COPD has led to the development of health status assessment tools in
COPD.
The St Georges Respiratory Questionnaire is a well validated tool in assessment of
health status in chronic respiratory disease. It is reproducible in stable COPD and
correlates with exercise capacity, MRC symptom scores, disease activity, anxiety
and depression(411 ),(415, 416) There is a rather poor relationship between FEVi
and SGRQ in the region of r= 0.2(417, 418). It has been shown that SGRQ levels
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vary with the GOLD stages of COPD(419). SGRQ is also a useful prospective
predictor of mortality(411, 420-422) and risk of hospitalisation^ 4).
Assessment of clinical improvement in health status assessment is
problematic(389). Studies using the SGRQ have shown that a change of 4 points is
the threshold for clinical improvement, otherwise known as the Minimal Important
Difference (MID)(389), although this may vary; subjects with a poor health status
may benefit from smaller changes in scores(423). The SGRQ has been used in
previous studies to demonstrate changes in health status during
exacerbations(424), bronchodilator(425), long term oxygen therapy(426) and
inhaled corticosteroid (ICS) treatment(71). Recent work has shown that use of ICS
may reduce the rate of decline in health status(71, 427), the major factor in
reducing this rate of decline appears to be the ability of ICS to reduce frequency of
exacerbations(428). Health status decline is associated with frequency of
exacerbations with more frequent exacerbators having a more rapid rate of
decline(428).
Previous studies have shown an improvement in health status with placebo
therapy(71, 73, 414). A patient's assessment of health status is subjective.
Therefore it is to be expected that placebo treatment has some impact on this. An
improvement in health status was demonstrated in the placebo arm of this study.
This may simply reflect a placebo effect, however it was noted that a higher
number of subjects were not on inhaled corticosteroid at trial commencement and
were commenced on ICS at trial entry in the placebo group compared with the
20mg bd group.
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Those subjects in the placebo group who received ICS for the first time during the
trial show greater improvements in total SGRQ scores when compared with
baseline, Table 6.3, although this was not statistically significant. No firm
conclusion can be drawn from this due to the small numbers involved but it
suggests that part of the reason for the placebo effect may be the addition of an
ICS at trial commencement, Figure 6.1.
The St Georges Respiratory Questionnaire has three components; symptoms,
activity and impact. The changes shown in health status during the trial relate to
different components of the SGRQ in the different study groups. The improvement
in health status in the placebo group was due to changes in the impact component
at week 4 and the impact and activity components at week 12, with no effect on the
symptoms score. In contrast the improvement in the 20mg bd NAL group was due
to changes in all three components with symptom scores having the largest effect
at both week 4 and trial completion. All three components of the SGRQ improved
at week 4 of the trial in the 40mg bd NALgroup with all three components returning
to baseline at week 12, Figure 6.2.
In conclusion the changes in health status in the placebo group are due to the
changes in the impact scores, with activity having a lesser effect, whilst the
changes in the active treatment groups are because of improvements in all three
components. Overall the changes noted in SGRQ in the treatment groups during
the trial were not statistically significant. The mean total SGRQ score for the 58
patients who participated in the trial was 55.6 ±15.3 points prior to trial
commencement. Assuming that the health status distribution was normal and that
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three groups were of equal variance, a total of 181 subjects in each group would be
required to prove a null hypothesis to the power of 0.8 with a significance of 0.05.
This study was therefore significantly underpowered.
As noted in the results section, the 40mg bd treatment group demonstrated
significant improvement in health status after 4 weeks of therapy. These
improvements returned to pre-treatment levels at trial completion. One possible
explanation is that the side effects experienced in the 40mg bd NAL group during
the trial were responsible for the deterioration in health status.
Any side effects experienced during the trial were recorded and classified
according to system and severity (mild, moderate and severe). The number and
severity of side effects experienced during the trial were reviewed according to
treatment arm, Table 6.4.
Subjects in the 40mg bd group appeared to experience fewer side effects than in
the placebo and 20mg bd groups, although there were more withdrawals in this
group, and therefore the total trial duration was shorter, giving less time for
subjects to report adverse events. There did appear to be an increased number of
moderate or severe adverse events in the 40mg bd group compared with the other
arms of the study. However 6 of the moderate or severe events reported in this
group relate to one individual who unfortunately was subsequently diagnosed with
lung cancer, 3 months after trial completion. Expert opinion from Respiratory
Physicians out with the trial was sought and it was felt that this diagnosis was in no
way related to the NAL therapy. When this patient was removed from the analysis
the number of moderate or severe side effects in the 40mg bd group is similar to
placebo.
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The total number of recorded side effects did not appear to relate to the treatment
arm of the trial. As well as assessing the number of side effects in each group.
Further analysis was performed to investigate the relationship between side effects
and health status in the 40mg bd NAL group. One possible explanation for the
deterioration in health status at trial completion is that this relates to the side
effects of Nacystelyn. If this were the case we may expect to se a significant drop
in health status in those subjects who experienced side effects, with subjects who
tolerated the therapy having a different health status profile, with a significant
difference in the SGRQ between these two sub-groups.
Subjects in the 40mg bd group were therefore divided into those who experienced
one or more moderate or severe adverse events compared with those who did not.
The change in total health status from baseline was compared between the two
groups. Analysis was performed in both the intention to treat population and only
the subjects who completed the trial.
A total of 9 of the 19 trial subjects reported moderate or severe side effects in the
40mg bd group. Four of these patients withdrew from the trial, 3 within the first 4
weeks. Two subjects in the 40mg bd group withdrew from the trial without reporting
any moderate or severe adverse events (Table 6.5).
Subjects who did not experience a moderate or severe side effect during the trial
showed larger improvements in health status compared with those who did
experience significant side effects. Flowever these differences were not statistically
significant. The improvement noted at week 4 in the sub-group of subjects who did
not report side effects of the drug returned close to baseline at trial completion.
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Similar changes were seen in the sub-group reporting side effects, with
improvements at week 4 not sustained at trial completion.
In conclusion, there are several factors indicating that the lack of sustained
improvement in health status in the 40mg bd group is not as a result of side effects
of Nacystelyn. The number of side effects reported in this group was no different
from the other two treatment arms. The subjects in the 40mg bd group who did
experience side effects classified as moderate or severe withdrew from the trial
within the first 4 weeks and therefore did not impact on the rise and fall noted in
health status. Subjects reporting side effects that went on to complete the trial still
showed an improvement at week 4 and return to pre - trial levels. Furthermore, the
SGRQ deteriorated from week 4 to trial completion in those subjects who did not
report adverse events. Another possible explanation is that the observed changes
in health status were as a result of the chemical properties of the drug.
There is some evidence that at high concentrations low molecular weight thiols can
have a pro-oxidant effect due to autoxidation of sulfhydrl groups(429). This is
associated with the Fenton reaction(430) resulting in increased production of
superoxide ion and hydrogen peroxide(431).
Sprang et al studied the effect of a variety of doses of N-Acetyl Cysteine,
275mg/kg, 550mg/kg, 950mg/kg in a rat model of LPS - induced lung injury. This
study showed that at low dose NAC reduced plasma levels of hydrogen peroxide
and improved mortality, whilst high dose resulted in increased plasma levels of
hydrogen peroxide and worsened mortality.
Low dose NAC did not appear to alter the amount of total or reduced glutathione
compared with control prior to LPS challenge. After administration of LPS there
was a significant increase in the levels of GSH, reduced glutathione, without any
major change in the level of total glutathione compared with placebo. This is
suggestive that NAC resulted in increased anti-oxidant capacity without increasing
the total levels of glutathione.
In contrast high dose NAC appears to have resulted in increased levels of total
glutathione, without increased GSH, prior to administration of LPS. This indicates
that there were increased levels of GSSG, the oxidised form of glutathione, after
administration of high dose NAC resulting in reduced anti-oxidant capacity in the
lung.
Applying this paper to the NAL study is problematic. There does appear to be a link
however, with low dose treatment having a beneficial effect in contrast to high
dose.
301
On ICS Overall 40mg bd 20mg bd Placebo
Randomised 38/58 9/19 16/20 13/20
66% 47% 80% 65%
Completed 28/44 7/13 12/15 9/16
64% 54% 80% 56%
Table 6.3 Number of Patients on Inhaled Corticosteroid prior to Trial Recruitment
WkO Wk 12 WkO Wk 12
Figure 6.1 Changes in SGRQ Total Score in Placebo Group dependant on inhaled
steroid use prior to study recruitment
Subjects already on inhaled corticosteroid (n=8) had a mean change in total score from
56.1 ±11.2 at trial commencement to 52.4±6.5 at trial completion, steroid naive subjects
(n=7) had a mean change from 56.0±18.1 to 47.8±21.1.
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Week 4 Week 12
Week of trial







Figure 6.2 SGRQ Symptom (a), Activity (b), Impact (c) and Total Scores (d).
Change from Baseline at Weeks 4 and 12 of trial for the three treatment groups.
Mean SGRQ score was calculated for each treatment group at each of the three
study visits; baseline, after 4 weeks and 12 weeks of therapy. The baseline score
was then subtracted from the mean score at weeks 4 and 12 of the trial for each
treatment group. The three components of the SGRQ are expressed along with the
total score. Histograms represent the mean changes from baseline for placebo
(black), 20mg bd NAL (hatched) and 40mg bd (white). Error bars express the
standard error of mean.
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40mg bd NAL 20mg bd NAL Placebo
Total SE 54 62 70
Moderate/Severe 27 15 21
No of Patients 9 6 12







Week 4 10.4 n=14 12.4 n=8 6.8 n=6
Week 12 or ET 0.2 n=19 2.6 n=10 -2.7 n=9
Trial Completion
Week 4 11.1 n=13 13.0 n=8 8.0 n=5
Week 12 2.4 n=13 4.0 n=8 -0.2 n=5
Table 6.5 Changes in St Georges Respiratory Questionnaire during




Compliance with the diary cards appeared good with all subjects returning
completed diary cards. Diary card reporting of the number of days with no or mild
breathlessness in the 20mg bd group significantly improved compared with
placebo, sustained improvements from baseline in the 20mg bd group were also
noted in breathlessness, cough and number of days with mild or no cough. When
compared with the St Georges Respiratory Questionnaire there was no similar
improvement in diary card reporting of symptoms early in the trial in the 40mg bd.
Not every subject in the 20 mg bd group improved during the trial. Eight of the 15
trial completers demonstrated significant improvement in both breathlessness and
cough scores. Subgroup analysis was performed to identify if there were any
characteristics specific to these subjects.
Subjects in the 20mg bd group whose breathiessness improved during the trial
were more likely to have a high BMI (26.1±2.9 versus 21.4±2.8, p=0.009) and had
a trend towards worse health status scores (60.1 ±15.2 versus 44.9±18.6, p=0.09).
These subjects also had a higher baseline breathlessness score (2.4±0.7 versus
1.1 ±0.9, p=0.02).
Subjects in the 20mg bd group who show a 1 point or more improvement in cough
score at trial completion compared with baseline had a higher baseline cough
score (2.0±0.6 versus 1.0±0.3, p=0.009).
No other biomarker endpoint predicted those subjects who would improve their
cough score. Baseline SGRQ did not predict which subjects would improve.
Baseline FEVi did not predict improvement in cough or SOB score.
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These data suggest that there may be characteristics specific to subjects who
respond to Nacystelyn. The variable response noted may relate to different
phenotypes, subjects with high BMI and cough scores are traditionally viewed as
having chronic bronchitis as their predominate pathology. Low BMI and low cough
score is more suggestive of emphysema. The limited data presented regarding the
subject characteristics are by no means conclusive. However it may be speculated
that subjects with chronic bronchitis (and mucus hyper secretion) are more likely to
respond to this therapy.
6.4.3 Exacerbation Frequency
The exacerbation frequency of those subjects taking 20mg bd NAL was
significantly lower than in the placebo group. The exacerbation frequency in the
placebo arm of the study appeared high. However it does appear that close
monitoring of subjects with COPD demonstrates that these patients frequently
experience exacerbations of their disease without seeking medical attention.
Seemungal et al monitored 101 patients over two and a half years. These patients
experienced 504 exacerbations, over half of these, 254, were not directly reported
to the study doctors but were found on review of diary cards and spirometric
measurement(432) A further study from the same group demonstrated an
exacerbation frequency of 2.5 per year in moderate to severe COPD with more
than half of these exacerbations not reported to medical staff(433). The
exacerbation frequency, based on reporting of symptoms, in the placebo arm of the
Nacsytelyn study was equivalent to 2.3 per year.
306
6.4.4 Measurement of Plasma Biomarkers
Thiobarburic Acid Reactive Substances (TBARS) as an assessment of oxidative
stress should be interpreted with caution(434). Previous work has shown that
certain chemicals, including malondialaldehyde and amino acids, when present in
biological fluid can react with thiobarbituric acid leading to a falsely high level of
TBARS(435). However, TBARS do appear to have some discriminatory properties
in COPD. Higher levels of plasma TBARS have been shown in subjects with COPD
compared with control subjects, which is most marked after exercise(296, 436).
Oral N- acetyl cysteine has been shown to attenuate the increase in plasma
TBARS seen after exercise(296).
Plasma TBARS levels during the trial were significantly higher prior to trial
commencement when compared with measurements during the trial, independent
of the trial group. This may relate to the time that samples were stored in the
freezer, with MDA in frozen serum reacting and producing more TBARS. Another
possible explanation for this relates to the trial protocol.
Baseline plasma measurement was obtained at trial screening, at which stage
subjects not previously on steroids were commenced on inhaled corticosteroids
and those subjects already on ICS were standardised to Fluticasone 250mcg bd.
Plasma was sampled at this stage of the trial as the results of U+Es, LFTs and
FBC were required prior to randomisation. Plasma sampling was not repeated until
week 4 of the trial. Therefore there was no baseline measurement available after
initiation of ICS but before starting Nacystelyn.
Previous studies have shown that inhaled corticosteroids can have some effect on
markers of oxidative stress in COPD. Lower levels of nitrotyrosine and inducible
nitric oxide synthesase in induced sputum have been measured in subjects with
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COPD after treatment with ICS(303). COPD patients taking ICS have lower levels
of exhaled ethane compared with COPD steroid naive patients(288). In contrast
other markers of oxidative stress in the exhaled breath condensate of patients with
COPD do not appear to be altered. Steroid treatment has failed to demonstrate any
effect on levels of 8-lsoprostane, hydrogen peroxide, LTB-4, PGE2, PGD2 and
PGF 2a(263, 304-307).
Sub-group analysis was performed to investigate if inhaled corticosteroid use prior
to trial entry affected the levels of plasma TBARS measured when compared with
steroid naive subjects. TBARS levels of steroid naive subjects were statistically
higher compared with those already taking a form of inhaled steroid, 3.91 pmol/L ±
3.96 versus 1.34 pmol/L ± 2.43, p=0.035. This finding suggests that taking regular
ICS may lower the levels of plasma TBARS. However this is a relatively small
sample population and further investigation of this finding is required.
Further interpretation of this result is problematic. There was no further
measurement prior to randomisation. Those subjects who were previously steroid
naive were commenced on two new inhaled therapies, fluticasone at week -4 then
nacystelyn or placebo at week 0, both of which potentially could have an impact on
plasma levels of oxidative stress, prior to second assessment of levels at week 4.
Further analysis was performed dividing the three treatment arms into those
subjects who were steroid naTve and those who were on steroid prior to trial entry.
The changes in TBARS levels in the placebo group were analysed in an attempt to
identify the impact of ICS alone. TBARS levels in the treatment groups who were
already on ICS was also analysed to identify the impact of Nacystelyn alone.
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Levels of plasma TBARS in the steroid naive placebo group (n=7) fell from 3.3
pmol/L ± 4.0 at baseline to 1.3 pmol/L ± 2.0 at trial completion, p=0.12. TBARS
levels in the placebo group who were on ICS prior to trial entry were lower at
baseline (0.68 pmol/L ±1.1, p=0.09) when compared with the steroid naive
subjects and did not change significantly during the trial.
Subsequent analysis was performed on those patients receiving active treatment
who had previously been on steroid. Removing the steroid na'ive patients from this
analysis was based on the assumption that initiation of ICS may have an effect on
levels of TBARS.
A trend towards reduction in plasma TBARS levels is noted in the 20mg bd group,
0.8 pmol/L ± 1.4 at trial commencement versus 0.5 pmol/L ± 0.7 at week 12,
p=0.074. A further trend towards lower TBARS levels was noted in the 40mg bd
group at week 4 compared with baseline, again not statistically significant.
In conclusion, TBARS levels were significantly elevated at baseline when
compared with time points during the trial. This may in part relate to a significant
proportion of the trial subjects not being on ICS prior to trial entry. The subjects in
the placebo group who were steroid naive had a trend towards a fall in the TBARS
level after ICS treatment suggesting a possible effect of ICS on systemic oxidative
stress.
Further investigation of the role of inhaled corticosteroid on plasma measurement
of oxidative stress is merited. Specific points of investigation include the effect of
ICS on TBARS levels after initiation of treatment. Another area of interest is the
relationship between TBARS levels and exacerbation frequency. ICS have been
shown to reduce exacerbation frequency(437). It may therefore be that the lower
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level of TBARS seen in the steroid group relates to either a lower exacerbation rate




Steroid Naive n=6 3.4±3.3 0.6±0.6 1.2±1.8
20mg bd NAL
Steroid Naive n=3 5.9±6.2 0.2±0.2 3.7±6.0
Placebo
Steroid Naive n=7 3.3±4.0 2.7±4.2 1.3±2.0
40mg bd NAL
Steroid n=7 3.3±4.7 1.1±2.3 1.9±3.5
20mg bd NAL
Steroid n=12 0.8±1.4 0.5±0.7 0.5±0.7
Placebo
Steroid n=8 0.7±1.1 0.7±1.0 0.3±0.2
Table 6.6 Levels of plasma Thiobarburic Acid Reactive Substances
(pmol/L) in each treatment arm subdivided by inhaled corticosteroid
use prior to trial entry
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6.4.5 Measurement of Induced Sputum Biomarkers
Induced sputum collection was successful in the majority of patients at trial
commencement (81%) but only 56% of the patients who completed the trial were
able to provide sufficient sputum for analysis on all three occasions. As discussed
earlier in this chapter the proportion of subjects able to produce sputum in our
studies is lower than in previous published trials. Factors which may relate to this
reduced sputum production are also discussed above. Along with these
methodological issues affecting sputum production, it should be noted that
theoretically Nacystelyn has mucolytic properties(385). Diary card analysis
demonstrated trends towards reduced sputum production in the study groups.
Therefore the low sputum yield during the trial may in part be a drug effect.
A trend towards a reduction in induced sputum IL-8 was shown during the trial.
Although these changes were not statistically significant, the trends would be in
keeping with the study hypothesis. As mentioned earlier glutathione acts as a
major scavenger for free radicals, hydrogen peroxide and lipid peroxides ((438,
439). Increasing the amount of Glutathione in the ELF may potentially result in
reduced amounts of ROS, reduced activation of the NFkB pathway and reduced IL-
8 synthesis.
Further analysis of the induced IL-8 levels was performed, comparing IL-8 to health
status, diary card response and plasma TBARS. There was no direct correlation
between health status and IL-8 levels or with changes in health status and changes
in IL-8 levels. A similar picture was seen with the diary cards with no direct
relationship between the changes in diary card reporting of symptoms and levels of
IL-8 in induced sputum. No obvious trend was seen between TBARS and IL-8.
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IL-1(]> appears to correlate with IL-8 in induced sputum. This would be in keeping
with previous studies indicating that IL-1 G> stimulates production of IL-8(440). No
significant difference was seen in the levels of IL-1R> in the three treatment arms
during the trial or any correlation with markers of health status and systemic
oxidative stress.
Unlike IL-8, there was no change in levels of IL-6 measured in the two active
treatment arms during the study. IL-6 levels in the placebo group increased during
the trial. This may reflect the high frequency of exacerbations in this group, over
50% of subjects on placebo experienced an exacerbation during the trial compared
with 20% in the 20mg bd arm. Previous studies have demonstrated that levels of
IL-6 are elevated during exacerbations of COPD compared with stable conditions.
Furthermore subjects with high exacerbation frequency have higher mean levels of
IL-6 when stable compared with subjects with low exacerbation frequency(321).
Induced sputum IL-6 levels measured in the placebo group are significantly higher
in those subjects who experienced an exacerbation during the trial
(187.8pg/ml±263.1) compared with those who did not have an exacerbation of their
airways disease (33.7pg/ml±39.7), p=0.013, Figure 6.3.
The increase in levels of IL-6 noted during the placebo arm of the trial may
therefore be explained by the level of exacerbations of COPD seen in this arm of
the trial. This may reflect the frequency of exacerbations in this trial group. Another
possible explanation is that increased levels of oxidative stress and subsequent
airways inflammation are in themselves a trigger for exacerbations of COPD. The
lack of increase in levels of IL-6, and subsequent exacerbations of COPD, in the
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treatment arms could be explained by reduced oxidative stress due to treatment by
inhaled anti-oxidant.
No correlation was shown between sputum IL-6 and markers of health status and
systemic oxidative stress.
TNF-oc appeared to produce a relatively weak signal, and was not detected, or at
the limit of detection in the lowest quartile of each group. This may reflect our use
of DTT in sputum processing, previous work has demonstrated that DTT can
interfere with TNFoc analysis(441).
Previous work has shown that VEGF levels are dependant on the phenotype of
COPD with higher levels seen in chronic bronchitis compared with emphysema.
Strict characterisation of the phenotype of COPD was not undertaken in this study.
Diary card recording did allow some characterisation of the levels of cough
experienced each week. Scores ranged from 0, no cough, to 3, cough throughout
day. When the levels of VEGF measured are compared with the average diary card
symptoms of cough on the week prior to visit, subjects who scored 0 on the week
of sputum collection had statistically significant lower levels of VEGF
(425.5pg/ml±296) compared with those who scored 3, (1255.1 pg/ml±1099),
although it should be noted that there were small numbers in each group (n=8 in
both groups) Figure 6.4. As previously noted, subjects with high cough scores were
more likely demonstrate improvements in diary card reporting of cough and
breathlessness. There was however no significant relationship shown between
improving diary card symptom scores and VEGF levels.
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Figure 6.3 Mean IL-6 levels in induced sputum of placebo group during trial
dependant on exacerbation episode during trial. Induced sputum IL-6 levels measured
in the placebo group are significantly higher in those subjects who experienced an
exacerbation (black bar) during the trial (187.8pg/ml±263.1) compared with those who did











■ Cough Score 0 □ Cough Score 3
Figure 6.4 Mean VEGF levels in induced sputum dependant on cough score. Mean
Induced sputum VEGF levels in trial subjects with a cough score of 0 (black bar) are lower
than in subjects with a cough score of 3 (white bar), (425.5pg/ml±296 versus
1255.1pg/ml±1099), p=0.058.
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6.4.6 Exhaled Breath Condensate
Exhaled breath condensate collection in the Nacystelyn trial added little to the
study hypothesis. The biomarkers studied did not show any difference in levels
between the treatment and placebo arms. Although this may simply reflect the
limited utility of EBC biomarker measurement in COPD, several methodological
issues may have contributed.
Chapter 4 of this thesis discusses the reproducibility of hydrogen peroxide and 8-
Isoprostane measurement in EBC. Reproducibility over three visits in a four week
trial was reasonable with a concordance correlation co-efficient of 0.66, (95%
confidence interval 0.34 to 0.84, p=0.0007) for 8-lsoprostane and 0.48 (95%
confidence interval 0.00 to 0.77, p=0.057) for hydrogen peroxide.
In contrast the concordance correlation coefficient between visit 0 and visit 12 in
the placebo arm of the trial was -0.07 for 8-lsoprostane with 95% confidence
interval -0.43 to 0.30, p=0.77 and -0.20 (-0.73 to 0.50, p=0.60) for hydrogen
peroxide.
Whilst this variation may reflect the nature of COPD with day to day variability in
symptoms the correlation between visits is significantly less reliable than in the
Chapter 4 study. Similar subjects participated in the two trials and both the study
protocols and analysis techniques were identical. Several methodological issues
specific to this trial may have contributed to this variability. Exhaled breath
condensate was stored at -80°C until individual subjects completed the trial so that
the three samples obtained for each individual were analysed with the same
reagents and standards. Sample analysis was performed in batches of at least 12
individuals, again in an attempt to reduce between subject variations by using the
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same reagents. As a result first visit samples had been stored at -80°C for at least
3 months, many for longer than this.
When the levels of 8-isoprostane for all subjects, independent of treatment arm,
are compared with the stage of the trial, baseline levels are significantly lower than
week 4 of the trial, with a trend towards being lower than at trial completion. The
level at week 0 is on average 26.3pg/ml (±45.7), 89.8 (±172.1) at week 4 of the
trial, and 40.6 (±56.3) at week 12. This suggests that the duration of storage at -
80°C may have an impact on levels of 8-isoprostane measured, with some
degradation of samples as time progresses. A further factor relating to the
variability relates to the study protocol allowing one exacerbation during the trial. If
subjects experienced an exacerbation the study protocol was still followed and
EBC collection could only be deferred by one week. The duration of increased
oxidative stress in the lung after an exacerbation is not known. It is therefore
possible that increased levels of oxidative stress measured in EBC could be as a
result of a recent exacerbation. Subjects had to be exacerbation free for four weeks
prior to trial entry. However, the lower levels measured at trial entry, independent of
study group, compared with weeks 4 and 12 may be in part as a result of this
minimum time from last exacerbation.
In conclusion, 8-lsoprostane was not a reliable or stable marker in this trial with
significant variation in levels seen in the placebo arm. This does not allow further
interpretation of the data therefore it neither proves nor disproves the hypothesis
that inhaled antioxidant may have an effect on lipid peroxidation in the lung. Similar
high levels of variation were seen in the placebo arm with hydrogen peroxide,
nitrotyrosine and leukotriene B4. There were similar trends towards decreasing
3I8
levels dependant on the duration that the sample was in the freezer; however these
were not statistically significant.
6.4.7 Summary
In conclusion inhaled Nacystelyn (NAL) was well tolerated during the trial. A
significant improvement in health status was shown after 4 weeks of high dose
NAL. However this was not sustained during the trial. The lack of sustained effect
does not appear to relate to side effects from the drug and may be as a result of
the impact of the drug on the redox balance in the lung. Further study of the
medium to long term effect of inhaled NAL on redox status in humans is required.
Low dose NAL appeared to show a sustained effect, both in terms of health status
measures and diary card reporting of symptoms. The improvement was statistically
significant when compared with baseline, but not compared with placebo. A larger
powered study would be required to demonstrate any improvement compared with
placebo.
Diary Card reporting of breathlessness demonstrated an improvement in
symptoms in the 20 mg bd group when compared with placebo, with no significant
change shown in the 40mg bd group
Biomarker measurement in EBC during the trial did not mirror improvement in
reporting of symptoms and health status. Prolonged storage of breath condensate
may have an impact on levels measured and merits further investigation as does
the duration of increased oxidative stress in the lung after an exacerbation.
Induced sputum changes were suggestive of treatment benefit in the 20mg bd
group; again study numbers were not sufficient for confirmation of these trends.
Plasma measurement of Thiobarburic Acid Reactive Substances suggests that
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regular inhaled corticosteroid may impact on levels of systemic oxidative stress,
again this finding merits further investigation.
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6.5 Conclusion
This thesis has demonstrated that some biomarkers of oxidative stress and
airways inflammation, such as 8-lsoprostane, Hydrogen Peroxide and
Prostaglandin E2, can be measured in exhaled breath condensate, both in subjects
with COPD and healthy controls. Other biomarkers, including nitrotyrosine,
leukotriene B4, Myeloperoxidase, Tumour Necrosis Factor a and Interleukins 6, 8
and 10, could not be reliably measured in EBC.
Biomarker measurements in exhaled breath condensate were on or around the
limit of detection for the assays used.
The log of 8-lsoprostane was reproducible in the trial although the correlation
coefficient was low. Hydrogen peroxide in EBC was close to statistical significance.
Acute smoking and time from last exacerbation of COPD as well as methodological
issues may have had an influence on this
The reproducibility in induced sputum again may relate to methodological issues in
our study, although it should be noted that there was a wider range of disease
severity in our study compared to previous along with current smokers being
included in our study.
None of the biomarkers which were measured in EBC varied significantly between
subjects with COPD and controls. This is part may reflect the high level of co¬
morbidity in our control groups.
Quartile analysis of 8-lsoprostane levels in ex-smokers with COPD suggested a
possible relation ship with health status, symptom score and exacerbation
frequency. This suggests a role in future assessment of COPD.
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Treatment with an inhaled antioxidant had no significant impact on the identified
biomarkers in EBC. lnterleukin-6 levels did appear to rise in induced sputum in the
placebo group, possibly reflecting the increased exacerbation frequency in the
placebo arm when compared with the 20mg bd group.
High dose inhaled Nacystelyn (40mg bd) did have a significant impact on health
status compared to baseline after 4 weeks of treatment. However this returned to
pre treatment levels by the end of the study. Health status and diary cad symptom
scores improved in the lower dose Nacystelyn (20mg bd) group although the study
was not significantly powered to detect differences from placebo.
Several future areas of study have been identified in this thesis. Further analysis of
several methodological issues identified in exhaled breath condensate collection
may improve the reproducibility of this technique, specifically in 8-lsoprostane
collection, which shows some promise in assessing disease activity in ex-smokers
with COPD. The impact of non respiratory disease on EBC levels may also be of
interest.
This thesis has also shown a different clinical response to differing doses of
inhaled anti oxidant. This may reflect higher doses disturbing the oxidant-
antioxidant balance in the lung. Again this area merits further investigation.
In summary this thesis has been able to identify some reproducible biomarkers of
oxidative stress and airways inflammation in COPD and relate these to disease
severity. These biomarkers were not able to differentiate COPD from controls.
Inhaled anti-oxidant had some clinical response, which may reflect the mucolytic
properties of this chemical, but had no effect on biomarkers of oxidative stress.
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Appendix
Appendix 2.1 EXHALED BREATH CONDENSATE COLLECTION
Pre-test (subject)
1. Measure exhaled carbon monoxide.
Pre-test (equipment)
1. Turn on Condensate Machine 30 minutes before sampling.
Test
1. Select clean mouth piece, collection tube, collection port, saliva trap and
breathing valve.
2. Ask subject to rinse mouth with water prior to test.
3. Place nose clips on subject.
4. Ask subject to perform normal tidal breathing into mouth piece (whilst
seated) for 10-15 minutes. If there is a build up of saliva collect in tissue.
Subjects may come off the mouthpiece for up to 1 minute to rest (can occur
maximally twice), as long as total collection time is 10-15 minutes.
5. Place sample on ice immediately after collection.
6. Pipette as 0.25ml aliquots into autoclaved Eppendorf tubes and freeze at -
80°C.
7. Freeze within 30 minutes of collection.
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Appendix 2.2 INDUCED SPUTUM COLLECTION
Pre procedure
1. Subject should have a post bronchodilator (Salbutamol 2.5mg via nebpliser)
FEV1 recording to be used as a baseline.




2. Salbutamol nebples 2.5mg.
3. Sonix 2000 nebplizer unit.
4. Hypertonic saline - 3%, 4%, 5%.
5. Polystyrene 100ml sputum collection pot.
Procedure
1. Ask subject to rinse mouth with water and gargle vigorously.
2. COPD patients shopld be asked to expectorate any spontaneous sputum
and this shopld be discarded.
3. Fill Sonix 2000 nebplizer with 5ml sterile hypertonic saline and ask subject
to inhale the mist through the mouth piece for 5 minutes. The subject shopld
discontinue inhalation on development of any significant symptomology
such as wheeze, breathlessness or lightheadedness. The subject shopld be
supervised at all times by a nurse or doctor during this period.
4. On completion of above, ask to blow their nose and rinse their mouth with
water.
5. Ask subject to attempt sputum expectoration into a 100ml collection pot.
6. Any sample produced shopld be examined for presence of sputum plugs
and to assess if an adequate sample has been obtained.
7. Record a further FEVi reading on the subject.
8. If no suitable sample has been produced, and the subjects FEN^ is > 90%
pre procedure, then repeat steps 3) to7) using incremental doses of
hypertonic saline up until completion of the 5% saline or a total nebplised
period of 15 minutes. Subsequent attempts at expectoration shopld be into
the same sputum pot in order to obtain a cumplative volume. The pot shopld
be kept refridgerated between attempted collections.
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9. In event of FEVi falling to 80%-89% of baseline then continue to nebulise at
the same concentration of hypertonic saline up until such time as:
a. an adequate sputum sample has been produced
b. a total nebplized period of 15 minutes (3x5 minute periods with FEVi
checked between)
c. FEVi returns to > 90% of baseline - resume steps 3) to 7)
d. FEVi falls to< 80% of baseline - cease procedure
e. patient becomes uncomfortable or significantly symptomatic - cease
procedure
10. If FE\A falls to <80% of baseline procedure shopld be abandoned.
Additional Safety Points
1. A trained medical practioner shopld be contactable during the procedure
and able to attend promptly shopld an adverse event occur.
2. On completion of the procedure subjects shopld be given salbutamol
(2.5mg) if FEVi drops to <90% baseline or the subject feels significantly
more breathless or wheezy.
3. Subjects shopld remain in the unit until FE\A is >90% of baseline unless the
attending medical practioner instructs otherwise.
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Appendix 2.3 Induced Sputum Processing
PLUG REMOVAL
1. Weigh sputum and pot, and note down reading in the whole sputum/total cell
on the sputum form so that 13.5052g is rounded and written as 13505.
2. Empty sputum into a Petri dish.
3. Weigh empty pot and note as before but in the whole sputum/tara cell.
4. Weigh empty falcon tube and note reading as before but in the selected
sputum/tara cell.
5. Separate out plugs and weigh falcon tube containing plugs and note down in
the selected sputum/total cell.
6. Subtract whole sputum/tara from whole sputum total and note in whole
sputum /total-tara cell.
7. Subtract selected sputum/tara from selected sputum total and note in
selected sputum/total-tara cell, then note selected sputum/total-tara x4 in
DTT volume, note that answer will be in micro litres so to make into ml
convert 4234 to 4.234 etc.
SPUTOLYSIS
1. Freshly dilute 1% DTT by ten (0.1%DTT) using PBS(-).
2. Add volume of 0.1 % DTT as noted in sputolysin volume.
3. Break up plugs and place tube on ice on rocker for 15mins.
4. Add volume of PBS equivalent to that added of 0.1 % DTT.
5. Filter with gauze.
CLEANING
1. Centrifuge: 10mins, 4°C, 1200rpm.
2. Separate the supernatant, label and put on ice.
3. Add PBS to re-suspend pellet (cells) and centrifuge: 10mins, 4°C, 1000rpm
then put on ice.
4. Centrifuge the supernatant: 8mins, 4°C, 2000rpm then put on ice.
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CELL COUNTS
1. Remove and throw out supernatant from the cleaned cells, and re-suspend
in PBS at a volume that is more that 250pl and approximate density of
1x106cells/ml. Note suspension volume on sputum form in pi.
2. Dilute 10pl of cells with either 90pl Trypan blue (1:100) or with 10pl Trypan
blue (1:2) depending on how cloudy the cell suspension is and note dilution
on the sputum form.
3. Add to haemocytometer and count how many dead (blue), alive (clear) and
squamous (spread out) cells are in the four corners of large squares and
note cell count on the sputum form.
4. Calcplate viability by: alive/(dead+alive) x100.
5. Calcplate squamous by: squamous/(dead+alive+squamous) x100.
6. Calcplate cells/ml by mpltiplying the alive cells by 25,000 (dilution 1:100) or
by 5,000 (1:2) and note on sputum form in mpltiples of a million cells (z x
106).
7. Calcplate total cell count by dividing cells/ml by 1000 and mpltiplying by the
suspension volume, note on sputum form as mpltiples of a million cells (z x
106).
CYTOSPINS
1. Ideal cell concentration for a cytospin 1 x106 cells/ml, dilute where
appropriate with PBS by using the cells/ml calcplation as a guide.
2. Add 10OpI cell suspension to the funnel (with slide and filter) and spin for
3mins at 300rpm.
3. Leave to dry.
4 Aliquot supernatant into min of 0.5ml and max 9 aliquots.
5 Store in -20°C freezer until end of day, then relocate to -80°C
4. Fix and stain (3mins each stain) rinse with water/
5. Leave to dry.
6. Add DPX and cover-slip when ready to count.




1. Each venesection will involve collection of approximately 20 ml of blood. Whole
blood samples will be collected for subsequent separation into plasma and serum
constituents.
2. At each venesection, a volume of 9 ml of blood will be taken in a lithium-heparin
treated Vacutainer tube and 5ml blood in an EDTA Vacutainer tube.
3. The blood will be gently mixed after collection and then centrifuged at 2000 rpm for
20 min at 4°C.
4. Lithium heparin samples will be aliquoted into appropriately labelled tubes as
follows:
a. aliquots of 600pl into polypropylene tubes (for subsequent measurement of
C-reactive protein)..
b. 3 aliquots of 500jal/aliquot into autoclaved Eppendorf tubes.
5. EDTA samples will be aliquoted (3 aliquots of 500pl/aliquot) into appropriately
labelled autoclaved Eppendorf tubes.
6. All plasma aliquots will be stored at -80°C.
7. At each venesection, a volume of 5 ml of blood will be taken in an anti-coagplant
free tube.
8. Samples will be allowed to clot at room temperature (20-25°C) for 30 min until the
clot just begins to retract.
9. Once clotted, tubes can be kept for up to 2 hours in a refrigerator at 4°C or in an
ice-water bath before processing.
10. Spin the samples in a centrifuge at 2000 rpm for 10 min, 4°C.
11. Transfer the cell-free serum to a collection tube.
12. Serum will be stored as 2 x 500pl aliquots in appropriately labelled autoclaved
Eppendorf tubes.




Spirometry will be recorded using a Vitalograph spirometer.
1. Prior to use the machine shopld be calibrated.
2. Enter patient details as follows:
Age: age in years;
Height: heights in cms;
Sex: Press MALE or FEM;
Ethnic origin: Press CAUCASIAN or NON-CAUCASIAN.
3. To define which parameters are to be printed, press SETUP and choose option
2. Scroll up/down list and select the parameters you require before pressing
CONTINUE to return to main menu. Graphs to be printed can also be selected
from the SETUP menu.
4. To measure FEVi select option 2 from the main menu. Axes are drawn and
PERFORM TEST appears. The subject shopld be instructed to breathe in as
deeply as possible and then to blow into the mouthpiece as hard and as fast as
possible, and to continue breathing out until their lungs are empty.
5. As the subject finishes the first breath, press END TEST. When the subject is
ready press RETEST. At least 3 recordings shopld be made. On the second and
subsequent breaths, BEST TEST VARIATION will appear. This shopld be kept
within ±5%. If it is not, extra tests shopld be done.
6. When the test is over, press EXIT to return to the main menu. The resplts can
then be viewed in a number of ways, including printout option.
363
7. For reversibility testing (COPD patients at screen only in the current study),
press 4 (set post-mode) from the main menu and answer YES to ARE YOU SURE.
POST will light up on the keypad. Post-bronchodilator resplts can now be recorded
and resplts viewed in the same way as before. Administer 2.5mg of nebplised
salbutamol then repreat 4-6 15-30 minutes after administration of salbutamol.
8. After tests on each subject have been completed and printouts obtained, press 6
from the main menu to clear resplts before the next subject.
9. All printouts shopld be labelled with time of test, patient initials, study subject
number and shopld be initialled by the operator.
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Appendix 2.6 8-lsoprostane Protocol
Commercially available kit from Cayman Chemical
Contents
1 96 well coated EIA Plates
2 Tracer.
3 8 Isoprostane Standard.
4 EIA Buffer Concentrate.







1. EIA Buffer Dilute one vial (4) with 90ml_ pltrapure water.
2. Wash Buffer Dilute one vial (5) with 2 L pltrapure water
Add 1ml Tween 20 (5a).
3. Standard Dilute one vial (3) with 900pl pltrapure water (cone 5ng/ml).
4. 8 standards EIA Buffer, serial dilutions, from 500pg/ml.
5. Tracer Dilute one vial (2) with 6ml pltrapure water if 96 well kit, and
30ml if 480 well kit.
6. Anti Serum Dilute one vial (6) with 6ml pltrapure water if 96 well kit, and
30ml if 480 well kit.
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Assay Day 1
1. Each plate must have blank (BL), non specific binding (NSB), maximum
binding (Bo) and total activity (TA) in duplicate.
2. Wash plates once with wash buffer.
3. Add 100pl EIA buffer to NSB wells.
4. Add 50pl EIA buffer to Bo wells.
5. Add 50pl of sample/ standard to each well.
6. Add 50pl of tracer to each well except TA and BL RETAIN 10pl of tracer for
day 2.
7. Add 50pl of Antiserum to each well except TA. NSB and BL.
Cover plate with plastic film and incubate for 18 hours at room temp.
Assay Day 2
1. Reconstitute one vial of Ellman's (8) with 20ml pltrapure water (must use
within 24hrs, protect from sunlight).
2. Empty and wash wells (100plx3).
3. Add 200pl Ellman's to each well.
4. Add 5pl of tracer to TA wells.
5. Cover with film, shake in dark for 60-90 mins.
6. Read plate when Bo absorbance is between 0.3 and 0.8.
7. Read at 405-420nm.
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2.7 Hydrogen Peroxide Assay
Solutions
Citrate Buffer 0.42M, pH 3.8
1. Make 0.418M Sodium Citrate (3.075g in 25ml dH20)
2. Make 0.629M Citric Acid (3.0265g in 25ml dH20)
3. Add 20ml of Citric Acid to the Sodium Citrate and monitor the pH. Titrate the
last 5ml of the Citric Acid into the Sodium Citrate until it reaches pH 3.8. If all
the Citric Acid has been titrated yet the buffer is still not at pH 3.8 then
adjust using 10M Citric Acid.
NB: it is very important that the pH of the citrate buffer is accurate as the
sample may precipitate at a pH outside 3.8.
4. Store at 4°C and use within 4 weeks
Horseradish Peroxidase (HRP) - Make up fresh
1. Dissolve 1 mg of HRP (222 Puropurogallin Units) in 1 ml dH20.
2. Keep in darkness at 4°C and use within 24hrs.
TMB
1. Dissolve 10mg TMB in 1 ml of DMSO (4.2M).
2. Keep in darkness at 4°C. Note that DMSO freezes at 4°C so allow time to
thaw prior to use.
Stop Solution (1 M H2S04)
1. Add 2ml of 18N (2N = 1M) H2SO4 to 16ml of dH20 (total volume - 18ml) on
ice.
2. Store at room temperature.
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Protocol
1. Firstly check the molarity of the stock 30% H2O2 solution. This does not
need to be done every time the assay is run but should be performed every
month or so. To determine the molarity of H2O2, prepare the following
solutions:
2. 25gl of stock H2O2 in 5ml of 1 x PBS = 5ml of H2O2 at a 1:200 dilution.
3. 100gl of solution A + 900pl dH20 = 1ml of solution A at a 1:10 dilution
4. Measure the OD280 of solution B (blank against dH20) in a QUARTZ cuvette
and determine the concentration of solution A using the following
calculation:
5. Concentration of Solution A (mM) = OD?sn x30x10
6. The resplt is in mM so multiply the resplt by 200 to give the concentration of
the stock H2O2 in mM and then divide by 1000 to give the resplt in M. Using
the resplt calcplate the correct dilution factor to give an accurate set of
standards.
7. Make up the standard curve to the following concentrations diluting firstly
down to a 1M concentration, then to 10mM before diluting to the
concentration of the top standard. This is the serially diluted to give an 8
point standard curve across the range 100- 0.78pM.
8. Mix 90pl of Citrate Buffer, 10pl of TMB and 10pl of HRP together for each
well. This can either be done in the plate or made up (9ml of Citrate buffer,
1ml of TMB and 1ml of HRP mixed per plate) and 110pl added to each well.
9. Add 10OpI of standards/ samples to each well as per plate plan including a
blank containing 10OpI of dH20.
10. Mix and then leave for 20 minutes at room temperature.
11. After 20 minutes add 50pl of stop solution (1M H2SO4) and mix until fplly
stopped. If some wells remain blue after the stop solution has been added
then wait and it will turn yellow eventually.
















1M 1:10.2 100pl of 10.2M H202 in 920pl
dH20
1020pl
10mM 1:100 1Opl of std 1 in 990pl dH20 990pl
100pM 1:100 10pl of std 2 in 990pl dH20 990pl
50pM 1:2 500pl of std 3 in 500pl dH20 500pl
25pM 1:2 500pl of std 4 in 500pl dH20 500pl
12.5pM 1:2 500pl of std 5 in 500pl dH20 500pl
6.25pM 1:2 500pl of std 6 in 500pl dH20 500pl
3.13pM 1:2 500pl of std 7 in 500gl dH20 500pl
1.56pM 1:2 500pl of std 8 in 500pl dH20 500pl
0.78pM 1:2 500pl of std 9 in 500pl dH20 1000pl
text signifies dilutions made to reach the top standard from the stock




Bring all reagents to room temperature prior to use.
1. Dilution Buffer - mix the 10ml supplied with 100ml dw (distilled
water)
2. Nitrotyrosine Ab - reconstitute vial with 1 ml of dw (can be stored at
2-8°C for 1 month or at -70°C for longer)
3. Streptavidin Peroxoxidase reconstitute vial with 1ml dH20. Add 23ml of
working dilution.
4. Washing buffer - mix the 20ml supplied with 780 ml of working
dilution buffer
Preparing Standard Curves
1. Reconstitute Nitrotyrosine standard with dw as instructed on the label. This
gives a 4.5pM solution.
2. Label tubes 1-8.
3. Add 300pl of working dilution buffer to tubes 1-7 and 500pl to tube 8.
4. Add 150pl of Nitrotyrosine standard to tubel, mix, and continue to serially
dilute 150pl down to tube 7. Do not add any to tube 8 as this is the blank.
Tube 1 2 3 4 5 6 7 8
Cone nM 1500 500 166.7 55.6 18.5 6.6 2.1 0
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Assay Procedure
1. Prepare samples by defrosting on ice. If using plasma samples, dilute
samples 10:1 with working buffer dilution, e.g. 30pl with 270pl.
2. Add 10OpI of standard/sample to each well.
3. Cover and incubate for 1 hour at room temperature.
4. Wash 4 times with wash buffer.
5. Add 100pl Nitrotyrosine Ab.
6. Wash further 4 times.
7. Add 100pl Streptavidin Peroxidase.
8. Cover plate and incubate for 1 hour at room temperature.
9. Prepare TMB Substate 15 minutes prior to completion of above incubation.
This is done by mixing TMB Substrate, with Substrate Buffer, and Substrate
Dilution Buffer in a ratio of 1:1:2. ( Make up the required volume only which
is calcplated by multiplying the number of wells by 100pl. Store in darkness
by covering in tin-foil before placing in refrigerator. Use within 15 minutes.
10. Wash wells further 4 times.
11 .Add 100pl of freshly prepared TMB substrate.
12. Cover plate and surround with tin-foil to thus incubating wells in darkness for
the next 30 minutes.
13. Add and mix 100pl Stop solution.
14. Read at 450nm
Calculation
Note that the blank absorbance should be less than 0.4
1. Plot net absorbance against Log to base 10 concentrations.
2. Derive concentration by applying Power 10 function to Log concentration.
3. If samples diluted, correct by multiplying concentration by 10.
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2.9 IL-8 ELISA Protocol
Solutions (enough for one plate)
• PBS with calcium and magnesium (PBS+)
• DMEM with pen/strep + L-glut.
• Wash Buffer (add 250pl of Tween 20 to 500ml of PBS+)
• Blocking Buffer (5% sucrose and 1% BSA in PBS+) Add 1g of sucrose and 0.2g
of BSA to 20ml of PBS+ (make fresh - will require stirring).
• Reagent Diluent (0.1% BSA and 0.05% Tween20 in 1X TBS). Dilute 10ml of
10X TBS with 90ml of distilled water. Take 30ml of this solution and add 0.03g
of BSA and 15pl of Tween20.
• TMB (add 10mg to 1 ml of DMSO) (Keep in dark!!).
• Substrate Buffer (in fridge - see bottle for recipe).
• 1M H2SO4 (splphuric acid).
Coating the Plate ( Day before the ELISA)
Dilute 60pl of capture antibody in 10.6ml of PBS+. Add 10Opil to each well, then
cover the plate and incubate overnight at room temp.
ELISA Procedure - all incubations at room temp.
1. Remove the capture antibody and wash the wells 3x with 1OOpl of wash
buffer.
2. Add 10Opil of blocking buffer to each well, cover, then incubate for 60-90
minutes on the plate shaker.
3. Make standards (20pl standard in 1.8 ml media = 1000 pg/ml stock)
Standards from 800 - 0 pg/ml.
4. Remove the buffer and wash the plate 3x with 1OOpl of wash buffer.
5. Add 10OpI of standards and samples to each well, cover and incubate for 60-
120 minutes on the plate shaker.
6. Remove and wash the plate 3x with 10OpI of wash buffer.
7. Dilute 60pl of the detection antibody with 10.6ml of reagent diluent. Add 10OpI
per well, cover and incubate on the plate shaker for 60-90 minutes.
8. Remove and wash the plate 3x with 10OpI of wash buffer.
9. Dilute 50pl of streptavidin-HRP (supplied with the kit in the fridge) in 10ml of
reagent diluent. Add 10OpI per well, cover and incubate on the plate shaker
with foil on top for 20 minutes.
372
10. Remove and wash the plate 3x with 100pl of wash buffer.
11. Mix 100pl of TMB solution and 5pl of hydrogen peroxide in 10ml of substrate
buffer. Add 100pl per well and place in the dark to allow colour development.
WARNING - the colour develops extremely quickly!!!
12. Add 50pl of splphuric acid to each well to stop the reaction. Read with a test
wavelength of 450nm and a reference wavelength of 570nm.
Similar protocols used for measurement of IL-1(3>, IL-6, TNF-a and VEGF.
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2.10 C-Reactive Protein Assay
Contents of Kit
1. One Holder with precoated strips.
2. ELISA wash buffer concentrate.





8. ELISA stop soloution.







Wash Buffer dilute wash buffer concentrate with aqua dest 1:10. Crystals may
have formed due to high salt concentrate- these should be dissolved in water bath
at 37°C before dilution of concentrate. Diluted solutions at 2-8°C stable for one
month.
POD Labelled Antibody. Dilute to 1:100 in ELISA wash buffer. The antibody is not
stable after dilution.
Specimen Collection and Preparation




1. Reconstitute Antibody, wash buffer and dilute plasma
2. Wash strips 5 x 250pl ELISA wash buffer
3. Add 100pl of standards, sample or control into wells
4. Incubate for 1 hour, covered and shaking on a horizontal mixer
5. Aspirate the wells and wash with wash buffer 5 x 250pl
6. Add 100pl of prediluted Peroxidase labeled CRP Antibody
7. Incubate for 1 hour, covered and shaking on a horizontal mixer
8. Decant the content of the plate and wash with wash buffer 5 x 250pl
9. Add 10OpI of TMB Substrate into each well
10. Incubate for 5-10 mins at room temp in the dark
11. Add 50pl of stop solution then mix
12. Measure absorbance at 450nm
2.11 Thiobarbituric Acid Reactive Substances
Reagents Required
1. 10% TCA 0.815g TCA in 50ml of dw
2. 8.1% SDS 0.81 Og SDS in 10ml of dw (wear mask)
3. 20% Acetic Acid pH=3.5
4. 0.8% TBA 0.400g TBA in 50ml of dw
5. 1MTMP 165pl TMP in 1ml ethanol
6. 1N-butanol
Standard
1M TMP doubling dilutions from 10uM
Plasma
1. add 0.75ml plasma and 0.75ml 10% TCA
2. boil for 30 minutes at 95oC
3. cool with tap water
4. spin @ 3000 rpm for 10 mins
Procedure
1. add 300pl of supernatant
i. 150pl of SDS
ii. 150pl of Acetic Acid
iii. 300plofTBA
iv. 600pl of dw
v. (total volume = 1.5ml)
2. boil @ 95oC for 60 mins
3. add 1.5ml 1-N-butanol
4. vortex then centrifuge @ 2500 rpm for 10mins
5. remove organic layer
6. read with fluri-meter excitation @515nm, emission @553nm
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3.1 Reproducibility Study Inclusion / Exclusion Criteria
3.1.1 General
Subjects must be willing and able to attend the clinic and undergo
procedures as per\he study protocol.
Subjects must voluntarily give written informed consent to participate in the
study. The investigator will be responsible for obtaining written informed
consent before initiating any screening activities/procedures.
. At screening, subjects must be able to complete exhaled breath testing such
that >1 ml of exhaled breath condensate (EBC) is collected after 10-15
minutes tidal breathing. Subjects must also be able to complete sputum
induction with production a satisfactory sputum induction sample (defined as
adequate sputum for differential cell count and collection of > 400pl of
supernatant).
3.1.2 COPD patients
• Male or female out-patients 40-80 years of age with a documented
diagnosis of COPD as defined by the GOLD guidelines [1],
• No evidence of significant reversibility to inhaled salbutamol; significant
reversibility is defined as >12% improvement in FEX^ following salbutamol.
• Clinically stable COPD i.e. no history of COPD exacerbation or respiratory
tract infection within 1 month of screening and no history of hospitalisation
for COPD within 2 months of screening and no greater than 2 COPD
exacerbations within 6 months of screening (for the purposes of this study,
an exacerbation is defined as a change in baseline dyspnoea, cough and/ or
sputum production beyond day-to-day variability sufficient to merit a change
in management).
• COPD patients must be current cigarette smokers or ex-smokers (defined
as subjects who have given up smoking for > 6 months) with a minimum of
10 pack years of tobacco exposure.
• Post-bronchodilator spirometry at screening showing: FEVi/FVC <0.7 and
FEVi is <80% but >30% predicted for sex, age and height
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3.1.3 Healthy volunteers
• Male or female volunteers aged > 40 years
• For the "healthy smoker" subgroup, subjects will be current smokers with a
smoking history of >10 pack years; these subjects will be age-matched as
closely as possible (± 10 years) to subgroup of "smokers with COPD".
• For the "healthy ex-smokers" subgroup, subjects will be ex-smokers with a
smoking history of >10 pack years, having not smoked for at least 6 months
prior to screening; these subjects will be age-matched as closely as possible
(± 10 years) to "ex-smokers with COPD".
• For the "non/never-smokers" subgroup, subjects will either have never
smoked or have a smoking history of <1 pack year history having not
smoked for at least 5 years; attempts will be made to recruit subjects within
a similar age range as the COPD population (smokers and ex-smokers)
studied.
• All healthy subjects (smokers and non-smokers) must have spirometry
(without bronchodilator administration) showing both FEV-i and FVC of >
80% predicted and FEV^FVC ratio of >0.7.
• Volunteers must be free from clinically significant disease. A clinically
significant disease is defined as any condition which the investigator
considers could compromise either the volunteer's safety or the validity of
the study results.
3.1.4 EXCLUSION CRITERIA
• Subjects who are currently suffering from, or who have a past history
(childhood or adult) of, a clinically significant atopic/allergic disorder
(including seasonal allergic rhinitis, hayfever, asthma, eczema/dermatitis).
• Subjects who have a current or previous history of:
o any upper respiratory tract inflammatory disease e.g. rhinitis, sinusitis
(>1 episode).
o any lower respiratory tract disease (other than COPD) e.g. asthma,
bronchiectasis, pneumoconiosis, sarcoidosis, bronchiolitis, lung
cancer, tuberculosis.
o an upper or lower respiratory tract infection within 1 month of
screening
o unexplained chronic cough/wheeze/dyspnoea.
o any upper gastrointestinal tract inflammatory disorder (e.g.
pharyngitis, oesophagitis, gastritis).
• Subjects with an unexplained chest radiograph opacity.
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• Subjects who have received any experimental (i.e. non-marketed) drug
within four months of screening, or who have undergone sputum induction
or bronchoscopy within 1 month of screening.
• Screening sputum differential eosinophil count >3%.
• Subjects who have donated blood within 1 month of screening date, or
subjects who have a date for blood donation falling within the prospective
study period.
• Existence of any surgical or medical condition, as evident from medical
history, direct questioning or physical examination which in the judgment of
the Investigator might interfere with the conduct or results of the study.
In the opinion of the Investigator, a subject who is not likely to complete the
study for whatever reason.
3.1.5 Study Restrictions
3.1.5.1 Concomitant medications
• The following medications will not be permitted during the study (subjects
prescribed these medications must have stopped them for the indicated
period prior to screening to be eligible):
o Oral corticosteroids 8 weeks
o Leukotriene modulators (zafirlukast, montelukast) 8 weeks
o Nedocromil sodium or cromolyn sodium 8 weeks
• Subjects will be advised to take their usual bronchodilator medication, at the
usual time of day, prior to attending the Unit (screening and study visits).
Inhaled corticosteroids will be allowed throughout the study provided the
dose remains constant.
Subjects who require antibiotics (for any indication) should undergo
screening no less than 4 weeks after their final antibiotic dose and/or
termination of symptomatology necessitating the course. Subjects deemed
to require antibiotics during the study will be withdrawn and may not be re¬
entered.
• Subjects who are due to receive influenza or S. pneumoniae vaccination are
not eligible for the study if vaccination is due within 2 weeks of prospective
screening date, or between screening and visit 2.
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3.1.5.2 Caffeine
Subjects should refrain from ingesting caffeinated products (including tea, coffee)
for at least 8 hours prior to attending for screening or study visits.
3.1.5.4 Smoking
COPD patients and "healthy" subjects who smoke will be required to abstain from
smoking for a minimum of 8 hours prior to attending the Investigational Unit for
screening or study visit procedures.
3.1.5.5 Activity/exercise
Subjects should refrain from strenuous exercise for at least 24 hours prior to
screening or study visits.
3.1.5.6 Stability criteria
Any subject who experiences a respiratory tract infection and/or any clinically
significant deterioration of their COPD symptoms between screening and study
visit 1 will not be entered at that point. At the discretion of the Investigator, these
subjects may be re-screened, but re-screening may take place no less than 4
weeks following full resolution of the infection/exacerbation and return to their usual
therapeutic regimen.
If subjects experience a respiratory tract infection or any clinically significant
deterioration of their COPD symptoms in the period between study visit 1 and study
visit 2, then they will be withdrawn from the study and may not be re-entered.
Even in the absence of overt respiratory tract infection or clinically significant
deterioration in symptoms, if the FEVi measured for COPD patients or healthy
subjects on the study day is outside the range of 90-115% of the pre-bronchodilator
value at screening visit, they will not complete study procedures (including exhaled
breath collection, sputum induction and venesection) on that day. However,
assuming that no other evidence of a potential exacerbation is observed and no
alteration in the subject's medication is deemed necessary by the attending
physician, the visit may be rescheduled to occur 3-7 days thereafter. Failure to
obtain an FEVi value within the permissible range at this rescheduled visit will
result in withdrawal of the patient from the study.
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Appendix 4.1 Cross sectional Study Inclusion / Exclusion Criteria
4.1.1 General
. Subjects must be willing and able to attend the clinic and undergo
procedures as perXhe study protocol.
• Subjects must voluntarily give written informed consent to participate in the
study. The investigator will be responsible for obtaining written informed
consent before initiating any screening activities/procedures.
. At screening, subjects must be able to complete exhaled breath testing such
that >1 ml of exhaled breath condensate (EBC) is collected after 10-15
minutes tidal breathing.
4.1.2 COPD patients
• Male or female out-patients 40-80 years of age with a documented
diagnosis of COPD as defined by the GOLD guidelines [1],
• No evidence of significant reversibility to inhaled salbutamol; significant
reversibility is defined as >400ml improvement in FE\A following salbutamol.
• Clinically stable COPD i.e. no history of COPD exacerbation or respiratory
tract infection within 1 month of screening and no history of hospitalisation
for COPD within 2 months of screening and no greater than 2 COPD
exacerbations within 6 months of screening (for the purposes of this study,
an exacerbation is defined as a change in baseline dyspnoea, cough and/ or
sputum production beyond day-to-day variability sufficient to merit a change
in management).
• COPD patients must be current cigarette smokers or ex-smokers (defined
as subjects who have given up smoking for > 6 months) with a minimum of
10 pack years of tobacco exposure.
• Post-bronchodilator spirometry at screening showing: FE\A/FVC <0.7 and
FEVi is <80% predicted for sex, age and height
4.1.3 Healthy volunteers
• Male or female volunteers aged > 40 years
• For the "healthy smoker" subgroup, subjects will be current smokers with a
smoking history of >10 pack years; these subjects will be age-matched as
closely as possible (± 10 years) to subgroup of "smokers with COPD".
• For the "healthy ex-smokers" subgroup, subjects will be ex-smokers with a
smoking history of >10 pack years, having not smoked for at least 6 months
prior to screening; these subjects will be age-matched as closely as possible
(± 10 years) to "ex-smokers with COPD".
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• For the "non/never-smokers" subgroup, subjects will either have never
smoked or have a smoking history of <1 pack year history having not
smoked for at least 5 years; attempts will be made to recruit subjects within
a similar age range as the COPD population (smokers and ex-smokers)
studied.
• All healthy subjects (smokers and non-smokers) must have spirometry
(without bronchodilator administration) showing both FEVi and FVC of >
80% predicted and FEV^FVC ratio of >0.7.
• Volunteers must be free from clinically significant disease. A clinically
significant disease is defined as any condition which the investigator
considers could compromise either the volunteer's safety or the validity of
the study results.
4.1.4 EXCLUSION CRITERIA
• Subjects who are currently suffering from, or who have a past history
(childhood or adult) of, a clinically significant atopic/allergic disorder
(including seasonal allergic rhinitis, hayfever, asthma, eczema/dermatitis).
• Subjects who have a current or previous history of:
o any upper respiratory tract inflammatory disease e.g. rhinitis, sinusitis
(>1 episode).
o any lower respiratory tract disease (other than COPD) e.g. asthma,
bronchiectasis, pneumoconiosis, sarcoidosis, bronchiolitis, lung
cancer, tuberculosis.
o an upper or lower respiratory tract infection within 1 month of
screening
o unexplained chronic cough/wheeze/dyspnoea.
o any upper gastrointestinal tract inflammatory disorder (e.g.
pharyngitis, oesophagitis, gastritis).
• Subjects with an unexplained chest radiograph opacity.
• Subjects who have received any experimental (i.e. non-marketed) drug
within four months of screening, or who have undergone sputum induction




Subjects should refrain from ingesting caffeinated products (including tea, coffee)
for at least 8 hours prior to attending for screening or study visits.
4.1.5.2 Smoking
COPD patients and "healthy" subjects who smoke will be required to abstain from
smoking for a minimum of 8 hours prior to attending the Investigational Unit for
screening or study visit procedures.
4.2 MRC Dyspnoea Score
0 Not troubled with breathlessness except with strenuous exercise
1 Troubled by shortness of breath when hurrying or walking up a slight hill
2 Walks slower than people of the same age due to breathlessness or has to
stop for breath when walking at own pace on the level
3 Stops for breath after walking about 100m or after a few minutes on the
level
4 Too breathless to leave the house or breathless when dressing or
undressing
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status Other Medical History
L220 1 2 Pancreatitis colonic polyp
L030 1 2 PVD
L067 1 2 Peptic ulcer disease Hypocalcaemia
L071 1 2 Schizophrenia
L073 1 2 psoriasis anxiety , vocal cord polyps
Sigmoid colectomy Non specific shoulder pain
L076 1 2 OA Hiatus hernia Leg cramps
L077 1 2 cervical spondylosis
L082 1 2 Appendicectomy
L090 1 2 Knee op Slipped disc
L091 1 2 Chronic Schizophrenic Hearing impairment
L092 1 2 PVD intermittent claudication
L099 1 2
L100 1 2
L101 1 2 Renal Colic Restless leg syndrome occasional headache
L102 1 2
L104 1 2 PVD AFHypotension gout
L105 1 2 cirrhosis TURP Lumber discopathy
L106 1 2 Congenital nystagmus Childhood pneumonia
L109 1 2 Sub Arachnoid Haemorrhage Angina
Chronic back pain OA Depression PVD
L114 1 1 Depression
L119 1 1 Diptheria Atopy to metals heart murmur
L120 1 2 truncal Vagotomy & Pyloroplasty for Duodenal Ulcer
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L126 1 2 Depression
L129 1 2 CABG
L130 1 1
L132 1 2 BPH angioplasty and stenting
L133 1 1 BPH Cateract op
L134 1 2 PVD
L136 1 2 Sterilization
L137 1 2 Ventilated March 2005
L140 1 2 Dupuytrens contracture tonsilectomy
L148 1 2 Anxiety peptic ulcer disease bowel resection
L149 1 2 pneumonia & pleurisy age 12 prostatectomy
L151 1 2 Trochanteric Bursitis Left fractured neck of femur
L152 1 2
L154 1 2 Cerebral Aneurysm clipped Cervical spondylosis
L155 2 1 AF eczema
L157 2 1 Gout pancreatitis diverticulitis
L158 2 1 Diverticulitis EMD arrest
L160 2 1 Ml Depression
L162 2 1
L163 2 1 BPH Cataracts Angina.
L164 2 1 Diverticular Disease
L166 2 1 CABG Sciatica unstable bladder inguinal hernia
L167 2 1
L168 2 1 PVD Dyspepsia
OA
L170 2 1 TIA Dyspepsia
L173 2 1 Bilateral Hip Replacement
L174 2 1 Pneumothorax
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L175 2 1 DU Cholecystectomy
L176 2 1 Previous DVT
L178 2 1 Hypertension
L179 2 1 Ml 25yrs ago Gout.
L180 2 1 Hernia op
L181 2 1 Colectomy for Colonic ca Post op pneumothorax
L186 2 1
L187 2 Depression
L188 2 1 TIA esophagitis
L189 2 1
L190 2 1 Atrial flutter Prostatectomy for Ca 1988
L191 2 1 Glaucoma
L193 2 1 Enlarged prostate
L194 2 1 Trigeminal Neuralgia
L195 2 1 Osteoarthritis
L196 2 1 BPH
L197 2 1 OSA Vertebro-basilar insufficiencyOA
L198 2 1 Depression dyspepsia reflux
L199 2 1 Non hodgkins lymphoma 1995
L201 2 1 CABG
L202 2 1 Pleurisy age 18 mastoid op hypercholesterolaemia
L204 2 1 Hiatus Hernia duodenal ulcer
L205 2 1 BPH
L206 2 1
L209 2 1
L210 2 1 hypothyroidism osteoarthritis
L212 2 1 benign prostatic hypertrophy lumbosacral spondylosis
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L228 4 1 Contact dermatitis Pneumonia 1965 OA
L229 4 1 varicose veins Rosacea
L230 4 1 acne rosacea
L231 4 1 AF
L232 4 1 allergy to penicillin sinus problems
L233 4 1 Anaphylaxis to penicillin
L234 4 1 Back Injury - slipped L4 L5
L235 4 1 Bhronchitis/asthma as child Pylori oct 2004
L236 4 1 Dupuytren peumonia aged 12 anaemic
L237 4 1 Bowen's disease Allergy to iodine hypothyroidism
L238 4 1 bronchitis 10yrs ago
L241 4 1 Bronchitis age 19 no recurrance Varicose Veins
L243 4 1 bronchitis aged 22
L244 4 1 CABG 1992
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L245 4 1 CABG Ml BPH OA Cataract op PAF
L246 4 1 carpal tunnel syndrome
L247 4 1 Cholecystectomy Irritable Bowel Syndrome
L248 4 1 Depression OA steoporosis Pneumonia
L249 4 1 Depression late 1990's
L250 4 1 dyspepsia lower back pain hayfever
L251 4 1 Frozen Shoulder
L252 4 1 Gout
L253 5 0 H. pylori Gastritis
L255 5 0 hiatus hernia GORD psoriasis - uv treated
L256 5 0 Hypercholesterolemia - diet controled
L258 5 0 Hypertension not medicated
L259 5 0 Hypothyroid
L260 5 0 Hypothyroid
L262 5 0 Kidney probs unknown cause
L263 5 0 L hip bursitis2002
L264 5 0 Left nephrectomy acute arthritis
L265 5 0 Ml 1981 CABG 1991
L267 5 0 Ml 2002 angioplasty Migraine Diverticular disease
L268 5 0 Ml eye surgery Colostomy for colonic abcess - reversed
TURP for benign prostatic renal calculi.
L269 5 0 Migraine Psoriasis gluten intolerence
L270 5 0 Migraines
L272 5 0 Mild OA
L273 5 0 Neuromas siatica hysterectomy GORD
L275 5 0 Nil
L276 5 0 Nil
L280 5 0 pneumonia 1972 nasal polyps (op 2004)
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L281 5 0 Pneumonia age 14
L282 5 0 possible Erythromycin allergy
L283 5 0 Recurrent back problems
L285 5 0 sinusitis 6weeks ago
L287 5 0 Varicose Veins D+C benign breast cysts
Study Groups 1 = COPD smoker, 2= COPD ex-smoker, 3 = healthy smoker,
4 = healthy ex-smoker, 5 = healthy never smoked
Smoking Status 0 = never, 1= ex-smoker, 2 = current smoker
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5.1 Nacystelyn Study Schedule
Period Screenin Double Blind Treatment Follow-up
Visit 1 2 3 4 5/ET 6
Week - 0 2 4 12 14
Day -31 to-14 0 14 28 84 98
Visit Window (Days) - - (±3) (±3) (±3) (±3)
Informed Consent X
Demography X
Medical History X X
Inclusion/Exclusion Criteria X X
Randomisation X
Clinical Examination X X X X X X
SGRQ X X X
Symptom Score Patient Diary Completion X X X X
Reversibility Testing X
Pulmonary Function Tests f X X X X X X
Electrocardiogram (ECG) X
Concomitant Treatments X X X X X X
Training & Assessment on use of Inhaler X
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Device
Dispense (x) / Retrieve (o) Placebo Run-in
Medication
X 0
Dispense (x) / Retrieve (o) Study
Medication
X X 0 0
Dispense (x) / Retrieve (o) fluticasone X Xo X 0 0
Haematology & Serum Chemistry X X X
Serology (Screening for Hep. B and Hep.
C)
X
Urinalysis (* Including drug screening) X* X X
Serum Pregnancy Test X
Lipid Peroxidation in Plasma X X X
Breath Condensate X X X
Sputum Samples (Induced) X X X
Sputum Samples (Spontaneous) X X
Adverse Events / Serious Adverse Events X X X X X
f: Pulmonary function tests (forced expiratory volume [FEVi], forced vital capacity [FVC], and peak expiratory
flow rate [PEFR]) were performed both pre and post bronchodilator inhalation according to a standard
procedure. Patients were instructed not to take short acting p2-agonists at least 8 hours, long acting P2-
agonists at least 24 hours, and inhaled anticholinergics at least 8 hours prior to each study visit.
5.2 Nacystelyn Study Inclusion / Exclusion Criteria
Subject Inclusion Criteria
The patients who may be included in the trial are those:
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• Who are cooperative male or female outpatients aged >40 years
• Who are smokers or ex-smokers of 10 pack years or more.
• With COPD according to the ERS guidelines43, with an FEVt between 30% and
60% predicted and who demonstrate <15% reversibility from baseline and <200
ml improvement in FEVt after inhalation of 2.5 mg nebulised salbutamol.
• Who have chronic symptoms, i.e. chronic breathlessness with or without cough
and sputum production.
• Who have had at least 1 respiratory exacerbation (defined as seeking medical
advice and changing treatment to oral antibiotics and/or oral steroids) during
the winter season prior to the study.
• Who can properly use the MIAT monodose DPI.
• Who have signed a written informed consent.
SubjectExclusion Criteria
AtScreening
• Patients who have any history of asthma.
• Patients who are clinically unstable, i.e. who have had a respiratory
exacerbation <4 weeks before the start of the trial.
• Patients with unstable concurrent non-respiratory diseases.
• Patients with active lung disease other than COPD.
• Patients with, or at risk of contracting, tuberculosis, HIV, Hepatitis B or Hepatitis
C.
• Known hypersensitivity to nacystelyn or fluticasone.
• Patients who are intolerant of lactose.
• History of non-compliance to medical regimens and patients who are
considered potentially unreliable.
• Treatment with any investigational drug within the past month or 10 half lives,
whichever is longer.
• History of malignancy of any organ system, treated or untreated, within the past
five years whether or not evidence of local recurrence or metastases exists are
excluded, with the exception of localised basal cell carcinoma of the skin.
• Patients involved in disease-related litigation.
• Women who are pregnant or lactating
Subject Withdrawal Criteria
The patient will be advised in the Informed Consent Forms that they have the right to
withdraw from the study at any time without prejudice, and may be withdrawn at the
Investigator's/Chiltern's/Laboratoires SMB's discretion at any time. Prematurely
discontinued patients will not be replaced.
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In the event that the patient drops out of the study or is withdrawn from the study, the
patient should undergo an early termination visit. All Visit 5/ET procedures should be
carried out as required and the Investigator should record the details of the withdrawal on
the study completion page of the CRF. If possible the patient should also return for the
follow up visit 14 days after their ET visit to have a clinical examination and pulmonary
function tests carried out. Where this is not possible a follow up telephone call should be
made to the patient to determine if any SAEs have occurred since the termination of study
drug. (N.B. All SAEs occurring up to 30 days after a patient stops taking the study
medication should be recorded and reported as detailed in section 9.3 of this protocol).
Reasonable effort should be made to contact any patient lost to follow up during the course
of the study in order to complete assessments and retrieve any outstanding data and study
medication/supplies.
The following are reasons for patient dropout/withdrawal:
• Adverse event
• Protocol deviation (e.g. dosing regime, failure to comply with clinic visit schedule)
• Administration of an excluded medication
• Co-existing disease
• Worsening of condition
• Pregnancy
• Clinical significant abnormal laboratory value(s)
• Other
The patient requested withdrawal due to:
• An adverse event for which the Investigator did not consider removal from the study
necessary.
• Perceived insufficient therapeutic effect.
• Co-existing disease




• Lost to follow-up
• Administrative problems
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5.4 Nacystelyn Study Patient Diary Symptom Score
e.g. Day 1 Day 2 Day 3 Day 4
Date: dd / mm 15/07 / 1 / /
1. How many times did you awake during last night
because of your chest problems? (enter number
of times)
1
2. How breathless have you been in the last 24
hours? 0 0 0 0 0
Score(0-4)
(circle appropriate score)
1 1 1 1 1
2 2 2 2 2
3 3 3 3 3
4 4 4 4 4
3. How much have you coughed in the last 24 hours?
Score (0-3)
(circle appropriate score)
0 0 0 0
1 1 1 1 1
2 2 2 2 2
3 3 3 3 3
4. How much sputum have you produced in the last
24 hours? 0 0 0 0 0
Score (0-3)
(circle appropriate score)
1 1 1 1 1
2 2 2 2 2
3 3 3 3 3
5. What colour has your sputum been in the last 24
hours? 0 0 0 0 0
Score (0-4)
(circle appropriate score)
1 1 1 1 1
2 2 2 2 2
3 3 3 3 3
4* 4 4 4 4
6. Have you missed any time from work or usual
activities in (he last 24 hours because of your chest None None None None None
problems
(circle appropriate answer)
Half day Half day Half day Half day Half day
Full day Full day Full day Full day Full day
7. Have you needed any assistance from a caregiver
(paid or unpaid) in the last 24 hours because of None None None None None
your chest problems?
(circle appropriate answer)
Half day Half day Half day Half day Half day




1. Remove the cap. 2. Steadily hold the base and
open the inhaler turning the
the nozzle anti-clockwise
(see the arrow on the nozzle).
3. Introduce the capsule
into the loading chamber.
5. Firmly press the two red buttons,
keeping the inhaler in the
vertical position.
6. Breathe out deeply.
7. Introduce the whole nozzle into
the mouth and breath in, closing
the lips (avoid air passing
around the nozzle)with the head
bent backwards. Hold your breath
for 3-5 seconds. Repeat until the
capsule is completely empty.
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